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ABSTRACT
Fluorescence imaging can be used both as a tool to diagnose diseases and guide
treatment in clinical settings, and as a technique to monitor dynamic events or biological species
in basic research. Therefore, there is a great need for the development of a multitude of
fluorescent probes that can be incorporated with fluorescence imaging techniques to track and
report endogenous enzymes with high specificity and selectivity. In contrast to always-on and
targeted always-on fluorescent probes that continually emit light, activity-based substrate probes
either emit low numbers of photons or are completely quenched. They can be converted to highly
fluorescent reporters by specific upregulated enzymes, thus offering a high target-to-background
ratios contrast. Fluorescent probes have a promising impact in fluorescence-guided cytoreductive
surgery, but complete resection in every patient is highly unlikely. Probes that emit near-infrared
(NIR) light are more suitable for in vivo imaging. Therefore, in this work, hNQO1-activatable NIR
imaging probes (Q3STCy and Q3NTCy) with different eliminating linker and different affinities for
hNQO1 were developed. These probes were successful in imaging clinically relevant multicellular
tumor spheroids (MCTSs) possessing spatially heterogeneous NQO1 activities and in identifying
sub-millimeter dimension metastases in a preclinical mouse model of human ovarian serous
adenocarcinoma. To further diversify the research, ratiometric probes (GalNap and CysTy) with
the capability to quantify the enzyme -Galactosidase and cysteine were developed. GalNap was
used in the real-time detection of -Galactosidase in human ovarian cancer cells and CysTy was
used to detect cysteine in human plasma. As an initiative to contribute to effective cytoreductive
surgery, a chemical agent (Q3Pyro) was designed and synthesized that can not only light up, but
can also be toxic toward hNQO1-expressing tumor tissues. With various imaging and cell assays,
the probe was validated to perform as both a profluorogenic probe and a prodrug.

xxi

CHAPTER 1
INTRODUCTION
1.1

Research Goals and Aims
Rapid, selective, and noninvasive reporting of disease-linked enzymatic activities and

functions in complex biological processes will lead to a better understanding of tumorigenesis at
the molecular level and development of precision medicine applications in oncology.1-4
Collaborative work amongst engineering, chemistry, and biology is necessary to decipher their
mysterious functions in living systems. Compared to traditional clinical imaging modalities (i.e.,
MRI, CT, and PET), fluorescence imaging has a relatively shallow penetration depth. However,
due to its high spatiotemporal resolution and high sensitivity, fluorescence imaging is gaining
immense popularity, both as a powerful clinical tool to diagnose diseases and guide treatment,
and as an imaging technique to monitor dynamic biological species/events in basic research. 5-6
Therefore, there is a great need for the development of a multitude of reactivity-based fluorescent
substrate probes to incorporate with fluorescence imaging techniques so as to track and report
endogenous enzymes with high sensitivity and selectivity. Unlike always-on and targeted alwayson fluorescent probes that emit light regardless of the presence of enzymes, reactivity-based
probes that weakly emit can be converted to highly fluorescent reporters by upregulated enzymes,
thus offering the advantages of low background fluorescence signal, fluorescence signal
amplification in the targeted area, and high tumor-to-background ratios. The overall goal of my
research is to develop enzyme-activatable (i.e., NQO1 and -galactosidase) fluorescent substrate
probes for differentiating diseased tumor cells from healthy cells in vitro and in vivo, and exploring
their potential applications for quantifying enzymes of interest.
NQO1 is a two-electron reductase, whose expression is 2- to 50-fold higher in numerous
human solid tumors (e.g., pancreas, colon, breast, ovarian, and non-small cell lung carcinoma)
than the surrounding normal tissue.7 NQO1 has been traditionally used as a cancer biomarker for
developing targeted anticancer drugs.8 Recently, the upregulation of NQO1 in malignant cells has
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led to the development of quinone-based, NQO1-activatable fluorescent probes.9-13 However,
these NQO1-specific probes absorb and emit light in the visible energy range. Near-infrared light
has the advantages of high tissue penetration depth, low tissue autofluorescence, and low tissue
absorption, all which are more attractive for in vivo imaging applications.
The first aim of my research was to design and synthesize a fluorescent probe, Q 3STCy,
that emits near-infrared light upon its NQO1 activation to yield a fluorescence active reporter, and
to examine its applicability for visualizing NQO1-expressing cells and small tumors. The crafted
NQO1-specific fluorescent probe has a tripartite structure (trigger, linker, and reporter). Upon
NQO1-catalyzed reduction, the probe exhibited a fast and large fluorescence increase, thus
allowing the immediate differentiation of NQO1-expressing cells from NQO1-non-expressing cells
in two-dimensional (2D) cell culture with high integrity. Because 2D cell culture lacks features of
real tumor microenvironments, a three-dimensional (3D) multicellular spheroid (MCTS) model can
better mimic tumor characteristics. The usefulness of Q3STCy was validated by the successful
imaging of clinically relevant MCTSs possessing spatially heterogeneous NQO1 activities, and
fluorescence-assisted identification of sub-millimeter dimension metastases in a preclinical
mouse model of human ovarian serous adenocarcinoma.
However, Q3STCy had a relatively slow reporter production rate and an off-on
fluorescence mode. To overcome these drawbacks, my next aim was to develop a fluorescent
probe with rapid reporter production rate triggered by NQO1 and possessing unique NQO1response modes. I used a rigid and fast-eliminating linker to replace the flexible linker in Q3STCy,
and developed a second NQO1-selective fluorescent probe, Q3NTCy. In this design, both the
probe and the reporter exhibited strong NIR fluorescence in different energy ranges of the
electromagnetic spectrum, thus the probe/reporter pair act as an on-on imaging system.
Subsequent enzyme evaluation and reporter release determination of Q3NTCy confirmed that its
NQO1-initiated signal generation was faster than Q3STCy. Celluar imaging via confocal
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microscopy further demonstrated the ability of Q3NTCy in the differentiation of hNQO1-expressing
cell lines from an hNQO1-nonexpressing cell line in both off-on and on-on fluorescence modes.
My final aim was to develop a ratiometric fluorescence-based probe to explore its
applications in quantifying cancer-associated enzymes. Different from intensity-based probes,
ratiometric fluorescent probes can simultaneously give two signals that originate from the
unreacted probe and its reacted reporter, and they have the advantages of eliminating problems
stemming from variabilities in excitation and emission efficiencies, sample environment (e.g., pH
and polarity), and distribution of the probe.14 -Galactosidase (-gal) is an important transgene
reporter enzyme that is widely used to study gene transcription in biological systems. Because of
the upregulation of -gal in senescent cells and in primary ovarian cancer cells, it has been
explored as a biomarker to develop small-molecule fluorogenic probes for detecting and imaging
senescent cells and ovarian cancer cells. The use of a -gal–responsive ratiometric fluorescent
probe can potentially provide a simple and sensitive way to quantify the concentration of -gal
under cellular conditions. I developed a novel and well-described ratiometric fluorescent probe,
GalNap, capable of achieving the real-time detection and imaging of the endogenous -gal in
human ovarian cancer cell lines in both off-on and ratiometric modes.
1.2

Molecular Imaging in Cancer
The advancement of multiple non-invasive molecular imaging modalities has greatly

contributed to the world’s understanding of pathological processes, and aided in effective disease
diagnostics and therapeutics.15-18 For example, molecular imaging techniques allow us to know
the size and location of tumors, the expression levels of specific molecules (e.g., enzymes and
other proteins), and physiological processes and cellular metabolism (e.g., blood flow and glucose
uptake).19 The most commonly used imaging modalities include X-ray computed tomography (CT),
magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasonography (US),
and optical imaging. The imaging modalities are complementary rather than competitive. The
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imaging modalities exploit the different levels of energy in the electromagnetic spectrum that
interact with the human body to generate images, Figure 1.1.20 Although CT, MRI, and US can
acquire anatomical information based solely on energy-tissue interactions, exogenous contrast
agents for them and other imaging modalities are necessary to be administered to enhance the
image contrast and monitor the species/events of interest.

Figure 1.1 Common imaging modalities and their employed frequency ranges on the
electromagnetic spectrum.20
Each of these modalities has its advantages and limitations.16 By processing the X-ray
signal, CT can generate three-dimensional images of the scanned anatomical structures.21 Due
to its high scan speed and relatively high resolution, CT is one of the most commonly used clinical
imaging techniques for cancer diagnosis. Although it is especially suitable for acquiring skeletal
structure information, CT alone is not sensitive enough to image soft tissues. The administration
of iodinated contrast agents at high concentrations (~ 10–2 M) is necessary to improve the image
contrast of soft tissues with millimeter resolution. MRI has evolved as an alternative imaging
technique that is superior to CT.22 Under high magnetic field conditions, the MR signal is
generated by exciting ubiquitous hydrogen nuclei present in the human body with radio frequency
energy. The collected MR signal is processed to construct three-dimensional MR images. The
ionizing radiation used in CT is not applied in MRI, thus making MRI a safer imaging technique.
Because MRI is very sensitive to soft tissues, it is an ideal technique for obtaining physiological
4

information of soft tissues. To improve the MR image contrast, paramagnetic contrast agents (e.g.,
gadolinium chelates and iron nanoparticles) are often administrated to alter the spin properties of
hydrogen nuclei in the targeted tissue area. The properties of hydrogen nuclei can be influenced
by the MR contrast agents at long distance (up to 50 times the dimension of the paramagnetic
particle).16, 23 Therefore, a smaller amounts of MR contrast agents (M) are required than that for
CT.
PET is a highly sensitive imaging technique. Gamma rays emitted indirectly by
radionuclides (e.g.,

18

F and

11

C) are detected and utilized to construct three-dimensional PET

images. Monitoring the distribution of radionuclide-labeled biological molecules can provide
physiological and pathological information (glucose uptake and cancer metastasis).24 PET is often
integrated with CT or MRI, the latter providing information about the location of the targeted
biological events/species.
Another clinically used imaging modality is US that exploits reflected ultrasound pulses
(1–10 MHz) to generate real-time images.25 US is often used to image soft tissue structures
(muscles, vessels, tumors, and internal organs) and diagnose diseases and visualize pathological
tissues. Microbubbles can be used as contrast agents for US to study the angiogenesis of
tumors.26 Other emerging imaging techniques such as mass spectrometry imaging and
photoacoustic imaging are also playing important roles in the field of oncology.27-28
Fulfilling the current requirements for imaging systems will not only enable doctors to
better determine the location, stage, and size of a tumor, but also provide knowledge about the
expression and activity of specific molecules, cells, and biological processes at the molecular
level.29 Although the above-mentioned methodologies have achieved great success in clinical
diagnosis and staging of cancer, not all of them are suitable for molecular imaging due to their
lack of selectivity and high limit of detection. For example, the disease-associated species, such
as enzymes and proteins, are present in very low concentrations (nanomolar to picomolar).30 PET
is an imaging technique with high sensitivity. However, it suffers from low spatial resolution (1–2
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mm), radiation exposure, high cost, long acquisition time, and a shortage of radionuclide-labeled
biological molecules.16 The decay of radioactive contrast agents causes handling to be an
inconvenience. 2-deoxy-2-[18F]fluoro-D-glucose (18FDG), the most available PET contrast agent,
is not ideal for cancer imaging due to its high uptake in many normal tissues. 31 Moreover, the
above-mentioned imaging modalities are mainly used as preoperative diagnostic techniques. It is
difficult to incorporate them into the intraoperative workflow to collect real-time information with
high spatial resolution.5
In contrast, optical imaging techniques are emerging as powerful tools with the potential
to satisfy current molecular imaging requirements.29 Photons emitted by either endogenous or
exogenous molecules are collected to construct a two or three-dimensional image. Optical
techniques can detect picomolar or even femtomolar concentrations of fluorescent or
bioluminescent molecules.32 Depending on the applications, optical imaging can reach
micrometer resolution for in vivo imaging and nanometer resolution for super-resolution optical
microscopy.29 High sensitivity and high spatial resolution of optical imaging make it possible to
visualize abnormal cellular pathways and early disease progression at the molecular level.33 Other
advantages of optical imaging include utilization of non-ionizing radiation, economic efficacy, realtime imaging, and ease of integrating with interventional surgery.
1.3

Optical Imaging and Its Applications
Optical imaging is a collective group of techniques that detect light. It dates back to the

12th century when people combined two refractive lens to observe far and enlarged objects.34 The
buildup of compound microscopes to observe tiny biological specimens has greatly contributed
to the advancement of the life sciences. Currently, optical imaging has gained immense popularity
due to it being a powerful clinical tool to diagnose diseases, guide treatment, and as an imaging
technique to monitor dynamic biological species/events in basic research.32, 35-36 As other imaging
modalities require contrast agents to improve their imaging ability, optical imaging techniques
benefit from the use of endogenous and exogenous molecules that can interact with light
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(absorption, fluorescence, phosphorescence, and bioluminescence) as a contrast agent to
generate images.37 In this section, I will focus on fluorescence and bioluminescence imaging and
their applications.
1.3.1 Fluorescence Imaging
Fluorescence imaging generates images that rely on the photons emitted by energetically
excited fluorescent molecules. In this method, the targeted molecules present in samples are
excited by a light source at an appropriate wavelength, and they subsequently emit light at longer
wavelength.32 The emitted photons are detected by charge-coupled device (CCD) or
photomultiplier tube (PMT) to generate images, which are interpreted to get the dynamic
distribution information of the observed species/events.
Both endogenous and exogenous fluorescent molecules can be the targeted molecules
to be measured. Endogenous fluorescent molecules include nicotinamide adenine dinucleotide
(NADH), flavin adenine dinucleotide (FAD), and porphyrins. Through monitoring the fluorescence
of NADH and FAD, their dynamic metabolic pathway can be observed and studied to unravel their
functional roles in their native state.38 The endogenous existence of porphyrins in some types of
tumors has been used to differentiate tumors from healthy tissues under the ultraviolet illumination
conditions.39-40 Although the autofluorescence from endogenous molecules is useful for the
determination of abnormal tissue morphology and lesions, only limited numbers of endogenous
fluorescent molecules are present in living subjects. Exogenously introduced fluorescent
molecules (e.g., fluorescein and indocyanine green) are the most commonly used contrast agents
in both basic research and clinical practice. Fluorophores and their design strategies for
fluorescence imaging will be discussed later.
Depending on the applications, fluorescence imaging techniques with various detection
scales (microscopic and macroscopic) have been developed. For example, the development of
confocal and super-resolution microscopy with high spatial resolution enables molecular-level
study of gene expression, protein functions, and cellular metabolism.41-43 On the other hand,
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macroscopic imaging such as optical coherence tomography, can be used to visualize cancer,
precancerous lesions, and heart disease for small animal whole-body imaging.36 One of the
clinical applications of fluorescence imaging is to guide surgeons in determining the boundary
between diseased tissues and healthy tissues, as well as to identify and remove small foci of
tumors.5, 44-46 Currently, several endoscopic and robot-assisted imaging techniques have been
available in the intraoperative assessment of patients.5
1.3.2

Fluorescence-Guided Surgery (FGS)
Although great biomedical advancement has been made in the field of oncology, surgery

remains one of the most employed and effective techniques for the treatment of cancer. 47 The
degree of cancer removal has a significant influence on cancer recurrence and patient survival
rate. The residual cancer cells after surgery are the main cause of poor patient outcomes. In the
current surgical workflow, removal of tumors heavily relies on surgeon visual inspection and
palpation, thus limiting the complete resection of small-sized tumors. CT, MRI, and PET are
conventionally used as preoperative imaging modalities for cancer diagnosis and surgery
planning. Recently, intraoperative CT and MRI have been developed for the guidance of
neurosurgical resection during surgery.48 However, the imaging systems are expensive, big in
size, and their use interrupts surgical workflow.46 Also, they have a low spatiotemporal resolution,
limiting their differentiation of small-sized tumors (< 1 mm) in real-time. In this regard,
fluorescence-guided surgery (FGS) has been developed for enabling surgeon ability to resect
tumors in a fast, precise, and complete manner, Figure 1.2.49-50
FGS was first applied to localize a brain tumor during neurosurgery based on the passive
accumulation of sodium fluorescein in malignant tissues in the 1940s.51 In 1992, Folli et al.
exploited antibody-conjugated fluorescein to target colorectal carcinomas in patients, which
became the first clinical trial with targeted fluorescence imaging. 52 Recently, Van Dam et al
achieved the intraoperative visualization of ovarian cancer cells with a folate-conjugated
fluorescein agent by taking advantage of the overexpression of folate receptor- in epithelial
8

Figure 1.2 Schematic representation of fluorescence-guided surgery.5
ovarian cancers.53 In recent years, FGS has been widely used in select applications, including
determination of diseased and healthy margins, sentinel lymph nodes mapping, identification of
tumors, plastic surgery, monitoring of cardiovascular diseases, lymphatic imaging, ureter imaging,
bile-duct imaging, and angiography.46 In comparison with other imaging modalities, FGS has a
high spatial resolution, provides real-time and economic efficacy, and it is easily incorporated into
the surgical workflow. Its progress depends on the advancement of imaging instruments and
availability of fluorescent contrast agents.
Currently, several FGS instruments with different excitation/emission filters have been
approved by the US Food and Drug Administration (FDA).54 The first FDA-approved FGS
instrument is The Novadap SPY system (2005), and it was used to monitor skin perfusion and
blood flow with indocyanine green (ICG) as the contrast agent. After that, several new imaging
systems such as the Hamamatsu PDE system, the fluobeam 800 clinical imaging device, and the
VS3-IR-MMS system were developed and FDA-approved for various imaging applications.
9

Despite the availability of numerous FDA-approved imaging systems, there are only four FDAapproved non-targeted imaging agents for clinical use, including ICG, methylene blue (MB),
fluorescein, and the imaging precursor 5-aminolevulinic acid (5-ALA). Their imaging abilities rely
on their passive non-specific biological distribution. Efforts to develop more FDA-approved
fluorescent molecular agents will greatly benefit the FGS area, and their clinical use can be
immediately achieved considering the availability of imaging systems.1
Although many fluorophores are commercially available, most of them emit light in the
visible region of the electromagnetic spectrum (350–650 nm) with even shorter excitation
wavelengths. Light in the ultraviolet (UV) and visible range suffers from several drawbacks such
as phototoxicity, overlap with tissue autofluorescence, large tissue absorption, and shallow tissue
penetration. Although light in the green emission range is useful for superficial surface imaging of
tissues, it is not suitable for the in vivo deep tissue imaging. In contrast, near-infrared (NIR) light
(650–900 nm) has optimal imaging properties and is desired for in vivo imaging applications. 5, 5557

Biological tissue has the least absorption in the NIR range. Visible light (< 650 nm) is highly

absorbed by endogenous molecules (e.g., oxy- and deoxy-hemoglobin) and infrared light (> 900
nm) is absorbed by water and lipids, Figure 1.3.4 Although visible light can only penetrate tissues
with a dimension of micrometers, NIR light has an enhanced tissue penetration depth (millimeters
and up to centimeters) due to reduced tissue absorption, thereby enabling NIR light to be suitable
for deep tissue imaging.58-59 Another advantage of NIR light is that the biological tissues have very
low autofluorescence in the NIR range. Endogenous fluorophores (e.g., NADH, FAD, and
porphyrins) present in the biological tissues emit strong fluorescence mainly in the UV and visible
range. Employment of fluorophores emitting NIR light can avoid overlap with background
autofluorescence, thus resulting in a very high target signal-to-background contrast. Because NIR
light is invisible to unaided human eyes, the use of NIR fluorophores in surgery will not alter the
intraoperative white-light image of the cut area, thus allowing the surgeon to perform the normal
surgical procedure without color interference. Considering the discussed advantages of NIR light,
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development of molecular agents that emit light in the optimal “NIR window” are in great demand
for the pre-clinical and clinical whole-body imaging.

Figure 1.3 Absorption spectra of water, and oxy- and deoxy-hemoglobin in the visible to NIR
wavelength range.4
1.3.3

Bioluminescence Imaging
Bioluminescence is another useful optical technique for imaging of tissue in small

laboratory animals.29, 60 The bioluminescence signal (photons) is generated by the simultaneous
presence of luciferase, enzymatic substrate luciferin, adenosine triphosphate (ATP), Mg 2+, and
O2; Figure 1.4. In this process, luciferase catalyzes the oxidation of luciferin, the latter producing
photons in the visible range ( = 537 nm). Although numerous types of luciferases are available
for bioluminescence, such as the firefly (Photinus pyralis) luciferase, the marine copepod
(Gaussia princeps) luciferase, and the sea pansy (Renilla reniformis) luciferase, firefly luciferase
is the most commonly used one due to its rapid reaction rate and high luminescence efficiency.6061

In contrast with fluorescence imaging, bioluminescence imaging does not require excitation

light, thus making the route free of phototoxicity and autofluorescence effect. Due to the minimal
background

bioluminescence

of

tissues

and

enzyme-catalyzed

signal

amplification,

bioluminescence is a very sensitive technique for in vivo imaging.32 This technique has found its
broad application for studying gene transcription,62-64 tracking tumor growth and metastasis,65-66
imaging of infectious diseases,67-69 and so on.70 However, several drawbacks of bioluminescence
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remain. The light produced by firefly luciferase has a broad emission spectrum with a peak around
560 nm, thus making it prone to tissue absorption. Luciferase variants with longer emission
wavelengths are preferred to increase their tissue penetration depth. Compared to fluorescence,
the number of photons produced by bioluminescence is small, thus requiring the CCD detector to
be very sensitive. Specialized CCD detectors in a light-tight box under super-cooled conditions
are required to reduce noise and increase signal.71 Considering the light-production process is
influenced by the presence of many species, detector efficiency, and tissue attenuation, the
collected light intensity might not quantitatively represent the expression level of luciferase.60 The
requirement of luciferase gene transfection hinders its application in humans. Despite the
disadvantages, bioluminescence is still a powerful tool to study biological processes in pre-clinical
animal models.32

Figure 1.4 Schematic representation of bioluminescence mechanism. Firefly or click beetle
luciferase enzyme expressed in cytoplasm of engineered cells catalyze the substrate luciferin to
produce light photons in the presence of oxygen and ATP.
1.4

Fluorophores
Fluorophores are a group of fluorescent molecules capable of re-emitting photons upon

excitation by light. They act as signal-generating reporters in the design of molecular imaging
agents and determine the efficiency and sensitivity of the monitoring process for the biological
species/events. Generally, fluorophores are divided into three types—inorganic nanoparticles
(e.g., semiconductor quantum dots (QDs) and upconversion nanoparticles), 72-74 genetically
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encoded proteins (e.g., green fluorescent protein (GFP)),75 and small organic molecules (e.g.,
fluorescein, ICG, and MB),76 Figure 1.5.

Figure 1.5 Representative materials from the three categories of fluorophores – quantum dots
(fluorescent inorganic nanoparticles), green fluorescent proteins (genetically encoded proteins),
and fluorescein (small organic molecules).
1.4.1

Fluorescent Inorganic Nanoparticles (FINPs)
Over the last few decades, a large variety of fluorescent nanoparticles have been

developed and applied in materials science and biomedical research.77-79 Fluorescent
nanoparticles are a group of fluorescent materials with a size in the nanometer range. There are
two general categories of fluorescent nanoparticles: organic-based nanoparticles (polymer- and
lipid-based nanocarriers containing fluorescent organic dyes) and inorganic nanoparticles. 80
Fluorescent inorganic particles (FINPs) are prepared with inorganic materials, mainly including
QDs, silica nanoparticles, upconversion nanoparticles, noble metal nanoparticles, and carbon
dots.81 Their fluorescence is generated either from their intrinsic electronic properties or from the
encapsulation of fluorescent species. Due to the characteristic optical properties of FINPs, such
as high photostability, high fluorescence efficiency, tunable excitation/emission wavelengths,
narrow emission bands, and fluorescence not being affected by the biological microenvironment,
they have been explored as fluorescent reporters in various applications, such as in vivo
fluorescence imaging,79 intracellular analyte sensing,82 photodynamic therapy,83-84 and
immunoassays.81, 85 The enhanced permeability and retention (EPR) effect is a well-established
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phenomenon in which nanometer-sized particles tend to passively accumulate in tumor sites.
FINPs with an appropriate size (> 5 nm) can be coupled to the EPR effect so as to detect and
image tumors.86 Although the EPR effect for small-sized (< 5 nm) FINPs is counterbalanced by
their diffusion out from tumor sites, they can be conjugated with tumor-targeting ligands to
enhance their tumor imaging ability and improve the signal-to-background ratio.72
QDs have outstanding fluorescence properties and have been one of the most studied
and employed FINPs.87-89 QDs are small semiconductor particles composed of elements from the
II-VI, III-V, and IV-VI periodic groups, such as ZnO, ZnS, CdSe, InP, and PbS. The sizes of QDs
(typically 2–12 nm) are comparable to the exciton Bohr radius, resulting in the quantum
confinement effect.81 The created band gaps of QDs are directly correlated to QD size. The bigger
is QD size, the smaller the energy level of the band gap. Therefore, QDs with the same
composition can emit light with different wavelengths if their size is properly adjusted. Due to the
advantages of QDs, such as broad absorption band, narrow and size-tunable emission band, and
good photostability, QDs are attractive in various applications for bioimaging and biomedical
diagnostics.90-91 The hydrodynamic sizes of QDs greatly affect how the QDs are expelled by the
body. Although QDs with small sizes (5–6 nm) are eliminated rapidly through urinary excretion
and thus have low toxicity, QDs with bigger sizes stay in reticuloendothelial system organs such
as liver and spleen for a long time and are cleared through hepatobiliary excretion, thus leading
to high toxicity.92-93 To improve the biocompatibility of QDs, QDs can be coated with hydrophilic
polymers (e.g., poly(ethylene glycol) (PEG)). The propensity of QDs to nonspecifically bind to
proteins is reduced by the coatings, thus yielding QDs having less non-specific cellular uptake
and longer circulation times.94 QDs can also be conjugated with targeting ligands to improve their
selective accumulation in the targeted area.95 Although organic coatings and targeting ligands
improve the biological performance of QDs, they also increase their size, thus making them more
toxic in some cases. Another toxicity concern hindering the further clinical applications of QDs is
the existence of toxic elements (e.g., cadmium and arsenic) in their composition. To overcome
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this problem, development of QDs with appropriate sizes and without heavy metal doping may
make their clinical applications more promising.96-97 Silicon QDs do not contain heavy metals, but
they exhibit size-dependent fluorescence; they are an alternative to conventional QDs.98 The
drawback for silicon QDs is that their fluorescence efficiencies are weak in comparison to
conventional QDs. Reducing the size of silicon QDs and doping with impurities are the main
strategies to improve their fluorescence performance.99-100
Upconversion nanoparticles (UCNPs) are another class of FINPs with unique optical
properties.101-103 UCNPs consist of an inorganic host and trivalent lanthanide dopants (Ln3+), and
usually have sizes less than 100 nm. The emission of UCNPs arises from the 4f-4f or 4f-5d
transitions of the lanthanide dopants. In contrast with other fluorophores, UCNPs can emit shortwavelength light when excited by multiple photons of a longer wavelength. Because Ln3+ ions
have various energy levels of 4f orbitals and 4f-4f transitions, the upconversion emission of
UCNPs is caused by different mechanisms, mainly excited state absorption (ESA), photon
avalanche (PA), and energy transfer upconversion (ETU).104 Among the Ln3+ ions, ytterbium
(Yb3+), erbium (Er3+), thulium (Tm3+), and holmium (Ho3+) have relatively high upconversion
efficiencies, thus resulting them being the mostly used dopants in UCNPs. The selection of host
materials is also critical to maintain or enhance the upconversion efficiency of UCNPs. The host
materials should have high light transparency and low phonon frequency.101 In this regard, rare
metal fluorides are often used as the host material. The upconversion phenomenon was first
recognized in the 1960s and has been applied in solid-state lasers and solar cells.105 The
advancement of nanotechnology over the last decade has greatly broadened the applications of
UCNPs in biological fields, including biological labeling,106 photodynamic therapy,84 multimodal
imaging,107-108 cell and tissue imaging,109 and in vivo animal imaging.110-111 UCNPs have several
beneficial optical properties for these applications. The optical properties of UCNPs includes
narrow absorption and emission bands, long luminescence lifetimes, and high photostability.
More importantly, UCNPs can be excited by NIR light, thus resulting in a low background
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autofluorescence signal. Chatterjee et al. first studied the in vivo imaging of UCNPs
(polyethyleneimine-coated NaYF4:Yb,Er nanoparticles) in small animals and found that UCNPs
exhibited strong fluorescence with deep tissue penetration and high photostability. 110 However,
several disadvantages of UCNPs hinder their further applications. UCNPs are usually too large
and their cellular toxicity is high due to heavy metal leakage. In addition, the water solubility of
UCNPs is often very low; although surface modification can increase their water solubility, this
method is time-consuming, increases particles sizes, and it potentially affects the luminescence
efficiency.103 Because UCNPs normally have low luminescence efficiencies at present,
development of UCNPs with smaller dimensions and brighter luminescence will greatly contribute
to their further applications in imaging avenues.
Noble metal nanoparticles and carbon dots are two other groups of FINPs. Although there
is no valence-conduction bandgap in bulk-sized metals, the bandgap exists in metals having
dimensions in the nanometer range due to structural discontinuity, thus leading them to fluoresce
upon appropriate excitation.112 Gold, silver, and recently copper, are broadly investigated noble
metals to form fluorescent nanoparticles. Sensing and intracellular imaging applications of noble
metal nanoparticles have also been widely studied.113 Difficulty in precise control of the size, and
low fluorescence efficiency of noble metal nanoparticles are the main challenges for their
development. Carbon dots are a new type of FINPs that have attracted lots of attention recently.
Although the reason that carbon dots are fluorescent remains unclear, several possible
mechanisms have been proposed, such as quantum confinement effect and the presence of
defects on the surface.114-115 Because carbon dots have the advantages of tunable
absorption/emission wavelengths, biocompatibility, photostability, low molecular weight, and low
toxicity, they are also used in sensing and imaging.116
1.4.2

Fluorescent Proteins (FPs)
Another large family of fluorophores is that based on FPs, which have become an essential

tool for current cell biology study.117 Since the green fluorescent protein from Aequorea victoria
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jellyfish (avGFP, ex = 395, 475 nm, em = 508 nm, and  = 0.8) was genetically encoded and
expressed in cells in 1994, great efforts have been made to engineer and explore more FPs with
improved biochemical and fluorescent properties.117-118 Besides avGFP and its mutants, the
discovery of more prototypical FPs and their mutants (e.g., DsRed, mFruit, eqFP, TagRFP, to
name a few) greatly enriched the FP family. Currently, a large variety of FPs emitting light covering
the entire visible light spectrum are available, Figure 1.6.75

Figure 1.6 An ensemble of fluorescent proteins which are derived from Aequorea GFP or
Discosoma RFP. Their emission light covers the entire visible light spectrum from 440 nm to 650
nm. This photo is a time exposure of fluorescence excited at different wavelengths and viewed
through different cutoff filters.75
The fluorescence of GFPs originates from the small-molecule imidazolinone derivatives
embedded within the FPs.118 The principle fluorophore of GFP is formed by three adjacent amino
acids—serine, tyrosine, and glycine at the positions of 65, 66, and 67, Figure 1.7. Its location at
the center of a rigid and hydrophobic -barrel consists of 11 -sheets, which play crucial roles in
the formation and fluorescence of the fluorophore.119 The amino group of Gly-67 first attack the
carbonyl group of Ser-65, resulting in a heterocyclic ring system. Subsequent oxidation by O2
gives the fluorescent conjugated imidazolinone fluorophores. The fluorophore formation process
is known as protein maturation. Although the synthetic analogs of the imidazolinone derivatives
are non-fluorescent by themselves, they are highly fluorescent in GFPs, due to their restricted
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molecular structure.120 Therefore, changes of the environment around the fluorophore can greatly
alter its photophysical properties (absorption/emission wavelength, fluorescence efficiency, and
photostability). Mutations of the FP residues are often employed to improve the fluorescent
properties of FPs (e.g., higher brightness ( × ) and longer emission wavelength), optimize the
maturation rate of FPs at 37 °C, enhance protein expression, and prevent oligomerization.121-124
For example, the single point mutation S65T in GFP greatly increased the brightness and
photostability of the mutant.125 The F64L mutation of GFP (EGFP) significantly improved the GFP
maturation rate at 37 °C, thus making efficient the formation of fluorescent GFP under cellculturing conditions.126

Figure 1.7 The formation steps of the principle fluorophore in GFP.127
Because most FPs themselves are fluorescent without the need of cofactors or substrates,
they are excellent tools to visualize biological structures and processes, and monitor gene
expression in cells and living organisms.117, 128 Methods for their expression in bacteria, mammals,
and human cells have been established. By fusing specific gene products expressing proteins of
interest with gene sequences of FPs and transfecting the fused gene sequences into cells, the
localization, movement, and turnover information of the targeted proteins in cells can be
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monitored. FPs can also be modified to act as biosensors to report biological events,129 measure
calcium ions,130 sense transmembrane voltage,131 and ablate cells.132-133 For example, by
connecting CFP and YFP with a kinase C specific peptide, Violin et al. reported a genetically
encoded reporter, which can reversibly detect kinase C activity in Hela cells.134 A genetically
encoded singlet-oxygen-generator protein, miniSOG, was reported by Qi et al. to selectively
induce cell ablation with light in Caenorhabditis elegans.133 Despite their useful applications, there
remain several concerns with the utilization of FPs. FPs have relatively large dimensions (2–4 nm)
and molecular weight (~ 25 KD), potentially interfering the function of targeted proteins. Compared
to other fluorophores, FPs have low photostability, thus they easily lose their signaling ability. The
overexpression of FPs relative to endogenous proteins in cells can disrupt the cellular physiology,
and thereby being toxic. To acquire fluorescence of FPs in cells, gene sequences of FPs must be
transfected into host cells, thus making FPs unsuitable for clinical applications.
The last two decades have led to tremendous success in the engineering of a wide array
of GFPs with improved properties, including high brightness, good photostability, efficient
expression in cells, reduced oligomerization and toxicity, and increased resistance to
environmental perturbations (e.g., pH, ionic concentrations, and solvent polarity); these effects
have resulted in their extensive applications in cell biology. However, most of them fluoresce in
the visible light energy range, and engineering of various NIR fluorescent FPs (IFPs) remains a
big challenge.57 Because IFPs can not be obtained through modifications of GFPs, other
prototypical FPs, such as bacterial phytochromes (BphPs), have been investigated as templates
to engineer IFPs.117 Biliverdin (BV) can bind to BphPs and is the fluorophore responsible for their
fluorescence. Like the principle fluorophore for GFPs, BV is non-fluorescent by itself and becomes
fluorescent upon binding to BphPs. Based on the template, Shu et al. developed IFP1.4 (ex =
684 nm, em = 708 nm, and  = 0.07) and first applied it for deep tissue imaging in mammalian
animals.135 IFP 2.0, the improved version of IFP1.4, was applied to monitor neuronal processes
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in Drosophila larvae and image brain tumors in mice.136 iRFP (ex = 690 nm, em = 713 nm, and

 = 0.06) was also engineered from RpBphP2 and used for imaging mouse liver.137 Although it
has a slightly lower fluorescence efficiency than IFP1.4, it exhibited higher brightness in cells due
to its more effective binding to endogenous BV. However, one drawback of BphP-derived IFPs is
that their fluorescence relies on the concentration of BV. Therefore, the exogenous addition of
BV, or co-expression of heme oxygenase 1 (HO-1) that produces BV by metabolizing heme, is
required. Besides the BphP-derived IFPs, a new group of IFPs was engineered from an
allophycocyanin -subunit (APC), such as smURFP (ex = 642 nm, em = 670 nm, and  =
0.18).138
1.4.3

Small Organic Molecular Fluorophores
Small organic fluorophores have been a powerful tool for visualizing biological

species/events in cells and living organisms, ever since the discovery of the first organic
fluorophore, quinine sulfate, in 1845.139 Before the advent of genetically encoded fluorophores in
the 1990s, small organic fluorophores were the only choices for labeling biomolecules and
staining cells. Without a doubt, small organic fluorophores have paved the way for, and will
continue to contribute to our understanding of the dynamic and complex biological processes in
living subjects.76, 140-146
Small organic fluorophores typically have molecular weights less than 1500 Da and
dimensions less than 1 nanometer, thus allowing their attachment to proteins of interest without
affecting the functions and nature of the proteins. Their widespread applications also benefit from
their immediate availability, either from large commercial supplies or from facile synthesis in the
laboratory. By applying modern organic chemistry strategies, their well-defined chemical
structures can be easily and efficiently modified to provide the desired optical and chemical
properties. Many biosensors can be constructed by attaching fluorophores to specific functional
groups including pH-responsive groups, receptor-targeting moieties, enzymatic substrates, and
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metal-chelating components. Although countless fluorescent molecules with various applications
are now present, most of them are based on a small number of fluorescent platforms with
conjugation structures, Figure 1.8.140 Among them, the most investigated fluorescent platforms in
the visible and NIR range include fluorescein, rhodamine, borondipyrromethane (BODIPY),
porphyrin, and cyanine.

Figure 1.8 Core structures of common small molecule fluorophores.
Fluorescein is one of the most used and versatile fluorophores for biological labeling, and
it was the first one approved by the FDA for clinical applications.147 Protein-labeling probes can
be easily constructed by appending amino or thiol-reactive groups on the fluorescein core (e.g.,
succinimidyl and maleimidyl fluorescein derivatives, and fluorescein isothiocyanate (FITC)).
Fluorescein has a xanthene structure with absorption/emission wavelengths in the visible light
range. The dianion form of fluorescein is the most fluorescent form with a pKa ~ 6.4, thus allowing
it to act as a pH sensor to monitor pH changes in cells. 148 However, the pH-dependence makes
fluorescein-based probes unsuitable for quantitative analysis. To overcome this drawback, 2’,7’difluoro fluorescein (Oregon Green) was developed with a lower phenolic pKa at 4.6 due to the
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decreased electron density of the fluorescein core, thus making Oregon Green suitable for
applications under acidic conditions. Another property of fluorescein is that it can exist in either
an “open” fluorescent quinoid form or a “closed” non-fluorescent lactone form. Caging both sides
of the oxygen atoms with analyte-responsive groups can make fluorescein exist in its nonfluorescent lactone state, thus yielding non-fluorescent probes. For example, probes to detect galactosidase and esterase were developed based on this property.149-151 Although it had been
believed for a long time that the carboxylic group of fluorescein was indispensable for the strong
fluorescence of fluorescein, in 2005, Urano et al. demonstrated that the role of the carboxylic
group is to hinder rotation of the benzene moiety.152 Replacing the carboxylic group with a methyl
group yielded a group of fluorescein derivatives (TokyoGreens) having strong fluorescence.
Modifications to the xanthene core of fluorescein were used to shift the absorption/emission
wavelengths. By replacing the oxygen atom of the xanthene core with a gem-dimethyl group,
Grimm et al. constructed carbofluorescein that exhibits red-shifted absorption/emission
wavelengths with a high quantum efficiency under basic conditions.153 However, the pKa of
carbofluorescein is around 7.4, thus making it suffer from severe pH influences in biological
environments. Grimm et al. further fluorinated the carbofluofluorescein structure, thus yielding
2’,7’-difluorocarbofluorescein (Virginia Orange) with a slightly decreased pKa at 6.75.154
Substituting the xanthene oxygen with a dimethylsilyl group yielded another class of fluorescein
derivatives (TokyoMagentas) with large red-shifted absorption/emission wavelengths.155-156
Despite its widespread applications, fluorescein suffers from several disadvantages including low
photostability, fluorescence quenching upon binding to biopolymers, broad absorption/emission
spectra, cellular impermeability, and cellular expulsion due to its negative charge.
Rhodamines, another large family of fluorophores possessing xanthene structures, share
several similar optical and chemical properties with their counterpart fluorescein. In contrast to
fluorescein,

rhodamines

exhibit

several

advantages

including

longer

and

tunable

absorption/emission wavelengths, pH-independence, and higher photostability. A large number
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of rhodamine derivatives with various applications are commercially available (e.g., Rhodamine
6G, Rhodamine 123, Rhodamine B, Texas red, Rhodamine 800, to name a few). Masking both
amino moieties of rhodamine results in the non-fluorescent “closed” lactone form that has been
exploited to design latent fluorescent probes to detect enzymes.157-158 The carboxylic group of
rhodamine can be replaced with mercapto-methyl and hydroxymethyl groups to improve the
spirocyclization efficiency.159-160 The rhodamine with the mercapto-methyl group exhibits a strong
spirocyclization tendency due to the strong nucleophilicity of the sulfhydryl group, thus requiring
harsh chemical reactions to open the five-membered ring and reveal its fluorescence. On the
other hand, hydroxymethyl rhodamine green (HMRG) has a moderate spirocyclization tendency
and has an open/closed equilibrium in aqueous solutions. By appending electron-withdrawing
groups such as acetyl to the amino group of HMRG, the resulting HMRG analog is mainly present
in non-fluorescent close form. This strategy is of great use for developing latent fluorescent probes
to detect enzymes.161-162 To improve the brightness of rhodamine, the N,N-dimethylamino group
in tetramethylrhodamine (TMR) was replaced with a rigid four-membered group azetidine, which
resulted in a rhodamine derivative with higher fluorescence efficiency than its parent molecule
due to inhibited nonradiative decay.163 This strategy also applies to other core fluorescent
scaffolds (e.g., coumarin, naphthalimide, and rhodol). Similar to fluorescein, substitution of the
xanthene oxygen atom with carbon and silicon atoms yielded carborhodamine and Si-rhodamine
with large bathochromic shifts (respectively 55 nm and 90 nm).153, 164-165 The absorption/emission
wavelengths of Si-rhodamine can reach the NIR range, thus making it promising for in vivo
applications. Other atomic substitutions (e.g., P, Ge, Sn, Se, and Te) were also widely
investigated to improve the photophysical properties of rhodamine.153
Another effective strategy to build useful fluorescent scaffolds with unique optical and
chemical properties is to craft hybrid fluorophores. An example is Rhodol that has a hybrid
structure of fluorescein and rhodamine, and it has low pH-dependence, high fluorescence
efficiency, and high photostability.166-167 In contrast to fluorescein, rhodol has only one phenolic
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moiety, which can be masked to form the non-fluorescent closed form. By replacing the carboxylic
group with a hydroxymethyl group, Urano et al. synthesized a series of rhodol derivatives, which
were utilized to develop several latent fluorescent probes for the detection of enzymes. 168-169 By
extending the conjugation of the xanthene core, Lin et al. developed a series of xanthene-cyanine
fused fluorophores (Changsha dyes) with NIR absorption/emission wavelengths.170-171
Since the first synthesis of BODIPY in 1968, it has played an important role in biological
imaging.172-174 BODIPY exhibits several unique optical properties, including high photostability,
high extinction coefficient, high quantum yield, narrow absorption/emission bands, pHindependence, and environmental insensitivity, thus allowing it to be especially useful in protein
labeling and multicolor imaging. These properties can be attributed to its highly rigid structure.
BODIPY dyes are usually hydrophobic and have a net charge. These properties are beneficial for
the binding of their ligand conjugates to receptors; however, these characteristics can also result
in low water solubility. The biolabeling field has also benefited from the large quantity of
commercially available amine- and thiol-reactive BODIPY dyes. For example, BODIPY dyes can
be functionalized with succinimidyl esters, carboxylic acids, acid halides, and maleimides, suitable
for immediate target moiety conjugation. Most of the conventional BODIPY dyes absorb and emit
light in the visible light range. To increase their absorption/emission wavelengths, extended
conjugation groups are often incorporated into the core structure of BODIPY. 175 However, this
strategy often leads to increased hydrophobicity, thus limiting their biological applications under
aqueous conditions. By replacing the meso-carbon atom of BODIPY with an imine type nitrogen
atom, the aza-BODIPY scaffold results. Aza-BODIPY attracts great attention because it has NIR
absorption/emission wavelengths while maintaining the optical advantages of conventional
BODIPY.
The cyanine dyes are a large class of fluorophore molecules, whose structures include
two nitrogen-containing aromatic rings connected by a polymethine conjugated chain.176-177
Depending on number of the double bonds in the polymethyl chain, cyanines can have different
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absorption/emission wavelengths, ranging from the visible range to the NIR range (e.g., Cy3, Cy5,
and Cy7). Numerous functionalized cyanine dyes are available for DNA and protein labeling. For
example, cyanines can be conjugated with N-hydroxysuccinimidyl, maleimide, or isothiocyanate
groups to form amine- and thiol-reactive labeling agents. Within the cyanine family, heptamethine
cyanine dyes have been the most investigated, due to their NIR absorption/emission wavelengths
that are suitable for in vivo applications.178 Most of the currently used NIR fluorescent agents are
based on the heptamethine scaffold. Besides ICG, several heavily investigated heptamethine
cyanine dyes are IR-780, IR-783, IR808, IRDye800-CW, ZW800-1, and MHI-148. IRDye800-CW
and ZW800-1 have recently been approved for clinical trials. Most cyanine dyes are prone to
aggregation in aqueous solution, leading to their decreased fluorescence efficiency. To solve this
challenge, cyanine dyes are often modified with sulfonate groups that increase dye water solubility
and photochemical stability, while also decrease cytotoxicity. However, it might result in a cellular
impermeability problem. Although cyanine dyes normally have reasonable quantum yields in
organic solvents, their quantum yields in aqueous solutions are low, because the vibration of the
flexible polymethine chain leads to energy losses in this non-radiative pathway. Incorporation of
chloro-cyclohexenyl or chloro-cyclopentenyl groups into the central polymethine chain rigidifies
the cyanine structure, resulting in improved quantum yields.179-180 Further substitution of the
chlorine atom with oxygen, sulfur, or nitrogen leads to the formation of new heptamethine
fluorophores with unique photophysical properties.181-183
1.5

Fluorescent Probes in Cancer Imaging and Design Strategies
The advancement of optical imaging modalities has revolutionized the fields of cell biology,

biomedical research, and in vivo imaging. In the FGS area, administration of exogenous
fluorescent probes is required to enhance the visualization of tissue structures, monitor blood and
lymphatic flows, and determine the location of tumors and margins between healthy tissue and
tumor lesions.44,

46, 56

Therefore, development of specific fluorescent probes to enhance

visualization are in great demand. Although fluorescent imaging probes can be designed based
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on all the previously discussed fluorophores, small-molecule, fluorophore-based fluorescent
probes hold the most promise for in vivo imaging and clinical applications, and thus will be the
focus in the following discussions. Most of the current fluorescent probes can be divided into three
categories: passive always-on probes, targeting always-on probes, and activatable probes,
Figure 1.9.184

Figure 1.9 Illustration of the different modes of action for signal generation with the three
categories of fluorescent probes.184
1.5.1

Passive Always-On Fluorescent Probes
The target-to-background (TBR) contrasts for passive always-on probes are based on

their passive accumulation and non-specific biodistribution in tissues. To date, all the current FDAapproved fluorescent probes (fluorescein, ICG, MB, and 5-ALA) belong to this category. For
fluorescence tumor imaging applications, passive always-on fluorescent probes can accumulate
in or around tumors. Fluorescein was the first fluorophore used for tumor identification, and it can
be used for identifying brain tumors during neurosurgery.51,

185

ICG is a well-known NIR

fluorescent probe with very low toxicity, and it is historically employed in lymph node mapping,
angiography, cardiac output, and hepatic function.46, 56 Because ICG is primarily removed by the
liver, it is intraoperatively applied to identify primary hepatocellular carcinomas and hepatic
metastases.186-187 Horowitz et al. reported that ICG accumulated in ovarian metastases upon its
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intravenous injection.188 They proposed that the binding of ICG to proteins increases its
hydrodynamic diameter, thus enabling accumulation of ICG in tumors due to the EPR effect. The
dark blue dye MB can be used as an NIR fluorophore when sufficiently diluted; also, it was recently
approved by the FDA for clinical uses. Although its accumulation mechanism in tumors is unclear,
MB has been used to differentiate primary and metastatic insulinomas from normal pancreas
tissues and other abdominal structures.189 5-ALA is a substrate molecule in the synthesis of the
fluorescent protoporphyrin IX, which takes place mainly in epithelial and neoplastic tissues. It has
been used for identifying several cancers, including gliomas,190 oral malignant lesions,191 and
bladder cancer.192 Because 5-ALA has photodynamic activities, its use for cancer imaging should
be carefully managed due to the high risk of skin sensitization. Although a large number of
fluorophores are available, only two new fluorophores are currently undergoing clinical trials
(IRDye800-CW and ZW800-1).193-194 These types of probes have no inherent specificity for tumors,
and their success for providing meaningful tumor imaging relies heavily on the tissue clearance
pathway of the probes.
1.5.2

Targeting Always-On Probes
To improve the specific accumulation of probes in targeted areas, a new approach

requires conjugation of the fluorophores to targeting ligands (e.g., antibodies, peptides, and folic
acids) that specifically bind to the overexpressed receptors on tumor cell membranes.1, 195 The
targeting ligands can allow for their binding to their respective receptors upon fluorophores
delivery to the targeted area, thus increasing the fluorophore accumulation and retention at the
targeted site. This design strategy can also benefit from the availability of both the FDA-approved
antibodies and fluorophores. For example, bevacizumab, an FDA-approved monoclonal antibody,
was conjugated to IRDye800-CW, and the afforded probe has been used to visualize vascular
endothelial growth factor (VEGF) specific tumors in clinical trials.196 Prostate-specific membrane
antigen (PSMA),197-198 v 3 integrin,199 epithelial growth factor receptor (EGFR),200 matrix
metalloproteinase-2 (MMP-2),201 and folate receptor   are among the most investigated
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surface receptors that have been targeted to develop fluorescent probes. Several developed
probes based on this strategy have undergone clinical trials. One example is the intraoperative
detection of ovarian cancer metastases with a folate-receptor-targeted fluorescent probe
OTL38.202 With the aid of OTL38, the surgeons were able to remove 29% more malignant lesions
that were not identified under white light illumination; during surgery, this proved the usefulness
of targeting probes in clinical applications. Although these targeting always-on probes hold
advantages over passive always-on probes, they still suffer from several drawbacks. The TBR
contrast generated by this type of probe relies on the effective accumulation and retention of the
probes, as well as rapid clearance of the unbound probes. Therefore, a long waiting time after
their i.v. administration is typically required to acquire adequate TBR contrast. Also, the
receptor/probe binding does not allow the fluorescence signal amplification. The large size of the
antibody conjugated probes often increases their circulation time in the body, thus resulting in a
high background signal. The EPR effect that results from large probe size also interferes with
efficiency of receptor-binding. Because the optical and chemical properties of fluorophores can
also be altered by the large size of the conjugated antibody, the fluorescence efficiency and
toxicity data of the fluorophores need to be further validated. The TBR contrast is also
compromised by the low receptor expression level of tumor lesions. The number of surface
receptors per cell is around 104, which can lead to a bound probe concentration around 17 nM,
assuming the probe/receptor binding ratio of 1:1.30 Therefore, even though the targeting strategy
can improve the tumor-specific accumulation of the probes, the large fluorescence background
caused by unbound fluorescent probes can often result in low TBR values.
1.5.3

Activatable Fluorescent Probes
Tumors have different physiological properties (e.g., pH, pO2, proteases, and enzymes)

from normal tissues, which can be exploited to design activatable probes.1, 4, 6, 184, 195, 203 These
kind of probes are nonfluorescent in their unactivated state due to various quenching mechanisms.
However, upon interacting with a tumor-specific target, the fluorescence quenched probes are
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activated, thus releasing highly fluorescent fluorophore. Tumor-specific enzymes can act as
catalysts, amplifying the fluorescence signal. The lower fluorescence emission of unactivated
probes gives decreased background, thus significantly improving the TBR contrast compared to
always-on probes. Weissleder et al. attached several NIR fluorophores based on Cy5.5 to a polyL-lysine

backbone to yield a non-fluorescent probes, due to fluorophore autoquenching.204 Upon

intravenous injection into a preclinical animal model, the probe accumulated in solid tumors,
where was released the fluorescent fluorophores via lysosomal proteases; this approach gave
the adequate tumor detection with a high TBR (12:1). Urano et al. developed a target-cell-specific
activatable probe by conjugating a pH-sensitive BODIPY dye to the monoclonal antibody
trastuzumab.205 The probe first binds to human epidermal growth factor receptor type 2 (HER2)
upregulated in lung cancer cells, then it is internalized by cells through endocytosis, and the dyes
becomes fluorescent in the acidic endosomes/lysosomes. LUM015 is the first activatable probe
approved for clinical trials to detect soft-tissue sarcomas and breast cancer.206 LUM015 was
formed by connecting a NIR Cy5 fluorophore and a QSY21 quencher with a pan-cathepsin GlyGly-ARG recognition sequence. The fluorescence of LUM015 is quenched in its unactivated state
in normal tissues. However, in a variety of tumors that overexpress a capthesin protease, the
covalently attached QSY21 quencher is eliminated, thus revealing the fluorescence of the Cy5.
Most of the current activatable fluorescent probes are activated with extracellular and
membrane enzymes. The released fluorophores may diffuse out of the tumor region, leading to
decreased tumor signal, and an increased background signal. To address the diffusion issue,
lipids,207 PEG linkers,206 amide bonds,208 or cell-penetrating peptides209-210 have been appended
on the probe structures to enhance signal retention. By exploiting the cell-penetrating peptide
strategy, Tsien and his colleagues have developed several activatable probes to detect
thrombin211 and matrix metalloproteinases (MMPs).209, 212 However, as previously discussed, the
large size of these polymer, antibody, and peptide-based activatable probes can result in slow
uptake into tumors and a long time (hours to days) to dequench the fluorescence, making it difficult
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to incorporate them into the intraoperative surgical workflow. Activatable fluorescent probes
based on small organic fluorophores with rapid tumor uptake, and effective enzymatic kinetics,
hold the most promise to overcome the mentioned challenges. Urano et al. developed a smallmolecule substrate probe, gGlu-HMRG, to detect -glutamyltranspeptidase (GGT) that is
overexpressed on the cell membrane in various tumor cells.161 Upon topically spraying the probe
on implanted tumors in a living mouse, an immediate fluorescence increase in tumors (< 5 min)
was detected endoscopically. Peritoneal administration of gGlu-HMRG also enabled the
successful visualization of small-foci (< 1 mm in diameter) ovarian cancer metastases.
To acquire the activatable probes with desired photochemical properties, the fluorescence
of the developed probes needs to be modulated. This can be achieved through various
mechanisms, such as fluorescence resonance energy transfer (FRET),213-214 photo-induced
electron transfer (PeT),152, 215 intramolecular charge transfer (ICT),181, 216 and spirocyclization of
xanthene dyes.160,

217

These strategies can lead to two general impacts on the fluorophore:

quench/decrease the fluorescence intensity and shift the absorption/emission wavelengths. FRET,
the most explored mechanism, involves two homo/hetero fluorophores in close proximity (1–10
nm) allowing the energy to be transferred from one fluorophore (the donor) to the other (the
acceptor) due to dipole-dipole interactions. To achieve efficient energy transfer, the emission
spectrum of the donor is required to have a significant overlap with the absorption spectrum of
the acceptor. If the two fluorophores are identical, they absorb energy from each other’s excited
state leading to a diminished fluorescence of the entire system (self-quenching). If the
fluorophores are different, the donor, in its excited state, transfers energy to the acceptor, and the
FRET pair either emits the photons from the acceptor or the donor is quenched by the acceptor.
In both homo- and hetero-FRET systems, breaking apart the two fluorophores by targeted
species/events can make them fluoresce in the wavelength range of the donor. However, because
FRET efficiency is greatly influenced by the distance between the donor and the acceptor, the
FRET pair is sensitive to the environmental factors, such as pH, polarity, and viscosity.
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PeT is another widely explored fluorescence quenching strategy for the development of
activatable probes. Unlike a FRET pair that requires the existence of at least two fluorophores,
the PeT system requires only one fluorophore, that can act as either the electron donor (d-PeT)
or the electron acceptor (a-PeT) to complete the electron transfer with neighboring
electron-deficient/-rich moieties. Both d-PeT and a-PeT processes can significantly decrease the
fluorescence intensity of the fluorophore. Cleavage or changing the electronic state of the
electron-deficient/-rich groups by specific targets can inhibit the electron transfer, thereby
revealing the fluorescence. Fluorophores with ICT properties have both electron-donating and
electron-withdrawing groups, and exhibit a different dipolar moment of the excited state from that
of the ground state. Caging the electron-donating group can decrease the ICT effect, which leads
to a different absorption/emission profile. Therefore, caging/uncaging the ICT fluorophores can
be exploited to develop activatable fluorescent probes. Intracellular spirocyclization of xanthene
dyes (i.e., fluorescein and rhodamine) can break their conjugation structure, leading to
fluorescence quenching. It has become an effective strategy to develop activatable probes to
manipulate the open/closed state of the xanthene dyes. Some other fluorescence modulation
strategies include aggregation-induced emission (AIE), excited state intramolecular proton
transfer (ESIPT), and the combination of these and other mechanisms.
1.6

Enzyme-Activatable Fluorescent Probes
Enzymes are a large family of proteins that catalyze almost all metabolic processes in

living organisms and play fundamental roles to sustain life. Aberrant expression and changes of
their functionalities are related to the onset and progression of various human diseases, thus
making crucial the accurate and sensitive tracking of enzymatic activities in a dynamic manner
for diagnostics and treatment of the diseases. As discussed earlier, optical fluorescence imaging
is a highly sensitive technique for the study of biological processes. Therefore, development of
substrate molecules that can be specifically activated by the targeted enzymes will greatly aid the
direct visualization of their catalytic activities.2, 203, 218-219 The first example of visualizing enzymatic
31

activities is alkaline phosphatase detection in mammalian tissues by precipitating the enzymeproduced phosphate, as outlined by Gomori in 1939.220 In 1998, Tsien et al. developed a cellpermeable fluorescent probe to measure the enzymatic activity of -lactamase in living cells,
which opened the door for employing fluorescent substrate probes to study the physiological
functions of enzymes in living cells and living animals.221 Currently, a variety of diseaseassociated enzymes have been targeted to develop enzyme-activatable fluorescent probes.
Some common examples of targeted enzymes are phosphatases,222-224 esterases,225-229
peptidases,161,

230-232

-galactosidase,152,

168

-lactamase,221,

233

cysteine cathepsins,234-235

caspases,236-237 and human NAD(P)H: quinone oxidoreductase 1 (hNQO1).9-13
1.7

NAD(P)H: quinone Oxidoreductase 1 (NQO1)
NQO1 (EC 1.6.99.2) is a flavinprotein with a homodimer structure, which functions as a

two-electron reductase that catalyzes the reduction of quinones to hydroquinones using the
reduced nicotinamide adenine dinucleotide (phosphate), NAD(P)H, as cofactor.238 Each monomer
is composed of 273 residues and has two domains – a large catalytic domain and a small Cterminal domain. The two monomers interlock with each other and form two catalytic pockets at
the dimer interface, each non-covalently bounds to one adenine dinucleotide (FAD) molecule.239
The catalysis function follows a “ping-pong” bi-bi mechanism. In this mechanism, NAD(P)H binds
to the active site and transfers its hydride to the FAD molecule, and the resulting NAD(P) + is
subsequently displaced by quinone substrate molecules. The substrate molecules accept the
hydride from the reduced FAD (FADH) and are reduced to their hydroquinone forms. Depending
on the source, NQO1 has different amino acid sequences. For example, rat NQO1 (rNQO1) has
a higher enzymatic activity than mouse NQO1 (mNQO1), because of a different amino acids at
position 104 (tyrosine in rNQO1 and glutamine in mNQO1).240 Human NQO1 (hNQO1) has a
similar catalytic efficiency compared to mNQO1, due to the 94% similarity in their structures. A
single point nucleotide mutation (cytosine to thymidine, C609T) of the NQO1 gene leads to the
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amino acid substitution (proline to serine, Pro187Ser) at position 187 in the protein yielding a
variant enzyme NQO1*2.241 NQO1*2 exhibits significantly lower enzymatic activity and can be
rapidly ubiquitinated and degraded by the proteasome, resulting in complete loss of its function.
Because of this gene mutation, the non-small cell lung cancer cell line (H596) has no
demonstrable NQO1 activity.242 In humans, NQO1 has been found to be widely distributed in a
variety of cell types in widely different amounts, with the exception of the liver. NQO1 is
predominantly localized in the cytoplasm (> 90%) of cells.243-244
NQO1 plays multiple cytoprotective roles in living subjects, such as a radical scavenger,245
tumor suppressor protein (p53 and p73) stabilization,246 and detoxification of a broad range of
quinone substrates, quinone epoxides, and nitroaromatic compounds.247-248 NQO1 is reportedly
linked to tumorigenesis, and its upregulation is indicative of the early carcinogenic process. 7
NQO1 expression is regulated through the Keap1/Nrf2/ARE pathway that combats increased
cellular oxidative stress, Figure 1.9.249 In the normal cellular environment, the Keap1 (Kelch ECH
associating protein 1) binds to the transcription factor Nrf2 (nuclear factor E2-related factor 2) to
promote the degradation of Nrf2 through ubiquitination and a proteasomal degradation process.
However, in response to increased oxidative stress, Keap1 is oxidized and loses its ability to
target and degrade the Nrf2 transcription factor because of the oxidation of the reactive cysteine

Figure 1.10 Reductase expression in cells in response to increased oxidative stress through
Keap1-mediated Nrf2 regulation.
33

sites of the Keap1 protein. The stabilized Nrf2 transcription factor accumulates in the nucleus
where it binds to an ARE (antioxidant response element) sequence and triggers the transcription
of NQO1.250-252
The expression of NQO1 in numerous human solid tumors (e.g., pancreas, colon, breast,
ovarian, and non-small cell lung carcinoma) is 2- to 50-fold higher than the surrounding normal
tissue.7 Therefore, NQO1 has long been considered a biomarker for targeted anticancer therapy. 8
Compared to conventional anticancer drugs that usually have significant toxicity to normal tissues,
biomarker-directed anticancer prodrugs have selective toxicity to cancerous tissues, thus having
the potential to increase therapeutic effectiveness. Some quinone-based prodrugs (e.g.,
mitomycin C (MMC), E09, diaziqunone (AZQ), RH1, and -lapachone) can be converted to
cytotoxic drugs by the NQO1-mediated reduction process. Although mitomycin C in its original
state is inactive, reduction of mitomycin C by NQO1 or other reductases leads to the production
of a reactive alkylating molecule, which crosslinks and breaks the strands of DNA. 253

-

Lapachone is an NQO1-specific anticancer drug that is currently undergoing clinical trials for
pancreatic cancer.254 -Lapachone induces high levels of superoxide through the NQO1mediated redox cycle, which causes damage of DNA and extensive NAD+/ATP depletion,
ultimately leading to apoptosis of NQO1-overexpressing cells.
Although the upregulation of NQO1 in tumors has long been established and broadly
explored in the development and implementation of antitumor drugs, only recently has NQO1
been exploited as a biomarker to craft profluorogenic small molecule probes pioneered by the
McCarley research group.9-13,

158, 255-256

NQO1-activatable profluorogenic probes that target

elevated hNQO1 in solid tumors will be of great significance for understanding enzymatic
processes at the molecular level, developing tools to differentiate cancerous lesions from normal
tissues during surgery, and evaluating drug action and efficacy in vivo. Because NQO1 is an
intracellular enzyme mainly localized in the cytoplasm, the developed NQO1-specific probes are

34

internalized and activated inside cells, thus diminishing the diffusional loss of released fluorescent
reporters, which is beneficial for attaining a high TBR ratio. Silvers et al. developed the first latent
fluorescent probe, Q3NI, that was successfully used to differentiate NQO1-expressing and NQO1non-expressing cells via the unaided eye, flow cytometry, and fluorescence imaging.13 After that,
several other NQO1-activatable turn-on fluorescent probes were developed with improved
properties (e.g., improved TBR values and longer emission wavelength) and applied for detection
of NQO1 in the cellular environment.9-10, 12, 256 A summary of the developed probes for detection
of NQO1 is listed in Table 1.1. However, the probe/reporter systems have absorption/emission
wavelengths in the visible light range, which limit their further applications in vivo. Therefore,
development of the probe/reporter systems that emit light in the NIR range is in great demand for
in vivo applications. Besides the development of NQO1-activatable fluorescent probes,
development of NQO1-activatable photodynamic agents, luminescent probes, and photoacoustic
probes will greatly benefit the fields dedicated to NQO1 detection in tissues.
Table 1.1 Summary of Probes for Detection and Measurement of NQO1
Probes

Detection Methods

table continued
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Applications

Fluorescence

Detection and
measurement of
hNQO1 in an
aqueous solution.158

Fluorescence

Detection and
imaging of hNQO1
in vitro.13

Probes

Detection Methods

table continued
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Applications

Fluorescence

Detection and
imaging of hNQO1
in vitro.9

Fluorescence

Detection and
imaging of hNQO1
in vitro.12

Fluorescence

Detection and
imaging of hNQO1
in vitro.10

Fluorescence

Detection and
imaging of hNQO1
in vitro, in threedimensional tumor
mimics, and in
mouse xenograft
models.11

Probes

Detection Methods

table continued
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Applications

Fluorescence

Detection and
imaging of hNQO1
in vitro.256

Fluorescence

Monitoring of
hNQO1-activated
drug release in
vitro.257

Fluorescence

Monitoring of
hNQO1-activated
drug release in
vitro.258

Fluorescence

Detection and
imaging of hNQO1
in vitro and in
animals.259

Probes

Detection Methods
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Applications

Fluorescence

Detection and
imaging of hNQO1
in vitro.260

Fluorescence

Detection and
imaging of hNQO1
in vitro.261

Fluorescence

Detection and
imaging of hNQO1
in vitro and in
vivo.262

Fluorescence

Detection and
imaging of hNQO1
in vitro.263

Fluorescence

Monitoring of
hNQO1-activated
drug release in
vitro.264

1.8

Visualization of  -Galactosidase with Different Imaging Modalities

1.8.1

-Galactosidase
-Galactosidase (-D-galactohydrolase, EC 3.2.1.23, -gal), encoded by the lacZ gene, is

a glycoside hydrolase enzyme. Its function is to catalyze the hydrolysis of terminal linkages of D-galactosides,

such as the disaccharide lactose, into monosaccharides through recognition and

cleavage of the -D-galactose moiety.265 Even though -gal is able to hydrolyze fucosides and
arabinosides, the hydrolysis efficiency is significantly lower than that for -D-galactosides. -Gal
has a homotetrameric structure composed of four identical polypeptide chains, with each
monomer possessing one reactive site.266 The monomers interact with each other through noncovalent bonds (hydrophobic effects, hydrogen bonds, and electrostatic interactions). Because
the catalytically active site of each monomer requires collaboration with other amino acids from
the same polypeptides, as well as other polypeptides in the tetramer, splitting up of tetrameric gal into dimers leads to loss of its enzymatic activity.267-268 Upon substrate binding and its
movement deeper within the active site, two sequential catalytic steps are involved in the
hydrolysis mechanism of -gal.265 The first step, known as galactosylation, involves the substrate
being attacked by the amino group of glutamic acid via a nucleophilic substitution reaction. The
substitution results in -gal forming a covalent bond with galactose, thereby producing a covalent
intermediate. In the second step (degalactosylation), the previously formed -N-glycosidic bond
is broken by water attack, which ultimately leads to the formation of galactose. Yuan et al. found
that when Glu-537 of -gal expressed by Escherichia coli (E. coli) was replaced by aspartic acid
(Asp), glutamine (Gln), or valine (Val), the catalytic efficiencies of the mutants were significantly
reduced (100-fold, 30000-60000-fold, 160000-300000-fold less for the respective Asp-, Gln-, and
Val-mutants).269 That study indicated that Glu-537 is the amino acid responsible for acting as the
nucleophile in the hydrolysis catabolism, which hinges on nucleophilic attack and breaking down
of glycosidic bonds. This finding is contrary to the initial thought that Glu461 is the catalytic
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nucleophile.270 In a similar study, by isolating and identifying the glycosyl enzyme intermediate in
the catabolism process using high-performance liquid chromatography coupled with tandem
mass spectrometry, McCarter et al. found that Glu-268 is the catalytic nucleophile in endogenous

-gal in human beings.271
1.8.2

-Galactosidase-Activatable Probes
Due to its extensive applications as a reporter gene and enhanced upregulation in

senescent cells and ovarian cancer cells, a great amount of effort has been made to establish
methods to detect and measure -gal activity through the use of magnetic resonance imaging
(MRI),272-278 positron emission tomography (PET),279-282 photoacoustic imaging,283 and optical
imaging.152, 169, 284 A summary of the developed probes for detection of -gal is listed in Table 1.2.
Because -gal is an exo-type hydrolase that recognizes and cleaves the end part of its substrates
(here, -D-galactose), masking strategies are often employed to design -gal-responsive contrast
agents.2 The key signal-generating structure is masked by the -D-galactose recognition moiety,
resulting in an inhibited signal generation process. However, upon specific and effective cleavage
of the masking moiety by -gal, the signal generation capability is recovered.
Table 1.2 Summary of Probes for Detection and Measurement of -gal
Probes

Detection Methods

Applications

MRI

Visualization of lacZ
gene expression in
Xenopus
laevis
embryos

MRI

In vitro detection of
-gal in the presence
of human serum
albumin

EgadMe 274

[Gd-5] 275
table continued
40

Probes

Detection Methods

Applications

MRI

In vitro detection of
-gal

MRI

Detection of -gal
with
lacZ
gene
transfected
HEK293T cells

PET

In vivo visualization
of expression of lacZ
gene

PET

In vivo visualization
of expression of lacZ
gene

PET

In vivo visualization
of expression of lacZ
gene

[Yb(dota-Bz-Gal)]272

Gd-DFP-Gal273

18

FDL280

Radiolabeled ONPG Derivatives281

[125I]IBDG282
table continued

41

Probes

Detection Methods

Applications

Color;
Photoacoustic

Blue-white Screen;
Staining
of
histochemical
samples

Color

In vitro detection of
-gal in cellular
lysates

Color

In vitro detection of
-gal in cellular
lysates

Absorption;
Fluorescence

In vitro detection of
-gal;
In
vivo
imaging of lacZ gene
transfected tumors

Fluorescence

In vitro detection of
-gal in cellular
lysates and human
blood serum

Fluorescence

Detection of -gal in
single yeast cell with
flow cytometry

X-gal 283, 285-286

ONPG 287

CPRG 287

DDAOG 288-289

MUG 290

RG 291
table continued
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Probes

Detection Methods

Applications

Fluorescence

In vitro detection of
-gal in cellular
lysates

Fluorescence

Imaging of lacZ
expressed -gal in
living cells

Fluorescence

Ex vivo Imaging of
avidin--gal
conjugated tumors

Fluorescence

Imaging of lacZ
expressed -gal in
living cells

FDG 149

TG-Gal 152

AM-TG-Gal 284

2-Me-TM-Gal 292
table continued

43

Probes

Detection Methods

Applications

Fluorescence

Imaging of lacZ
expressed -gal in
living cells upon
microinjection

Fluorescence

Imaging
of
galactosidase
activity
in
D.
melanogaster wing
disks

Fluorescence

Imaging of lacZ
expressed -gal in
living cells

Fluorescence

Labeling of lacZ
expressed -gal in
living cells and living
tissues

Fluorescence

Ex vivo and in vivo
visualization
of
ovarian metastases
endogenously
expressing -gal

GMF-Gal 293

HMDER-Gal 169

Gal-HMRG 160

R = H: SPIDER-Gal-1 294
R = F: SPIDER-Gal-2

HMDef-Gal 295
table continued
44

Probes

Detection Methods

Applications

Fluorescence

Imaging of lacZ
expressed -gal in
living cells

Luminescence

In vivo imaging of
lacZand
luctransfected tumors

Luminescnece

In vivo imaging of
lacZ-transfected
tumors

Photodynamic
therapy

Selective killing of gal-expressing cells
in Drosophila larval
wings

Fluorescence

Imaging
senescent cells

SA-Gal 296

Lugal 297

GalactoLight PlusTM 298

HMDESeR-Gal 299

SG1

300

table continued
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of

Probes

Detection Methods

Applications

Fluorescence

In vivo imaging of
lacZ-transfected
tumors

Fluorescence

Imaging of lacZtransfected cells

DCM-Gal 301

NI-Gal 302

MRI is an important clinical imaging technique, widely employed for disease diagnosis in
hospitals.303 Unlike computed tomography (CT), MRI utilizes strong magnetic fields and radio
waves to construct “pictures” of the organs in the human body, and X-rays are not involved in its
imaging procedure. Therefore, MRI is believed to be a safer imaging system versus CT. It is also
becoming a prominent scientific tool to study gene expression and enzyme activity, due to its
potential to obtain three-dimensional images of opaque living organisms.304 Louie et al. developed
a -gal responsive gadolinium-based MRI contrast agent, EgadMe, to visualize lacZ gene
expressing tissues within living Xenopus laevis embryos with deep penetration and cellular
resolution.274 EgadMe is comprised of a chelator binding to the gadolinium core with high affinity,
and a galactose moiety that recognizes -gal with high specificity. The access of water molecules
to the paramagnetic gadolinium core is blocked by the galactose moiety, leading to decreased
MR signal in T1-based images. Upon the removal of the -galactose moiety by -gal, water
molecules are allowed to interact directly with gadolinium and have shortened T1 relaxation times,
resulting in the MR signal increase in the -gal-expressing tissues. Some other strategies were
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also explored to manipulate MR signal by reaction of the developed probes with -gal. For
example, Hanaoka et al. took advantage of a receptor-induced magnetization enhancement
(RIME) phenomenon to develop a contrast agent, [Gd-5].275 RIME is related to changes of the
proton relaxation time of water (T1 and T2) in the presence of specific acceptors. [Gd-5] is
composed of a -galactose moiety, an albumin-binding moiety, and a gadolinium based MR
signal-generating moiety. [Gd-5] does not exhibit the RIME phenomenon, because the albuminbinding moiety is masked by the -galactose moiety. Upon reaction with -gal, [Gd-5] released
the compound [Gd-8] with an exposed albumin-binding site and recovered its capability of binding
to human serum albumin (HSA). The binding of gadolinium ion to HSA slows the molecular
rotation of the chelating gadolinium complex and significantly increases the relaxation rate (r1) of
its neighboring water protons.
Paramagnetic chemical exchange saturation transfer (PARACEST) is another strategy
exploited by Chauvin et al. to design -gal-responsive MRI contrast agents.272 A lanthanidechelating unit was coupled to the -D-galactose recognizing moiety with a self-cleavable linker.
Enzymatic cleavage of -D-galactose by -gal breaks the initial carbamate bond into a free amine,
accompanied by a change in the PARACEST properties of the lanthanide complex. All of the
aforementioned contrast agents are employed to build 1H MRI images. One of the shared
drawbacks is that the background signals are very high due to the prevalence of 1H nuclei in the
human body and enhanced 1H MRI signals need to be carefully discriminated from background
signals.
To avoid this limitation,

19

F MRI is an alternative technique used to study physiological

events in living systems, due to the high sensitivity and endogenous absence of

19

F nuclei in the

human body. Mizukami et al. reported a 19F MRI contrast agent to detect -gal activity in vitro and
in fixed HEK293T cells.273 Based on the design, the

19

F MRI signal was quenched by the

covalently connected paramagnetic chelated gadolinium complex. Upon enzymatic hydrolysis of
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the contrast agent by -gal, the contrast agent was broken down into an 19F-bearing moiety and
a gadolinium complex. Cleavage of the gadolinium quenching group leads to a great

19

F MRI

signal increase.
PET is another important imaging modality widely utilized to monitor metabolic processes
in the body upon the administration of radionuclide-labeled tracers. Three-dimensional images
are constructed by detecting pairs of gamma rays emitted by the radionuclides. Due to it providing
deep tissue penetration and high sensitivity, this technique was also exploited to monitor
enzymatic activities.279 Bormans et al. developed a radioactive probe, -O-D-galactopyranosylFDG with -D-

(1,4’)-2’-[18F]fluoro-2’-deoxy-D-glucopyranose (18FDL) through coupling

18

galactose.280 18FDL was designed to investigate its usefulness in monitoring in vivo expression of
lacZ gene. By the design, after 18FDL entered -gal-expressing cells, 18FDL was hydrolyzed by 18

gal, resulting in the released
hexokinase. Even though

FDG that could be trapped inside cells due to phosphorylation by

FDL exhibited effective activation by -gal in vitro, it failed to allow

18

visualization of lacZ-expressing tumors in vivo. The authors attributed this observation to the
cellular impermeability of

18

FDG. Another two radiolabeled probes are

18

F- and

11

C-labeled

derivatives of ortho-nitrophenyl--D-galactopyranoside, which were developed for in vivo
visualization of lacZ gene expression.281 Both of them were demonstrated to be good substrates
of -gal in vitro, and they exhibited good cellular permeability and faster uptake by -galexpressing cells (2.5 and 7.5 fold). However, the -gal cleaved products tended to leak out of the
cells leading to significant signal loss, and thus low signal-to-background ratio.

Upon

administration of both probes in vivo, -gal-expressing tumors were not visualized, and
accumulation of the probes in kidneys and liver were found. Van Dort et al. reported a 125I-labeled
probe 5-[125I]Iodoindol-3-yl--D-galactopyranoside ([125I]IBDG), designed for PET imaging of gal-expressing tumors.282 Based on their design, after [125I]IBDG was hydrolyzed by -gal, the
formed [125I]iodoindoxyl aglycone compound would experience oxidative dimerization and be
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immobilized at the active site. Even though [125I]IBDG exhibited effective hydrolysis by -gal in
vitro and more efficient trapping of radioactive signal in -gal-expressing tumors than -gal-nonexpressing tumors with intratumoral injection, it failed to visualize both -gal-expressing and gal-non-expressing tumors, likely caused by rapid renal clearance of [125I]IBDG upon intravenous
administration. The slow oxidative dimerization rate of the produced [125I]iodoindoxyl aglycone at
very low concentrations relative to its rate of free diffusion out of cells might be another cause of
the unsuccessful visualization.
Optical imaging is a well-known light-harvesting imaging technology with broad
applications for basic research and medical science.35, 305 Compared to MRI and PET imaging
modalities, optical imaging holds the advantages of high sensitivity, high spatiotemporal resolution
(< m), real-time, lack of ionizing radiation, ease of use, and economic effectiveness. Many
chromogenic,286-288 fluorescent,152, 160, 169, 284, 289,

292-296, 300-302, 306-312

and luminescent297-298, 313-314

probes have been developed and applied to detect -gal in vitro and in vivo. X-gal is a
conventionally and widely used chromogenic probe to report gal presence in histochemical
samples.285-286 Hydrolysis of X-gal by -gal produces -D-galactose and 5-bromo-4-chloro-3hydroxyindole. The latter experiences spontaneous oxidative dimerization and forms insoluble
blue 5,5’-dibromo-4,4’-dichloro-indigo precipitate, which is indicative of effective lacZ gene
expression.

ortho-Nitrophenyl--galactoside

(ONPG)

and

chlorophenol

red--D-

galactopyranoside (CPRG) are two other chromogenic substrates for -gal detection.287 Upon gal activation, colorless ONPG and yellow CPRG can be converted into compounds with
respective yellow and red colors. Another -gal substrate 9H-(1,3-dichloro-9,9-dimethylacridin2-one-7-yl) -D-galactopyranoside (DDAOG) was initially developed by Corey et al. to measure
lacZ gene expression, with the advantages of a large absorption change, high solubility, high
enzymatic affinity (low Km), and high catalytic efficiency (large kcat value).288 With the advancement
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of near-infrared imaging techniques, this substrate probe was further explored by Tung et al. to
investigate in vivo detection and imaging of lacZ-transfected tumors.289
Fluorescence imaging is a sensitive technique to measure analytes of interest.
Measurements based on fluorescence can be several orders of magnitude more sensitive than
those based on absorption. The development of small-molecular fluorogenic substrate probes
responsive to -gal will greatly expand the methods for detection and measurement of -gal.
Fluorescent probes such as 4-methylumbelliferyl β-D-galactopyranoside (MUG),290 fluorescein di-

-galactopyranoside (FDG),315 resorufin--D-galactopyranoside (RG),291 and DDAOG289 have
traditionally been employed to study -gal activity with their fluorescence modes. Through
masking both sides of phenolate moieties of fluorescein with -D-galactose, the non-fluorescent
FDG probe exists within cells in its spirocyclized structure. Upon reaction with -gal, FDG is firstly
converted to a moderately fluorescent fluorescein derivative (one unite of -D-galactose released),
which is subsequently converted to fully fluorescent fluorescein (two units released). Even though
FDG is a sensitive substrate to measure -gal activity in cellular lysates, it is not suitable for
applications in cells and living systems due to its slow activation, cellular impermeability, and low
sensitivity to changes in -gal activities.149
Due to its high catalytic efficiency and ease of acquisition, -gal is widely used as an
enzyme platform to examine design strategies of fluorogenic probes. These tested strategies
include photoinduced electron transfer (PeT),152, 284, 292 fluorescence resonance energy transfer
(FRET),293 spirocyclization,160, 169, 295, 311 and aggregation-induced emission (AIE).296 PeT is an
electron transfer process by which an excited electron is transferred from a donor to an acceptor.
Fluorescence quenching as a result of the PeT process is often exploited for design of
fluorescence-silent probes. Urano et al. found that fluorescence efficiencies of fluorescein
derivatives can be precisely tuned by the substituted benzene moieties with different energy levels
of the highest occupied molecular orbital (HOMO).152 A direct donor-acceptor system was
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constructed with the benzene moieties and the xanthene scaffold. The observed tunable quantum
yields of the fluorescein derivatives are caused by their different PeT efficiencies. Because
masking of phenolate anion changes the molecular orbital energy levels of the xanthene structure,
masked and unmasked fluorescein derivatives with a carefully-crafted, substituted benzene
moiety can have significantly different fluorescence properties. Based on this design strategy, TG-

Gal was developed through appending the -D-galactose moiety with the optimized fluorescein
derivative. TG-Gal is non-fluorescent at physiological pH due to its efficient PeT process. Its
fluorescence is revealed by -gal, because the cleavage of -D-galactose moiety unmasks the
phenolate ion and inhibits its PeT process. TG-Gal also has good cellular permeability to
measure intracellular -gal enzyme, making possible live cell imaging. However, the released
fluorescent TG product suffers from poor cellular retention, likely caused by exportation by organic
anion transporter commonly present in metastatic cancer cells.295, 316
To conquer the cellular retention issue, Kamiya et al. developed a fluorogenic probe, AMTG-Gal, by introducing an ester moiety onto the TG-Gal structure.284 The non-fluorescent AMTG-Gal releases the fluorescent product AM-TG upon reaction with -gal, with AM-TG
subsequently hydrolyzed by ubiquitous intracellular esterases so as to generates a hydrophilic
fluorescent product with high cellular retention. However, this probe cannot be applied in vivo or
in living tissues, due to the ubiquitous presence of extracellular esterases.
Both of these aforementioned probes generate green-emitting fluorophores, which are not
suitable for deep tissue imaging.5 Development of fluorescent probes emitting in a different
emission range is also beneficial for multi-color imaging. By replacing the oxygen atom on the
xanthene ring of fluorescein with a silicon atom, Egawa et al. developed a red-emitting fluorophore,
which was employed to craft a fluorogenic probe for detection of -gal.292 The PeT strategy was
exploited in the design, similar to the previous two probes. The fluorogenic probe of Egawa et al.
is non-fluorescent due to efficient electron transfer quenching, while cleavage of the -D-galactose
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moiety by -gal alters the molecular energy level of the xanthene core, thus inhibiting the PeT
process, allowing for the strong fluorescence of the reporter to be revealed.
FRET describes a distance-dependent energy transfer mechanism between a donor
fluorophore and an acceptor fluorophore. When these two fluorophores are in close proximity, the
donor fluorophore in its electronic excited state can transfer non-radiative energy to the acceptor
fluorophore, resulting in emitting light from the acceptor fluorophore.

Both OFF/ON and

ratiometric probes can be designed based on the FRET strategy, depending on the fluorescence
properties of the acceptor fluorophore. Komatsu et al. developed a ratiometric probe with 7hydroxycoumarin as the donor, and fluorescein as the acceptor, for detection of -gal.293 The
probe exhibited strong emission at 515 nm, corresponding to the fluorescence of fluorescein in
its initial state. Upon reaction with -gal, the probe had its emission switched to 460 nm,
corresponding to the fluorescence of 7-hydroxycoumarin. Its capability to detect -gal in living
cells was further demonstrated with lacZ-transfected cellular imaging experiments. However, the
disadvantages of this detection system are obvious. It can be inferred that the probe is not able
to pass through the cellular membrane, considering its large molecular weight and negative
charges. Microinjection of the probe into cells had to be performed to detect intracellular -gal.
This is also evidenced by similar work using cellular impermeable fluorescein.221 Another obvious
disadvantage of FRET-based ratiometric probes is that their energy transfer efficiency is greatly
impacted by environmental factors, such as viscosity, polarity, and protein binding.
Intramolecular spirocyclization is another widely used strategy for the design of fluorogenic
probes. Spirocyclization breaks the conjugated structure of xanthene dyes, resulting in
fluorescence loss of carefully designed molecules. FDG is an example of this strategy. Both sides
of the phenolate anion are masked by -D-galactose, which leads to the formation of its nonfluorescent spirocyclized structure. To decloak the strong fluorescence, masking groups on both
sides must be cleaved by -gal, which slows the activation rate and leads to low sensitivity for
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detection of -gal. Kamiya et al. developed a fluorogenic probe, HMDER-Gal, with an
intramolecular spirocyclized rhodol structure.169 The highly fluorescent HMDER fluorophore with
an open form was constructed by the unmasking of one -D-galactose moiety. HMDER-Gal was
employed to detect and visualize -gal in cells and in Drosophila melanogaster tissues. However,
released HMDER tends to leak out of cells, resulting in fluorescence loss over time. Doura et al.
modified HMDER-Gal by integrating it with a protein-reactive quinone methide moiety.294 Its
released intermediate, upon -gal activation, further reacts with intracellular proteins, and thus
anchors the fluorescent product inside cells for a prolonged time. Single-cell resolution was
achieved by this improvement. One of the shared disadvantages of these two probes is that their
pKcycl value is 6.9. That means, at pH 7.4, 25% of the probe exists in its open form, causing a very
large background signal. By replacing the two ethyl groups on the xanthene ring with electronwithdrawing groups, Asanuma et al. developed the fluorogenic probe HMRef-Gal, having pKcycl
of 4.5.295 HMRef-Gal exhibited minimum background signal and a significant fluorescence
increase upon reaction with -gal; it was successfully employed to visualize disseminated
metastases with small sizes (1 mm) in a xenograft mouse model. However, all the aforementioned
fluorophores suffer from pH dependence, which limits their applications in pH-sensitive situations,
thereby making them unattractive for quantitative analysis. Besides these three strategies for the
design of fluorogenic probes, intramolecular charge transfer (ICT) and AIE were also explored to
design fluorogenic probes.296
Luminescence imaging is another technique to visualize -gal activity, but it requires the
use of newly crafted molecules. In contrast to fluorescence imaging, no illumination is required,
which makes this technique free from phototoxicity, photobleaching, scattered light interference,
and autofluorescence problems. Wehrman et al. developed a bioluminescent probe 1-Ogalactopyranosyl-luciferin through direct coupling of galactopyranoside to luciferin.297 Upon
intraperitoneal administration, this probe was successfully utilized to track -gal expression in the
53

lacZ- and luc-transfected tumor in xenograft mouse models. One drawback of the bioluminescent
system is the necessity of luc-transfection, which limits its broad application for detection of
endogenous analytes of interest in wild-type tissues. Chemiluminescent probes hold the
advantages of measuring enzymatic activities without the need of gene transfection. Liu et al.
applied a commercially available chemiluminescent probe Galacto-Light PlusTM with 1,2dioxetane structure in xenograft models.298 With intravenous administration of Galacto-Light
PlusTM, significantly higher luminescence signal was observed in lacZ-transfected MCF7 tumors
than wild-type MCF7 tumors. However, it can be posited that its short luminescence wavelength
and low luminescence efficiency will cause issues in its further applications. Chemiluminescent
probes targeting -gal but with NIR wavelength and high luminescence efficiency will benefit this
area. Besides these applications, gal was also utilized as a biomarker to develop prodrugs,317318

photoacoustic,283 and photodynamic agents.299
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CHAPTER 2
A NEAR-INFRARED, WAVELENGTH-SHIFTABLE, TURN-ON FLUORESCENT PROBE FOR
THE DETECTION AND IMAGING OF CANCER TUMOR CELLS
2.1

Introduction
Hypoxia is one of the hallmarks of solid tumors, caused by ineffective oxygen

transportation into the avascular regions of solid tumors.1-2 Low oxygen distribution is proposed
to be the main cause of chemoresistance and radioresistance, which leads to ineffective cancer
therapies.1-2 On the other hand, hypoxic tumor cells often have elevated levels of reductases,
such as human NAD(P)H:quinone oxidoreductase type I (hNQO1), NADPH-cytochrome P450
reductase (CYP450), nitroreductase, azoreductase, etc. in comparison to normal cells as a
response to oxidative stress caused by the accumulation of reactive oxygen species (ROS).3 The
overexpressed reductases have been selected as specific targets in the development of
bioreductive anticancer drugs (e.g., mitomycin C4 and -lapachone5-6) to achieve selective
elimination of tumor tissue with minimal effect on healthy tissue. Meanwhile, rapid, selective, and
accurate signaling of cancer-associated species, events, and real-time determination of borders
between cancerous tissues and normal tissues during surgery poses a great challenge to
conventional analytical techniques. Development of new strategies for selective and sensitive
reporting of overexpressed reductases in solid tumors would be useful in understanding
tumorigenesis and could assist in diagnosis and personalized cancer treatments.
Optical imaging, especially fluorescent molecular imaging, has attracted attention
because it is a time and cost-effective, and is a sensitive technique for reporting enzymatic
processes of interest with the aid of enzyme-specific fluorescent agents.7-9 In this method,
fluorophores are incorporated with enzyme-targeting ligands or enzyme-specific triggers to form

This chapter, previously published as Shen, Z.; Prasai, B.; Nakamura, Y.; Kobayashi, H.; Jackson,
M. S.; McCarley, R. L. ACS Chemical Biology 2017, 12, 1121–1132, is reprinted here by
permission of American Chemical Society.
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always-on fluorescent or non-fluorescent turn-on imaging probes. Compared to always on probes,
turn-on probes have their fluorescence revealed from their native non-fluorescent state by specific
enzymes, offering an enhanced signal-to-background ratio (SBR).10 The various intensities of light
emitted from the enzyme-liberated reporters can provide information on enzyme concentration
and activity in different areas of the cellular microenvironment (e.g., cytosol). 11 These turn-on
probes can be also utilized to assist surgeons in identifying the border between diseased and
healthy tissue, based on abnormal enzyme activities of different tissue areas.12 With that in mind,
cancer-associated reductases such as hNQO113-17 and nitroreductases18-22 have been used as
targets for developing turn-on/activatable fluorescent probes.
hNQO1 is a cytosolic, 2-electron reductase whose expression is regulated by the
Keap1/Nrf2/ARE pathway like many other cytoprotective reductases.23 In normal physiology, the
Keap1 protein binds to the Nrf2 transcription factor and promotes degradation of Nrf2 through
ubiquitination and a proteasomal degradation process. However, in response to increased
oxidative stress, Keap1 loses its ability to target and degrade the Nrf2 transcription factor because
of the oxidation of the reactive cysteine sites of the Keap1 protein. The stabilized Nrf2 transcription
factor accumulates in the nucleus where it binds to an ARE DNA sequence and triggers the
transcription of hNQO1.24-26 The expression of hNQO1 is typically low in normal cells but is
overexpressed in many types of cancer cells including the pancreas, colon, breast ovarian, and
non-small cell lung carcinoma.27 Moreover, hNQO1 overexpression is reportedly associated with
tumorigenesis, as hNQO1 maintains redox homeostasis in response to the generation of large
oxidative stress.27 Therefore, development of hNQO1-activatable profluorogenic probes that
target the elevated hNQO1 found in solid tumors is useful for understanding enzymatic processes
at the molecular level and developing tools to determine borders between diseased and healthy
tissue during fluorescence-assisted surgery.
Although fluorescent probes emitting the visible light are useful tools for some specific
applications, they are not suitable for in vivo imaging applications because the visible light
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overlaps with tissue autofluorescence.13-17 The visible light (< 650 nm) is highly absorbed by
endogenous molecules (e.g., oxy- and deoxy-hemoglobin). Infrared light (> 900 nm) is absorbed
by water and lipids. Near-infrared light (NIR, 650–900 nm) is less absorbed by tissues, resulting
in its deeper penetration. Therefore, imaging probes emitting light in the optimal “NIR window” are
desired for the detection and imaging of hNQO1 in living animals.
Moreover, most of the probe/reporter pairs have the same absorption and emission
profiles. This not only produces large background signal, but also increases uncertainty in
differentiating the emission signal of the reporter from the background signal. I posit that a NIR
and wavelength-shiftable probe will overcome the drawbacks of previously reported probes.
Herein, I designed, synthesized, and evaluated an NIR fluorescent small-molecular probe
Q3STCy targeting to hNQO1. Fluorescence efficiency of Q3STCy was greatly decreased through
a photo-induced electron transfer (PeT) quenching mechanism, evidenced by their respective
redox potentials. Rapid fluorescence turn-on (193-fold) of Q3STCy was achieved by the addition
of hNQO1 under physiological conditions. Effective enzymatic kinetic experiments (high enzyme
affinity Km = 1.09 ± 0.471 M, and high catalytic efficiency Kcat/Km = 1.49 × 105 ± 0.682 × 105 M–
1 –1

s ) indicated that Q3STCy was a good substrate for hNQO1. Its ability to detect endogenous

hNQO1 was validated through fluorescence imaging of cells with varied hNQO1 activities (HT29,
H596 (+), SHIN3, and H596). The strong fluorescence from hNQO1 gene transfected H596 cells
clearly indicated that Q3STCy was activated by hNQO1 in a highly selective fashion.
Colocalization experiments showed that the produced TCy reporter mainly accumulated in
lysosomes pointing to enhanced cellular retention of TCy. Its capability in imaging colorectal
multicellular spheroids (1 mm diameter) with spatially heterogeneous hNQO1 activities and
detecting human ovarian cancer-derived metastases (0.5 mm dimension) in xenograft mouse
models holds much potential in applications that range from drug development to cancer imaging.
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2.2

Experimental Section

2.2.1

Synthetic Materials and Methods
All chemicals used in syntheses were purchased from Sigma-Aldrich or Fisher Scientific

and used without further purification. Aluminum-backed 60 F254 silica plates used to perform thinlayer chromatography were purchased from EMD Chemicals. A Biotage FlashMaster Personal
column system, with 50-g, 25-g, or 10-g silica columns from Biotage, were used to perform
separations. 1H and

13

C NMR spectra were recorded in CDCl3 or methanol-d6 on Bruker AVIII-

400 or Bruker AVIII-500 spectrometers at 25 ºC. All chemical shifts are reported in the standard

 notation of parts per million, with calibration achieved using residual protio-solvent of CDCl3

Scheme 2.1 Synthetic route for the hNQO1-activatable probe, Q3STCy, and the electronically
similar analogue, iBuTCy.
Reagents and conditions: (a) 2 M methylamine in methanol, DMF, 85 °C, 95%; (b)
carbonyldiimidazole, 2-mercaptoethanol, DCM/DMF/toluene, −10 °C, 40%; (c) i: phosgene,
THF; ii: sodium hydride, THF, 85%; (d) isobutyl chloroformate, DIPEA, DCM, 90%.
82

(7.26 for 1H and 77.16 for 13C) and methanol-d6 (3.31 for 1H and 49.00 for 13C). Absorption bands
in NMR spectra are listed as singlet (s), doublet (d), triplet (t), or multiplet (m), and coupling
constants (J) are reported in hertz (Hz).
2.2.2

Synthesis
The general approach for synthesis of the Q3STCy probe is outlined in Scheme 2.1. The

starting materials, quinone propionic acid (Q3PA), 1-ethyl-2,3,3-trimethyl-3H-indol-1-ium iodide
and 2-chloro-3-(hydroxymethylene)-1-cyclohexene-carboxaldehyde were synthesized through
reported procedures.19, 28

Synthesis of Cy7-Cl. A mixture of 1-ethyl-2,3,3-trimethyl-3H-indol-1-ium iodide (3.65 g,
11.6 mmol), 2-chloro-3-(hydroxymethylene)-1-cyclohexene-carboxaldehyde (1.0 g, 5.8 mmol),
and sodium acetate (1.9 g, 23.2 mmol) were dissolved in 15 mL acetic anhydride in a 50-mL
round-bottom flask under nitrogen atmosphere. The solution was heated to 130 ºC for 1 h, during
which the solution color changed from red to dark green, and then the resulting mixture was
cooled to room temperature and filtered. The dark green product Cy7-Cl (3.5 g, 95%) was
obtained after washing the precipitate with diethyl ether and aqueous potassium iodide solution.
H NMR (500 MHz, MeOD)  8.46 (d, J = 14.2 Hz, 2H), 7.53 (d, J = 7.3 Hz, 2H), 7.44 (t, J = 7.4

1

Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 7.30 (t, J = 7.4 Hz, 2H), 6.30 (d, J = 14.1 Hz, 2H), 4.23 (q, J =
7.2 Hz, 4H), 2.75 (t, J = 6.1 Hz, 4H), 2.01–1.93 (m, 2H), 1.74 (s, 12H), 1.42 (t, J = 7.2 Hz, 6H).
C NMR (126 MHz, MeOD)  173.93, 151.21, 145.70, 143.18, 142.78, 129.93, 127.95, 126.57,

13

123.56, 112.04, 101.94, 50.68, 40.38, 28.24, 27.38, 22.14, 12.47. ESI-HRMS: for [C34H40ClN2]+:
expected m/z = 511.2880 [M]+; found m/z = 511.2880 [M]+; 0.0 ppm error.
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Synthesis of TCy. Cy7-Cl (256 mg, 0.40 mmol) was dissolved in 20 mL anhydrous DMF
in a 50-mL round bottom flask under nitrogen environment, followed by the addition of 2 M
methylamine in methanol (0.8 mL, 1.6 mmol) using a syringe. The solution was heated to 85 ºC
for 3 h, during which the color changed from green to blue. The solvent was removed under
reduced pressure. The crude product was dissolved in DCM and purified by silica gel
chromatography with methanol/DCM (1:99 to 3:97) as eluent to afford product TCy (228 mg, 90%)
as a blue solid. 1H NMR (500 MHz, MeOD)  7.68 (d, J = 12.8 Hz, 2H), 7.34 (d, J = 7.4 Hz, 2H),
7.29 (t, J = 7.7 Hz, 2H), 7.11–6.97 (m, 4H), 5.75 (d, J = 12.7 Hz, 2H), 3.96 (q, J = 6.9 Hz, 4H),
3.45 (s, 3H), 2.57 (t, J = 6.3 Hz, 4H), 1.88–1.79 (m, 2H), 1.64 (s, 12H), 1.31 (t, J = 7.0 Hz, 6H).
C NMR (126 MHz, MeOD)  171.75, 167.75, 144.06, 141.31, 138.40, 129.34, 123.61, 123.03,

13

120.81, 109.51, 94.53, 68.84, 38.67, 37.66, 29.01, 26.90, 22.54, 11.61. ESI-HRMS: for
[C35H44N3]+: expected m/z = 506.3535 [M]+; found m/z = 506.3537 [M]+; 0.4 ppm error.

Synthesis of Q3PA-S. Q3PA (250 mg, 1.0 mmol) was dissolved in 2 mL anhydrous DCM
in a 25-mL round bottom flask under nitrogen environment, followed by the addition of 1,1’carbonyldiimidazole (211 mg, 1.3 mmol). The solution was stirred for 30 min at room temperature,
then diluted by toluene (4 mL) and DMF (0.3 mL) and cooled to −10 ºC. To the cooled solution
was added slowly 2-mercaptoethanol (0.075 mL, 1.1 mmol) diluted with DCM (1 mL). After stirring
at −10 ºC for 2 h, the solvent was removed under reduced pressure. The residue was purified by
silica gel chromatography with 1:2 ethyl acetate/hexane (RF = 0.2) as eluent to afford the Q3PA84

S

product

as

a

yellow

oil

(124

mg,

40%).

1

H

NMR

(400

MHz,

MeOD)

 3.56 (t, J = 6.6 Hz, 2H), 3.29 (s, 2H), 2.95 (t, J = 6.6 Hz, 2H), 2.13 (s, 3H), 1.98 (s, 6H), 1.45 (s,
6H). 13C NMR (101 MHz, MeOD)  200.00, 191.93, 188.55, 153.88, 144.42, 139.59, 139.32, 61.79,
57.55, 40.11, 32.20, 29.13, 14.39, 12.67, 12.03. ESI-HRMS: for C16H22O4S: expected m/z =
311.1317 [M + H]+; found m/z = 311.1306 [M + H]+; 3.5 ppm error.

Synthesis of iBuTCy. TCy (43 mg, 0.068 mmol) was dissolved in 10 mL anhydrous DCM
under nitrogen environment. Isobutyl chloroformate (93 mg, 0.68 mmol) and N,Ndiisopropylethylamine (DIPEA, 0.4 mL) were added using a syringe at room temperature. The
solution was stirred for 2 h, during which the color changed from blue to green. The solvent was
removed under reduced pressure. The residue was dissolved in DCM and purified using silica gel
chromatography with methanol/DCM (1:99 to 5:95) as eluent to afford a solid green product
iBuTCy (45 mg, 90%). 1H NMR (500 MHz, CDCl3) (rotamers)  7.62 (d, J = 14.0 Hz, 2H), 7.37 (m,
4H), 7.23 (t, J = 7.4 Hz, 2H), 7.16 (d, J = 7.9 Hz, 2H), 6.20 (d, J = 14.1 Hz, 2H), 4.25 (m, 4H), 4.01
(d, J = 6.5 Hz, 0.35H), 3.79 (d, J = 6.5 Hz, 1.65H), 3.28 (s, 3H), 2.80–2.58 (m, 4H), 2.05–1.87 (m,
2H), 1.77 (m, 1H), 1.66 (s, 6H), 1.59 (s, 6H), 1.44 (t, J = 7.2 Hz, 6H), 1.08 (d, J = 6.7 Hz, 1.15H),
0.73 (d, J = 6.7 Hz, 4.85H).

C NMR (126 MHz, CDCl3) (mixture of rotamers)  171.18, 156.03,

13

155.97, 141.93, 141.61, 141.40, 141.13, 129.01, 127.77, 125.31, 122.33, 110.79, 101.11, 72.38,
49.22, 40.20, 40.10, 38.63, 38.24, 28.47, 28.35, 28.26, 27.94, 25.18, 24.93, 20.88, 20.76, 19.37,
18.98, 12.58, 12.53. ESI-HRMS: for [C40H52N3O2]+: expected m/z = 606.4060 [M]+; found m/z =
606.4062 [M]+; 0.3 ppm error.
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Synthesis of Q3STCy. Phosgene (caution: highly toxic) in toluene (3 mL, 15% w/w, 4.2
mmol) was added to a solution of Q3PA-S (93 mg, 0.3 mmol) in anhydrous THF (12 mL) under
nitrogen environment. The solution was stirred for 12 h at room temperature. The solvent was
removed under reduced pressure, with any remaining phosgene deactivated with 2 M aqueous
NaOH solution in a vacuum trap. The resulting crude product was used for the next step without
further purification.
To the solution of TCy (35 mg, 0.055 mmol) in dry THF (10 mL) under nitrogen
environment, sodium hydride (2 mg, 0.083 mmol) was added. The solution was stirred for 20 min
at room temperature, during which the color changed from dark blue to orange. The crude product
from the previous step was dissolved in THF (2 mL) and then slowly added to the orange solution,
followed by the addition of DIPEA (0.06 mL, 0.34 mmol). The solution was stirred overnight, during
which the solution became green. The solvent was removed under reduced pressure, and the
residue was purified using silica gel chromatography with methanol/DCM (1:99 to 5:95) as eluent.
The Q3STCy product was afforded as a green solid (45 mg, 85%).

1

H NMR (500 MHz, CDCl3)

(rotamers)  7.58 (d, J = 14.2 Hz, 2H), 7.43–7.31 (m, 4H), 7.24 (t, J = 7.4 Hz, 2H), 7.16 (d, J = 7.9
Hz, 2H), 6.20 (d, J = 14.1 Hz, 2H), 4.33–4.22 (m, 4H), 4.17 (m, 0.4 H), 4.04 (t, J = 6.7 Hz, 1.6H),
3.37 (s, 0.4H), 3.26 (s, 3H), 3.20 (t, J = 6.5 Hz, 0.4H), 3.15 (s, 1.6H), 2.90 (t, J = 6.7 Hz, 1.6H),
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2.80–2.58 (m, 4H), 2.15 (s, 0.6H), 2.04 (s, 2.4H), 2.03–1.97 (m, 1H), 1.91 (m, 4.6H), 1.82 (s,
2.4H), 1.67 (s, 6H), 1.57 (s, 6H), 1.45 (m, 7.2H), 1.32 (s, 4.8H).

13

C NMR (126 MHz, CDCl3)

(rotamers)  197.92, 190.59, 187.46, 171.14, 155.46, 155.30, 151.78, 142.92, 141.95, 141.39,
141.13, 138.96, 138.63, 129.03, 127.79, 127.54, 125.36, 122.35, 110.82, 101.40, 101.30, 64.42,
57.03, 56.75, 49.22, 40.29, 40.17, 39.25, 39.15, 38.79, 38.46, 29.11, 28.98, 28.52, 28.38, 28.30,
27.92, 25.22, 24.97, 20.78, 14.45, 14.32, 12.84, 12.69, 12.67, 12.56, 12.28. ESI-HRMS: for
[C52H64N3O5S]+: expected m/z = 842.4567 [M]+; found m/z = 842.4565 [M]+; 0.2 ppm error.
2.2.3

Demonstration of Purity of the Q3STCy Probe by HPLC with UV Absorption and Mass

Spectrometry Detection
High-performance liquid chromatography (HPLC) analysis with ultraviolet-visible (UV-Vis)
absorption detection was performed to analyze the purity of the compound Q 3STCy. The
instruments were composed of a Waters 616 pump, Waters 2707 Autosampler, an Agilent Zorbax
300Extend-C18 column (5 m, 150 x 4.6 mm), and 996 Photodiode Array Detector, which were
controlled by Waters Empower 2 software. The separation was performed on the Agilent Zorbax
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Figure 2.1 HPLC spectra for Q3STCy with absorption detection at 786 nm (top) and 254 nm
(bottom).
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300Extend-C18 reverse phase column by a gradient elution resulting from mixing eluents A (0.1%
trifluoroacetic acid in water) and B (0.1% trifluoroacetic acid in acetonitrile). The gradient started
with 20% B and was changed to 80% B over a 40-min period. The flow rate was 1.0 mL min−1.
Detection was achieved using wavelengths of 254 nm and 786 nm, respectively, Figure 2.1.
HPLC-mass spectrometry. The separation was performed on an Agilent Zorbax SB-C18 (3.5 m,
30 x 2.1 mm) using a gradient resulting from mixing eluents A (0.1% formic acid in water) and B
(0.1% formic acid in acetonitrile). Detection was achieved by ESI-TOF mass spectrometry (150 V
ionization voltage). Separation and verification data of Q3STCy is shown in Figure 2.2.
2.2.4

Demonstration of both Q3STCy and iBuTCy Existing as Their Respective Rotamers
The 1d selective chemical-exchange experiment was performed with Bruker AVIII-500

spectrometers. An appropriate amount of Q3STCy and iBuTCy was dissolved in CDCl3 to acquire

Figure 2.2 HPLC data of Q3STCy (left) and its respective mass spectrum (right).
their respective 1H NMR spectrum. The residual protic peak of CDCl3 ( = 7.26) was used as the
standard calibration peak. Based on calibrated NMR spectra, peaks of interest were selected to
be excited. The desired 1D gradient NOE spectra were further obtained with the employment of
a 100 ms Gaussian pulse and a 1.0 s mixing time with a standard 1D gradient NOE pulse.29-30
2.2.5

Spectroscopic Measurement Methods
UV-visible absorption spectra were recorded in a 10-mm path length quartz cuvette on a

Varian Cary-50 spectrophotometer. Fluorescence spectra were recorded in a 10 mm × 10 mm
quartz cuvette on a PerkinElmer LS55 spectrofluorometer or a PTI QuantaMaster4/2006SE
spectrofluorometer. Water (> 18 MΩ cm) from a Barnstead NANOpure Diamond Water System
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was used to prepare pH = 7.4, 0.1 M phosphate-buffered saline/0.1 M KCl (PBS). Stock solutions
of Q3STCy, iBuTCy, and TCy (1 mM in DMSO) were used to prepare corresponding diluted PBS
sample solutions.
2.2.6

Quantum Yields and Molar Extinction Coefficients for Q3STCy, iBuTCy, and TCy
The fluorescence standard ICG was purchased from Sigma-Aldrich, and the HPDITCP

cyanine dye was synthesized by the reported procedure.31 Relative quantum yields () of Q3STCy
and iBuTCy in 2% DMSO/PBS solution (pH = 7.4) were calculated relative to ICG ( = 0.012 in
water)32 and that of TCy relative to HPDITCP ( = 0.161 in ethanol)33 using the following equation:
𝐺𝑟𝑎𝑑

𝛷x = 𝛷𝑠𝑡 (𝐺𝑟𝑎𝑑 𝑥 ) (
𝑠𝑡

𝜂𝑥2

2
𝜂𝑠𝑡

)

Where the subscripts st and x stand for standard and test sample, respectively. is the quantum
yield,  is the refractive index of solvent, and Grad is the gradient from the plot of integrated
fluorescence intensity vs absorbance. Absorbance at the excitation wavelength was maintained
between 0.02–0.10 to minimize reabsorption effects and maximize illumination homogeneity.
Emission spectra were recorded with the same parameters. Both absorption and emission spectra
at one specific concentration were measured three times.
Molar extinction coefficients () were determined by the plot of absorbance vs
concentration at the maximum absorption wavelength using the Beer-Lambert law. Each sample
at one specific concentration was prepared and measured three times.
2.2.7 Reaction of Q3STCy Probe with hNQO1 Demonstrated by HPLC with Mass Spectrometry
HPLC analysis was carried out as above. Q3STCy (60 M, 5 mL) was incubated with 2-3 g mL−1
hNQO1 in 100 M NADH in PBS for 1 h in a 37 °C water bath. The solution was kept in a
refrigerator at 24 °C until execution of the experiment.
2.2.8

Cyclic Voltammetry Measurements
Cyclic voltammetry (CV) experiments were performed using a Princeton Applied Research

Potentiostat/Galvanostat Model 273A with Power Suite-2.53 software. A glassy carbon working
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electrode, platinum wire counter electrode, and silver wire pseudo-reference electrode (Ag/Ag+)
were used in a 20-mL cell, with anhydrous acetonitrile (15 mL) and tetrabutylammonium
fluoroborate (0.1 M) as a solvent and supporting electrolyte. The solution was purged for 15 min
using nitrogen gas, at which point a nitrogen atmosphere was maintained above the solution
through the voltammetric measurements. Pretreatment of the working electrode was performed
by applying a +1.5 V potential for 10 min, which to activate the working electrode surface.
Ferrocene (1 mM) was used as an internal reference. Voltammograms were obtained for Q 3PA
(1 mM) and iBuTCy (1 mM) by applying cyclic potentials (+1.8 V to –1.8 V, then back to +1.8 V
vs Ag/Ag+) and (0 V to +1.8 V, then back to 0 V vs Ag/Ag+), respectively, at a scan rate of 0.1 V
s−1. The resulting E1/2 values were used to calculate the thermodynamic feasibility of PeT
processes via the Rehm-Weller equation:
GPeT = Eox − Ered − G00 − wp
Where Eox is the donor oxidation potential corresponding to the cyanine group attached to a stable
carbamate (iBuTCy) linkage; Ered is the Q3PA acceptor reduction potential; G00 is the first excited
singlet state energy of the fluorophore corresponding to that of iBuTCy; and wp is the Coulombic
attraction energy of the ion pair, which is 0.06 eV in acetonitrile.
2.2.9

Measurements of Enzymatic Kinetics Parameters
hNQO1 kinetic experiments with Q3STCy as substrate were performed using a

PerkinElmer LS55 spectrofluorometer at 37 ºC. Solutions of 0.1 M PBS/0.1 M KCl (pH = 7.4)
containing 100 M NADH and 0.007% BSA were prepared freshly and were used to make 0.5–5

M final concentration Q3STCy sample solutions. 1.5 mL of a given Q3STCy sample solution in a
2.0-mL cuvette was equilibrated at 37 ºC for 3 min, and then 3 L of a 0.25 mg mL−1 hNQO1
solution was added to yield a resulting in 0.5 g mL−1 hNQO1 concentration (250 U mL−1) that
initiated the assay. Fluorescence at the TCy reporter energy (ex = 600 nm, em = 755 nm) was
collected every 2 s over a 5-min time period (each assay was performed three times). Released
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TCy reporter concentration was obtained by converting the fluorescence signal with a calibration
curve of TCy in the same buffer system. By fitting the TCy reporter release velocities versus
Q3STCy concentrations with nonlinear least-squared analysis, the apparent kinetic parameters
Km and Vmax were obtained.
2.2.10 Monolayer Cell Culture.
HT-29 (human colorectal adenocarcinoma), and H596 (human nonsmall cell
adenosquamous lung carcinoma) were all purchased from American Type Culture Collection
(ATCC; Manassas, VA). The gene-transfected H596 cell line was provided by Dr. Molly Silvers
and Professor David Boothman at the Simmons Cancer Center of the UT Southwest Medical
Center.34 SHIN3-DsRed cells contain a red fluorescent protein (RFP DsRed2)-expressing plasmid
(Clontech Laboratories, Mountain View, CA, USA) that was stably transfected into SHIN3 cells,
as previously described.35 The SHIN3-DsRed cells serve as the standard of reference for cancer
location for in vivo optical imaging of peritoneal ovarian cancer metastases. 36 Unless stated
otherwise, cell culture media, fetal bovine serum albumin (BSA), and other supplements were
also purchased from ATCC. HT-29 cells were cultured in McCoy’s 5A medium, while H596 (+),
H596, SHIN3, and SHIN3-DsRed2 cells were cultured in RPMI-1640 medium, with all
supplemented with 10% fetal bovine serum, 10 IU mL−1 penicillin, and 10 g mL−1 streptomycin
(Life Technologies). Cells were incubated in 75 cm2 treated tissue culture flasks in the dark at
37 °C under 5% CO2/95% air in a humidified incubator.
2.2.11 3-Dimensional Cell Culture
Multicellular tumor spheroids (MCTSs) were cultured as previously described using the
liquid overlay method.37 HT-29 cells (20,000) in 100 L culture medium were pipetted into well of
a 96-well plate coated with agarose. MCTSs were cultured at 37 ºC under 5% CO2 in a humidified
incubator, and the fresh complete medium was added every other day.
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2.2.12 Western Blot and hNQO1 Activities
This work was performed by Bijeta Prasai and Milcah S. Jackson in the McCarley research
group. HT-29, H596 (+), SHIN3, and H596 cells were cultured in six-well culture dishes in for 1
day. The 24-h-old cells (0.2 million) were added with 1 mM phenylmethylsulfonyl fluoride in radio
immunoprecipitation buffer and the protease inhibitor cocktail. The cells were then placed in an
ice-water bath for 35 min with periodic agitation. The resulted solution with lysed cells was
centrifuged at 18,000 × g for 20 min. The supernatant was collected, aliquoted, and stored at –
80 °C until the following western blot assay and hNQO1 activity assay. Protein concentration in
the previous supernatant was measured using the BCA assay.38
Western blot experiments were performed by following the Bio-Rad recommended
protocol. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to
separate and measure hNQO1. The previously acquired cellular lysate containing 25 g protein
was loaded into the wells on the polyacrylamide gel, along with 10 L molecular weight marker
(Bio-Rad). The gel was run for 5 min at 50 V, then for 70 min at 100 V. After the separation, the
proteins on the gel were transferred onto the membrane in transfer buffer (25 mM Tris, 192 mM
glycine, and 20% (v/v) methanol; pH = 8.3). The blotted membrane was blocked by 5% non-fat
dry milk for 1 h, and incubated overnight in the solution of NQO1 monoclonal primary antibody
(A180, Thermo Fisher) at 4 °C. The membrane was further incubated with -actin monoclonal
primary antibody overnight at 4 °C. After the membrane was washed with Tris buffer (three times),
horseradish peroxidase (HRP) conjugated secondary antibodies were added and incubated with
the membrane for 1 h. The membrane was washed to remove the secondary antibody and put in
the working solution of the Pierce ECL substrate for 1 min. The resulting membrane was imaged.
The hNQO1-specific activities of different cellular lysates were measured using UV-vis
spectrometer. Dichlorophenolindophenol (DCPIP) is a substrate of hNQO1, and dicoumarol is a
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competitive inhibitor of hNQO1.39 Cellular lysates containing 5 g proteins was added to 0.75 mL
Tris buffer solution (25 mM, pH = 7.4) containing 200 M NADH and 0.014% BSA with or without
dicoumarol (20 M). 80 M DCPIP in 0.75 mL Tris buffer solution was mixed with the previous
solution with or without dicoumarol to start the reaction. Absorption decrease of DCPIP at 600 nm
was recorded for a 6-min time period using UV-vis spectrometer. The absorption decrease rate
at 600 nm was divided by the extinction coefficient of dicoumarol and the cuvette diameter, which
gave the reduction rate of dicoumarol. hNQO1-specific activities were further calculated by
subtracting the acquired reduction rate of the assay with dicoumarol from that of the assay without
dicoumarol.
2.2.13 Fluorescence Imaging of Monolayer Cells Using Confocal and Wide-field Microscopy
HT-29, H596 (+), SHIN3, and H596 cells (0.5 million each) were separated and cultured
overnight in dark at 37 ºC on 22 × 22 mm (no. 1-1/2; Corning) sterile glass coverslips before
treatment with Q3STCy probe. After replacement with fresh respective medium (2 mL), the cells
were treated by the addition of 10 L Q3STCy (1 mM in DMSO) to give a final probe concentration
5 × 10-6 M, with subsequent incubation at 37 ºC for 30 min. Then the cells were washed with PBS
(pH 7.3, Dulbecco) twice and fixed in 4% paraformaldehyde (PFA) for 15 min with shaking at room
temperature in the dark. After the PFA solution was removed, the fixed cells were covered using
coverslips coated with Immu-Mount. These slides were left in the dark overnight at room
temperature to allow the mounting medium to dry. Then the slides were used for confocal
microscopy and wide-field microscopy imaging experiments. For confocal microscopy, a Leica
TCS SP2 spectral laser-scanning confocal microscope was utilized to capture the cellular images.
A 40× oil immersion objective with numerical aperture 1.25 and a beam splitter TD 488/543/633
was utilized. The prepared cellular samples were excited with a 633-nm laser line of a heliumneon laser (laser intensity = 45%), and the emitted photons in the range of 660–820 nm
wavelengths were collected with a photomultiplier detector (PMT, voltage = 718 V) with the
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pinhole setting as 1.0 Airy unit (AU, 82 m). The resulting images were zoomed 3.3 fold and
captured with frame and line averaged 4 times. For wide-field microscopy, a Leica DM6 wide-field
microscope with a 40x/1.30 NA oil objective and an ORCA-Flash 4.0 Hamamatsu Digital CMOS
camera. The filter sets Cy5 (excitation: BP 590–650 nm, dichroic mirror: 660 nm; and emission:
BP 662–738 nm) and 50 ms exposure time were applied. Image analysis and statistical evaluation
of cytosolic intensities were accomplished with Fiji/ImageJ software.
2.2.14 Colocalization Study
For the live-cell colocalization studies, HT-29 cells (0.5 million) were cultured overnight on
35-mm glass-bottomed Mat Tek dishes. In fresh media, cells were incubated with 5 M Q3STCy
and corresponding organelle tracker (30 nM lysotracker for lysosome or 100 nM mitotracker for
mitochondria) for 30 min. The cells were washed with PBS, and the fresh warm phenol-free RPMI1640 medium was added, with subsequent imaging using a Leica TCS SP2 spectral laserscanning confocal microscope. A 63× objective with numerical aperture 1.4 was utilized. The
samples were excited with a 633-nm helium-neon laser line and their emitted light was collected
in the range of 660–785 nm wavelengths to construct cellular images of the activated probe.
Similarly, cellular images of lysosomes or mitochondria were built through collecting 500–600 nm
light with a 488-nm argon laser line as the excitation wavelength. Different laser intensities and
PMT voltages were applied for different images. Images of one sample spot were captured
sequentially to build probe and organelle images with the respective settings, and they were
utilized for colocalization analysis. Image analysis and statistical evaluation of colocalization
degree were accomplished using Fiji/ImageJ software with the coloc 2 plugin.
2.2.15 Wide-field Fluorescence Microscopy Imaging of 3-dimensional Cell Cultures
23-day old MCTSs were used for wide-field imaging. Q3STCy (5 M) solution was made
in phenol red-free RPMI-1640, and then MCTSs were incubated in the solution for 0, 30, 60, 90,
120, 150, and 180 min. Images were collected for all above mentioned time intervals using a
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Leica DM6 wide-field microscope with 10x/0.4 NA objective and ORCA-Flash 4.0
Hamamatsu Digital CMOS camera. Leica Application Suite X (LAS X) software was used to
capture the images. The filter sets Cy5 (excitation: BP 590–650 nm, dichroic mirror: 660 nm; and
emission: BP 662–738 nm) and Cy7 (excitation: BP 672–748 nm, dichroic mirror: 760 nm; and
emission: BP 765–855 nm) were used, with 500 ms and 50 ms exposure times, respectively.
Fiji/ImageJ software was used to perform image analysis.
2.2.16 Animal Model
The examination of Q3STCy with animal models and its ex vivo imaging evaluation were
a collaboration work with Dr. Hisataka Kobayashi of National Institutes of Health (NIH). All
procedures were performed in compliance with the Guide for the Care and Use of Laboratory
Animals10 and approved by the National Cancer Institute Animal Care and Use Committee. Sixto eight-week-old female homozygote athymic nude mice were purchased from Charles River
(National Cancer Institute, Frederick, MD, USA).

In order to generate the animal model,

intraperitoneal xenografts were established by intraperitoneal (i.p.) injection of 2 × 10 6 SHIN3DsRed cells suspended in 200–300 L of pH 7.4 phosphate-buffered saline (PBS) into the
peritoneal cavity of nude mice. Imaging was performed at 14–21 days after injection of the cells.
2.2.17 Ex vivo Imaging
To examine the sensitivity and specificity of Q3STCy for imaging peritoneal disseminated
cancer foci, Q3STCy (300 L of 100 M in pH 7.4 PBS) was injected into the peritoneal cavities
of RFP-transfected SHIN3 tumor-bearing mice. Mice were euthanized with carbon dioxide 1 h
after i.p. injection of probe. After euthanasia, the abdominal walls were removed, and the small
bowel mesenteries were extracted and spread out on a non-fluorescent plate.

Spectral

fluorescence images were acquired using the Maestro In-Vivo Imaging System (CRi, Woburn,
MA, USA). The following conditions were used for imaging RFP: band-pass excitation from 503
to 555 nm; long-pass emission above 645 nm. For experiments involving the Q3STCy probe, the
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following were used: band-pass excitation from 710 to 760 nm; long-pass emission above 800
nm). The tunable filter was automatically stepped in 10-nm increments from 600 to 800 nm for
RFP or 700 to 900 nm for Q3STCy, while the camera sequentially captured images at each
wavelength interval. The spectral fluorescence images consisting of autofluorescence, RFP, and
probe spectra were then unmixed, based on their spectral patterns, using the Maestro software.
2.3

Results and Discussion

2.3.1

Design Considerations of hNQO1-targeted Probes
To design a successful profluorogenic hNQO1-specific probe for practical applications in

living systems, many factors are required to be carefully considered. hNQO1 is an intracellular
enzyme present mainly within the cytosol. Its location can provide an advantage of in situ
activation of developed hNQO1-specific probes within targeted cells, and the step of enzymegenerated reporter transportation into targeted cells is avoided. In situ activation of hNQO1specific probes and retention of hNQO1-generated reporters offer discrimination of targeted tumor
cells from non-targeted normal cells or the ability to provide quantitative information on cellular
enzymatic activity levels. These properties are of great importance in the field of fluorescenceassisted cytoreductive removal of cancerous tissues that requires sustained and time-invariant
target-to-background ratios (TBRs).10 They are also beneficial for correlation of prodrug efficacy
and their hNQO1-based activation in cellular assays.40 In contrast, for extracellular or cellular
membrane-located enzymes fluorescent reporters generated by them are required to be
internalized into targeted cells to emit signal.41 Their ineffective internalization of reporters into
targeted cells and rapid reporters’ diffusion out cause significant signal attenuation resulting in
low TBRs. However, a big challenge for the design of hNQO1-specific probes is that the probes
are required to have appropriate lipophilicity to pass through cellular membranes and encounter
the targeted enzyme. In addition, effective cellular retention of the released reporter is essential
for a long-lasting and increasing fluorescence signal.
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To achieve an effective reporting of cellular hNQO1 activity, the probes must be
recognized and activated selectively by hNQO1 without interferences from competing reducing
agents (e.g., bio-thiols and reductases) present in the complex physiological environment. To
achieve a remarkable TBR values and be capable of distinguishing reporters’ emission signal
from background, the probe and the reporter should have distinctive photophysical properties
(quantum efficiency, absorption and emission wavelength, and Stokes shift). As such, the reporter
will have high photostability, independent of pHs and viscosity, high brightness (×) and large
Stokes shift (abs vs em). In contrast, the unactivated probe must possess a low quantum
efficiency, significantly different absorption and emission profiles from the reporter, and good
environmental stability.
Because NIR light has the advantages of high tissue penetration depth, low
autofluorescence from excited biological samples, low tissue absorption, and low phototoxicity, it
is the optimal emission range for in vivo applications.42-43 Therefore, the developed probes are
desired to have reporting signatures in the NIR range.
With these criteria in mind, the tricarbocyanine fluorophore (TCy) was selected as the
reporter because of its NIR emission wavelength, large Stokes shift, high quantum efficiency, and
photostability, Scheme 2.2.44-45 Importantly, the methylamine group in its meso position provides
a synthetic handle that can be functionalized with an hNQO1-specific trigger (Q3PA). Small
changes in the electronic properties of substituents at meso position can induce large changes in
photophysical properties of the TCy fluorophore due to the alteration of its -electron density
distribution.31, 46 Introduction of an electron-withdrawing carbamate bond at the meso position
decreases the energy level of the lowest occupied molecular orbitals (LUMO) of the molecular
backbone structure, thereby causing a dramatic bathochromatic shift of absorption/emission
wavelength of the TCy reporter. The trimethyl-locked quinone propionic acid (Q3PA), a highly
selective hNQO1 substrate, is capable of being reduced by hNQO1 to hydroquinone effectively
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with NAD(P)H cofactor.47 Q3PA has been successfully applied in the design of bioreductive
prodrugs,48-51 nanomaterials,52-53 drug delivery systems,28 and imaging probes.13-17 Due to its
electron deficient nature, Q3PA acts not only as an hNQO1-specific trigger, but also a
photoinduced electron transfer (PeT) quenching moiety to cloak the fluorescence of certain
fluorophores in close proximity. A flexible self-eliminating linker, 2-mercaptoethanol, is also
inserted between the Q3PA trigger and the bulky TCy reporter to enhance the enzyme affinity of
the probe.47 Based on these considerations, I designed an hNQO1-targeted profluorogenic small-

Scheme 2.2 Proposed TCy reporter release path by reaction of Q3STCy with hNQO1
molecular substrate probe Q3STCy with absorption/emission wavelength-shiftable characteristics
and an NIR reporting signature.
2.3.2

Synthesis of the hNQO1-Activatable Fluorogenic Probe Q3STCy
The synthetic route of Q3STCy is outlined in Scheme 2.1. Briefly, the tricarbocyanine TCy

reporter was synthesized by nucleophilic substitution of the chlorine of the cyanine dye Cy7-Cl
precursor with methylamine under DMF refluxing conditions. The self-eliminating linker, 2mercaptoethanol, was incorporated to Q3PA using 1,1’-carbonyldiimidazole as a coupling agent,
affording the thiol ester compound Q3PA-S. Q3STCy was eventually obtained through coupling
Q3PA-S to TCy through a carbamate bond using phosgene under basic conditions. To explain the
unique spectroscopic properties of Q3STCy and investigate the influence of Q3PA on the
photophysical properties of Q3STCy, an electronically similar structural analogue of Q3STCy,
namely iBuTCy without the Q3PA moiety, was also prepared. All compounds were characterized
with 1H-NMR, 13C-NMR, and ESI-HRMS.
98

2.3.3

Demonstration of Q3STCy and iBuTCy Existing as their Respective Rotamers Using 1D

Gradient Chemical-Exchange NMR Experiment
An interesting observation in the 1H NMR spectra of iBuTCy and Q3STCy was that the
peaks belonging to the same type of protons close to the carbamate bond were split into two sets
of peaks. For instance, in the 1H NMR spectrum of iBuTCy, it was observed that there are two
sets of doublet peaks at 0.73 and 1.08 ppm with the same J coupling constant 7.0 Hz that
appertain to the six equivalent protons labeled HA on the iBuTCy structure, Figure 2.3. Even
though a similar NMR spectrum of the TCy having a carbamate bond was also observed by
another research group, no possible assignment had been proposed.54 I sought to study the
cause of the NMR peak splitting. I first eliminated the possibility that impurity is the probable cause
of splitting with HPLC and HPLC-mass spectrometry. As described in Figure 2.1 and Figure 2.2,
the synthesized Q3STCy probe was demonstrated to be a pure compound showing only one
signal peak with HPLC separation. Considering its large molecular weight and the existence of a
carbamate bond of Q3STCy or iBuTCy, I hypothesized that the observed peak splitting of each
molecule was caused by the existence of rotamers. The relatively slow rotation rate of the
carbamate bond resulted in the same type of equilibrating protons having different transient
chemical environments, which ultimately led to the splitting of NMR peaks.
The existence of molecular rotamers is mostly studied by variable-temperature (VT) NMR,
solvent switching,55-56 or the introduction of a complexing agent.57-59 However, these techniques
are inconvenient when the examined samples are precious and need to be recovered. A simple
alternative technique is chemical-exchange NMR experiments. In my experiment, I employed 1D
selective chemical exchange NMR experiments to demonstrate that Q3STCy and iBuTCy existed
as their respective rotamers in solutions.29-30 As an illustration, if two sets of peaks in a compound
are attributed to equivalent protons, one set of peaks will behave the same spectroscopically as
the other set of irradiated peaks considering the chemical exchange nature of rotamers in a
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neutral chloroform solution. I first examined the six equivalent protons HA belonging to the two
terminal methyl groups of iBuTCy, Figure 2.3. When a selective pulse at 1.08 ppm was applied to
irradiate iBuTCy in deuterated chloroform, two peaks having the same phase at 1.08 and 0.73
ppm were created concomitantly, and vice versa. Peaks of the same phase were generated in
this case, which is different from that caused by normal nuclear overhauser effect (NOE). Normal
NOE-generated peaks will appear with opposite phase in response to an irradiated pulsed peak,
indicating two different types of protons in close proximity. The two sets of peaks are separated
from each other in a manner much larger than the NMR resolution. Observed peaks of the same
phase were not caused by the broadness of the irradiation window. The statement became clearer
when there is a third peak located between the two sets of peaks. For example, two sets of triplet
peaks at 2.93 ppm and 3.22 ppm with the same J coupling constant of 6.75 Hz belonging to the
two HB protons of the methylene group next to sulfur atom in Q3STCy, Figure 2.4. When the peak
at 2.93 ppm was irradiated, both peaks at 2.93 ppm and 3.22 ppm appeared. However, the singlet
peak in between did not appear on the spectrum. Therefore, appearance of peaks having the
same phase is not caused by the broadness of the irradiation pulse. This study showed that the
protons responsible for the split peaks behaved the same spectroscopically, indicating that
Q3STCy and iBuTCy existed in their respective rotamers form in solution.
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Figure 2.3 (A) 1H NMR spectrum of iBuTCy in CDCl3; (B) 1D gradient chemical exchange
spectrum of iBuTCy with an initial selective pulse irradiation at 1.08 ppm creating two peaks at
1.08 ppm and at 0.73 ppm; (C) irradiation at 0.73 ppm creating two peaks at 1.08 ppm and at 0.73
ppm; (D) irradiation at 4.01 ppm creating two peaks at 4.01 ppm and at 3.79 ppm; (E) irradiation
at 3.79 ppm creating two peaks at 4.01 ppm and at 3.79 ppm. All the newly created peaks are on
the same phase.

101

A
HB
3.22 ppm
HD
4.04 ppm

HB
2.93 ppm

HD
4.21 ppm

B

C

3.22 ppm
peak appears

2.93 ppm
selective pulse
center

4.21 ppm
peak appears
4.04 ppm
selective pulse
center

Figure 2.4 (A) 1H NMR spectrum of Q3STCy in CDCl3 ; (B) 1D gradient chemical exchange
spectrum of Q3STCy with an initial selective pulse irradiation at 2.93 ppm creating two peaks at
2.93 ppm and at 3.22 ppm;(C) irradiation at 4.04 ppm creating two peaks at 2.93 ppm and at 4.21
ppm. All the newly created peaks are on the same phase.
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2.3.4

Spectroscopic Characterization of Q3STCy and TCy
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Figure 2.5 (A) Absorption spectra and (B) emission spectra of TCy (2 M, red), Q3STCy (2
M, black) and iBuTCy (2 M, dashed grey) in 1% DMSO 0.1 M PBS/0.1 M KCl solution (pH
= 7.4). Emission spectra were measured at ex = 600 nm. T = 25 °C.
As shown in Figure 2.5, the spectral behaviors of the Q3STCy probe and the TCy reporter
were measured in aqueous phosphate buffered saline solution (PBS, pH=7.4). Q3STCy has its
probe

absorption maximum at 𝜆abs

probe

= 786 nm and its emission maximum at 𝜆em

= 798 nm. In
reporter

contrast, TCy has hypsochromic shifts in both absorption and emission maxima (𝜆abs
reporter

nm and 𝜆em

= 606

= 755 nm) and entirely different spectral profiles from the Q3STCy probe. This

wavelength-shiftable nature of the probe/reporter system is advantageous because the emission
signature the reporter can be easily differentiated from that of the probe even in a complex
biological environment. In cellular imaging applications, an illumination wavelength can be
selected to only excite the reporter rather than the probe, resulting in a smaller background
fluorescence signal. When irradiated at 600 nm, TCy had a 240-fold higher emission intensity at
765 nm than Q3STCy, which was partially caused by the absorption/emission wavelengthshiftable characteristics of the probe/reporter pair. Additionally, the TCy reporter has a remarkably
large Stokes shift (149 nm) due to its strong ICT effect. 44 A fluorophore with a large Stokes shift
is beneficial as a reporter, because it can avoid self-quenching and provide minimal background
scattering issues from illumination light.
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probe

Another observation is that Q3STCy and iBuTCy have similar absorption spectra (𝜆abs
iBuTCy

786 nm vs 𝜆abs

probe

= 783 nm) and similar emission spectra (𝜆em

iBuTCy

= 798 nm vs 𝜆em

=

= 798 nm).

It can be argued that their similar fluorophore skeletal structures with an electron-withdrawing
carbamate bond at the meso position give them equivalent electron density distribution, resulting
in similar HOMO and LUMO energy levels.
2.3.5

Molecular Orbital Calculations
The striking difference in spectral properties between Q3STCy and TCy was proposed to

be caused by the introduction of the carbamate bond at the meso position.31 I was motivated to
further investigate how the carbamate bond affects the HOMO and LUMO energy levels of the
Q3STCy probe. iBuTCy, an analogue of Q3STCy, is structurally similar to the Q3STCy probe, but
iBuTCy is more facile to study with computational methods. To gain a better understanding of the
phenomenon, the electron distribution and HOMO/LUMO energy levels of TCy and iBuTCy were
calculated using density functional theory (DFT) with the B3LYP functional and the 6-31G basis
set in Gaussian 09, Figure 2.6. For the HOMO orbital of the TCy reporter, electron distribution is
localized on the entire fluorophore excluding the carbon and nitrogen atoms at the meso position.
In fact, the electron density is almost zero on the meso carbon. In contrast, electron distribution
of the LUMO orbital is predominantly localized on the heptamethine chain including the meso
carbon and nitrogen atoms. Therefore, introduction of an electron-withdrawing group mainly
stabilizes the HOMO orbital. This was clearly observed on the calculated HOMO/LUMO of the
probe analogue iBuTCy. The HOMO of iBuTCy has a similar electron distribution and energy level
as that of TCy. However, the LUMO of iBuTCy has a stabilized electron distribution and a lowered
energy level. This electron redistribution due to the introduced carbamate bond, which led to a
decreased energy HOMO/LUMO gap of iBuTCy (1.35 eV) in comparison with that of TCy (1.63
eV). iBuTCy has a 0.28 eV smaller energy gap, indicating its longer absorption/emission
wavelength.
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Figure 2.6 HOMO/LUMO Frontier Molecular Orbitals of TCy and iBuTCy.
2.3.6

Quantum Yield Measurement
Quantum yields of Q3STCy and iBuTCy were measured in aqueous solution (2% DMSO:

98% 0.1 M PBS, pH = 7.4) using indocyanine green (ICG) in water ( = 0.012) as a standard,32,
60

while TCy was measured using an in-house synthesized 1,1’,3,3,3’,3’-hexamethyl-3,5-

propylene-4-(dimethylamino)-2,2’-indotricarbocyanine perchlorate (HPDITCP) in ethanol ( =
0.161) as a standard.33 ICG and HPDITCP were selected as the standards because their
absorption and emission profiles match well to their respective samples. This absorption/emission
match can avoid the variance of detection efficiency of the detector at different wavelengths,
resulting in more accurate measurement. The quantum yields of Q3STCy, iBuTCy, and TCy were
determined as 0.0046, 0.024, and 0.063, respectively, Table 2.1. A lower quantum efficiency for
Q3STCy was observed than that for iBuTCy (5-fold lower), and for TCy (14-fold lower).
Considering that the Q3PA moiety has a low electron density and is in close proximity with the
heptamethine fluorophore, photoinduced electron transfer from the excited fluorophore donor to
the Q3PA acceptor (d-PeT) was proposed as the cause of the low fluorescence efficiency of
Q3STCy, Figure 2.7.
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Compounds
iBuTCy
Q3STCy
TCy

Table 2.1 Photophysical data for iBuTCy, Q3STCy, and TCy
Solvent
abs (nm)
em (nm)
M−1cm−1)
PBS
783
798
111100
PBS
786
798
60600
PBS
606
755
36800


0.024a
0.0046a
0.063b

ICG ( = 0.012 in water) with ex = 725 nm; bHPDITCP ( = 0.161 in ethanol) with ex = 633 nm.

a

Figure 2.7 Schematic illustration of d-PeT process of the probe, Q3STCy.
2.3.7

Thermodynamic Feasibility of PeT Process
The proposed d-PeT process was further studied and demonstrated as the cause of the

fluorescence quenching of Q3STCy. As shown in Figure 2.7, in the d-PeT process, the
heptamethine fluorophore is the donor, and the electron-deficient quinone is the acceptor. After
the electron on the HOMO orbital of the fluorophore donor was excited to the LUMO orbital, it was
transferred to the LUMO orbital of the quinone acceptor, resulting in the fluorescence quenching
of the fluorophore. Because the carbamate bond greatly changed the HOMO/LUMO orbitals of
TCy, the fluorophore iBuTCy with a carbamate bond instead of TCy was an optimal representative
of the donor in the d-PeT system of Q3STCy. To demonstrate that the d-PeT process is
spontaneous, I measured the electrochemical and spectroscopic characteristics of the donor
iBuTCy and the acceptor Q3PA. The first excited singlet state energy (G00) of iBuTCy was
calculated to be 1.56 eV by converting the cross over wavelength for the absorption and emission
spectra (795 nm), Figure 2.8.
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Figure 2.8 Normalized absorption and emission spectra of iBuTCy in acetonitrile, showing the first
excited state at 795 nm (1.56 eV). T = 25 °C

Figure 2.9 Cyclic voltammograms of 1 mM solutions of iBuTCy (A) and Q3PA (B) in anhydrous
acetonitrile with 0.1 M tetrabutylammonium perchlorate as supporting electrolyte; scan rate = 0.1
V/s; iBuTCy: Epa = 0.46 eV, Epc = 0.38 eV; Q3PA: Epc1 = -1.16 eV, Epc2 = – 1.53 eV, Epa1 = – 0.46
eV, Epa2 = – 1.43 eV; T = 25 °C.
Cyclic voltammetry measurements showed that the oxidation potential of iBuTCy (Eox) was 0.42
V vs Fc/Fc+ and the reduction potential of Q3PA (Ered) was - 0.81 V vs Fc/Fc+, Figure 2.9. By
applying these outcomes in the Rehm-Weller equation
GPeT = Eox − Ered − G00 − wp
The Gibbs free energy change (GPeT) was determined to be – 0.39 eV, indicating that electron
transfer of Q3STCy is a thermodynamically feasible process. These measurements corroborated
107

that Q3PA is an effective quenching group to significantly decrease the fluorescence efficiency of
Q3STCy.
2.3.8

Spectral Rsponse of Q3STCy Toward hNQO1
I next examined the efficacy of Q3STCy activation by hNQO1 under physiological

conditions (at 37 ºC in 0.1 M pH 7.4 PBS buffer). The absorption spectra of Q 3STCy were first
recorded over time after the addition of 688 U mL–1 hNQO1 in the presence of NADH cofactor
(100 M), Figure 2.10. 1 U of hNQO1 will reduce 1 nmol of cytocytochrome c min−1 in the presence
of menadione substrate at 37 ºC.61 The absorption band of Q3STCy at 786 nm rapidly decreased
(50% decrease in 3 min, 90% decrease in 10 min), while a new band centered at 606 nm
increased concomitantly. The new band was presumably caused by the formation of TCy. An
isosbestic point at 665 nm was also observed. The solution color changed from green to blue
within 20 min, Figure 2.10 inset.

Figure 2.10 Time-dependent absorption spectral changes of 2 M Q3STCy in 0.1 M PBS/0.1 M
KCl solution (pH = 7.4) with 100 M NADH cofactor and 0.007% BSA initiated by the addition of
hNQO1 (688 U mL–1, U = nmol of cytochrome c reduced min−1). Inset is the solution color change
before and after treatment with hNQO1. T = 37 °C.
Under identical conditions, the emission spectral changes of Q3STCy were also recorded, Figure
2.11. Upon addition of hNQO1 to the Q3STCy solution, the fluorescence experienced an
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immediate increase at 798 nm, then gradually shifted to 755 nm, accompanied by a 193-fold
fluorescence increase at 755 nm within 20 min. The immediate fluorescence increase at 798 nm
was hypothesized to be the result of rapid formation of the fluorescent intermediate STCy,
Scheme 2.2. STCy has an intact carbamate bond, which has spectral properties similar to iBuTCy.
A subsequent fluorescence shift and increase at the emission maximum of TCy (755 nm) was
attributed to the ultimate release of TCy upon intramolecular cyclizative cleavage of the five-

Fluorescence, ex = 605 nm

membered ring compound 1,3-oxathiolan-2-one, Scheme 2.2.
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Figure 2.11 Time-dependent emission spectral changes of 4 M Q3STCy in 0.1 M PBS/0.1 M KCl
solution (pH = 7.4) with 100 M NADH cofactor and 0.007% BSA initiated by the addition of
hNQO1 (688 U mL–1, U = nmol of cytochrome c reduced min−1). Excitation slit width: 5.0; emission
slit width: 7.5; T = 37 °C.
2.3.9

Confirmation of the Enzymatic Activation Mechanism of Q3STCy
To further investigate whether the hNQO1-induced fluorescence turn on was indeed

caused by the release of TCy via the proposed mechanism, HPLC-mass spectrometry experiment
was further performed, Figure 2.12. Q3STCy (30 M) in aqueous solution (pH = 7.4) was treated
with 688 U mL−1 hNQO1 and 100 M NADH at 37 °C for 20 min. The resultant mixtures were
analyzed with HPLC coupled ESI-TOF mass spectrometry, Figure 2.12. Four products were
successfully separated and identified, having m/z values of 235.1356 [HQ3-L + H]+, error = 11.5
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ppm; 610.3458 [STCy]+, error = 1.4 ppm; 506.3539 [TCy]+, error = 0.8 ppm; and 842.4639
[Q3STCy]+, error = 8.6 ppm. The cleaved lactone product HQ3-L, the formed intermediate STCy,
the released TCy reporter, and the unreacted Q3STCy probe were identified as expected, which
confirmed my proposed enzymatic activation mechanism for Q3STCy. H2Q3STCy was not
observed, probably due to its rapid intramolecular lactonization rate (~ 1 min). The linker
cyclization product, 1,3-oxathiolan-2-one, was not observed, either because it eluted out in the
beginning 1–2 min elution of solvent or its ionization efficiency was too low in comparison with
other molecules’.

Figure 2.12 Upper: High-performance liquid chromatogram for separation of mixture resulted
from 30 M Q3STCy probe treated with 688 U mL−1 hNQO1 and 100 M NADH at 37 °C for 20
min. Lower: Mass spectra of corresponding peaks in the chromatogram.
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2.3.10 Enzymatic Kinetic Parameters for Q3STCy
As previously described in the design of an effective probe/reporter system, unactivated
probe is non-fluorescent until it react with a targeted enzyme, which rapidly convert the probe to
the highly fluorescent reporter. Simultaneously, the fluorescence of the released reporter should
last as long as possible to allow effective and efficient detection. Two aqueous solutions of
Q3STCy (4 M) containing NADH (100 M) and BSA (0.007%) were treated with or without
hNQO1 (688 U mL–1). The release rate of TCy was monitored by measuring the fluorescence at
755 nm with an excitation wavelength 605 nm, Figure 2.13. TCy release was not observed during
the 150-min examined time period in the untreated Q3STCy sample, indicating the stability of
Q3STCy in aqueous solution. In contrast, the Q3STCy solution, treated with hNQO1 at the 20-min
time point, exhibited rapid fluorescence increase, with the fluorescence reaching a plateau at
around 30 min. The fluorescence caused by the release of TCy was constant over a 90-min time
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course, indicating no sacrificed reporting capability of the probe/reporter system.
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Figure 2.13 The fluorescence intensity at 755 nm of 4 M Q3STCy solution (ex = 605 nm) was
recorded with (red line) or without (black line) the addition of hNQO1 (688 U mL –1) at the 20min time point. T = 37 °C.
To evaluate the hNQO1 efficacy in activating Q3STCy, the apparent kinetic parameters
were obtained by measuring the release rate of TCy with various Q3STCy substrate
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concentrations (0.5–5 M), Figure 2.14. The released TCy concentrations were first converted
from the measured fluorescence intensity with a linear calibration curve. The calibration curve
was established with TCy under identical measurement conditions. The obtained TCy
concentrations were used to calculate TCy production rate. Upon fitting the TCy production rate
to the Michaelis-Menten kinetic equation, the apparent Michaelis constant (Km = 1.1 ± 0.5 M) and
maximum velocity (Vmax = 0.31 ± 0.05 mol min–1 mg hNQO1–1) were determined. Based on these
acquired values, the catalytic constant or turnover number (kcat = 0.16 ± 0.02 s–1) and the catalytic
efficiency (Kcat/Km = 1.5 ± 0.7 × 105 M–1s–1) were calculated. The small Km value indicated strong
binding interactions between hNQO1 enzyme and Q3STCy probe. It was reasoned that the
hNQO1-recognizing quinone moiety was separated by the flexible 2-mercaptoethanol linker away
from the bulky moiety TCy, allowing its deep penetration into the active site of hNQO1. 47 The
catalytic efficiency was also higher than all the previously developed probes in the McCarley lab
or others.

Figure 2.14 Kinetic plot of hNQO1 (0.5 × 10–6 g mL–1, 250 U mL–1) with Q3STCy as a substrate
in aqueous solution (0.1 M PBS, pH = 7.4) containing 100 M NADH and 0.007% BSA. T =
37 °C. Values shown are the average of three trials with errors bars being ±1 standard
deviation; line is best fit to data (= 0.00076). Inset is Michaelis-Menten kinetic equation and
reaction equation.
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2.3.11 Physiological Stability of the Probe/Reporter System
pH fluctuations can occur in many cellular miroenvironments. For example, extracellular
fluids in tumor areas can yield an acidic pH.62 Cellular compartments, such as lysosomes and
endosomes, also have a low pH value (4.5–5.0) to facilitate their functions.63 To assure that the
probe/reporter pair can measure hNQO1 activity accurately, the fluorescence of Q3STCy and TCy
should not be influenced by pH fluctuations. As shown in Figure 2.15, the fluorescence signal of
Q3STCy and TCy at various pH values (4.5–9.5) was examined. The fluorescence intensity at 798
nm of Q3STCy was invariant across the pH range. Although the TCy structure has an amino group,
pH values in the range of 4.5–9.5 did not have a pronounced effect on TCy fluorescence. This
was must likely due to its low pKa value (less than 4.5), resulting from efficient conjugation of the
amino group with the heptamethine structure. Therefore, the developed probe/reporter system
provides signal response that are pH independent from pH 4.5 to 9.5, and it should function well
in cellular microenvironments.
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Figure 2.15 (A) Plot of fluorescence intensity at 755 nm for TCy (2 M, ex = 600 nm) and at
803 nm for Q3STCy (2 M, ex = 600 nm and 725 nm) in 0.1 M PBS/0.1 M KCl with 1% DMSO
at various pH values (4.5–9.5). T = 25 °C.
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Considering the abundance of reducing species in cells (e.g., thiols and NADH), a
significant concern for the probe/reporter system was whether the fluorescence of the released
reporter is stable in the presence of the aforementioned reducing species. To achieve noninterfering fluorescence is even more challenging for fluorophores that emit in the NIR range.
Because the NIR fluorophore often possesses a large -conjugated structure, the latter may be
easily attacked by biological nucleophiles. Interferent-induced quenching and redox reactions
may also pose a big threat to its reporting ability.61 The fluorescence intensity of TCy upon 120min incubation with high concentrations (1 mM) of various reducing species was compared with
that of the initial TCy solution, Figure 2.16. Less than 10% fluorescence decrease was found,
indicating that the reporting capability of TCy was not sacrificed by the presence of biological
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Figure 2.16 Fluorescence intensity at 755 nm (ex = 600 nm) of 4 M TCy in 0.1 M PBS/0.1 M
KCl (pH = 7.4) with 1 mM corresponding reducing agent. Green bars indicates the initial
fluorescence intensity and red bar indicates the fluorescence intensity after 120 min incubation
with corresponding reducing agent. T = 25 °C.
2.3.12 Selectivity of Q3STCy Toward hNQO1 Over Other Reducing Species in Cells
Another requirement for the probe/reporter system is high selectivity of Q3STCy toward
hNQO1 over reducing species present in the biological environment. Biological thiols and quinone
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reductases are commonly present in mammalian cells, which would presumably to be the main
potential interferents.64 Glutathione (GSH), ascorbic acid (AA), L-cysteine (Cys), L-homocysteine
(Hcy), dithiothreitol (DTT), NRH:quinone oxidoreductase 2 (QR2), and cytochrome P450
reductase (CPR) were selected to investigate their effects on possible fluorescence turn-on of
Q3STCy, Figure 2.17. Q3STCy solutions (4 M) were treated with high concentrated thiols (1 mM)
for 20 min at 37 ºC. No significant fluorescence increase was observed. The reductases QR2 and
CPR have the potential to reduce certain quinone species in the presence of their respective
cofactors, NRH and NADPH;13-14 their ability to activate Q3STCy was also investigated. The sole
presence of NRH (100 M) or NADPH (100 M) did not produce any fluorescence increase. QR2
(617 U mL–1) in the presence of NRH (100 M) produced a small fluorescence increase, that is
about 20% of that for the hNQO1 (688 U mL–1). However, the QR2 activity used is 275 times
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higher than the reported highest QR2 activity in human cancer cells.65 In the same type of human
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Figure 2.17 Normalized fluorescence intensity at 755 nm (ex = 600 nm) of Q3STCy (4 μM) in
0.1 M PBS/0.1 M KCl solution (pH = 7.4) after incubation with a given reducing agent for 20
min at 37 ºC. Reducing agent concentrations: 1 mM for ascorbic acid (AA) and thiols; 100 M
for NRH cofactor of NRH:quinone oxidoreductase 2 (QR2); and 100 M for NADH and
NADPH. The reductases were present at 688 U mL−1 for hNQO1, 617 U mL−1 for QR2, and
14.1 U mL−1 for cytochrome P450 reductase (CPR).
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tumor-derived cell lines such a prostate carcinoma (PC-3) and glioblastoma multiforme (U373MG and U87-MG), QR2 activity is merely 0.2% of hNQO1 activity. Moreover, the QR2 cofactor
NRH is unstable in aqueous and cellular environments, and its fleeting concentration in cells is
not enough to cause QR2 activation of quinone substrates.65 CPR (14.1 U mL–1) in the presence
of its cofactor NADPH (100 M) produced a signal 10% that of hNQO1. CPR activity used here
is roughly the same as that found in lung cancer cells, and is 4% of the hNQO1 activity in colorectal
cancer xenografts.66-67 In summary, Q3STCy exhibited low activation by the previously discussed
biological reducing species.
Considering the electron deficient nature of the quinone and heptamethine moieties, and
the strong nucleophilicity of thiols, the question came about: was it possible that the low thiolsinduced activation of Q3STCy was caused by the degradation of Q3STCy? To rule out this
possibility, the various thiol-treated Q3STCy solutions were subsequently treated by hNQO1
enzyme, thereby resulting in pronounced fluorescence increases, Figure 2.18. This data showed
that the thiol-treated Q3STCy solutions maintained their ability to be activated by hNQO1. The
Cys-treated Q3STCy solution showed the lowest fluorescence increase than the untreated
Q3STCy, indicating that Cys might cause the biggest interference for the detection of hNQO1 with
the Q3STCy probe through possible reaction with either Q3STCy or the released TCy. This
observation is most likely because Cys has the highest nucleophilicity among the tested thiols.
However, it is worth noting that the concentration of Cys used here was 1 mM, much larger than
its actual presence in biological environments. For example, in human blood plasma, unbound
Cys is around 10–20 M.68 Its intracellular concentration in human cells is also in M levels.
Another concern was that Q3STCy can bind to hNQO1 enzyme leading to its fluorescence
increase. However, no fluorescence increase was observed by the sole addition of hNQO1
enzyme.
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Figure 2.18 Fluorescence intensity at 755 nm (ex = 600 nm) of Q3STCy (4 μM) in 0.1 M
PBS/0.1 M KCl solution (pH = 7.4). Black bars: the solution was incubated with respective
reducing agents for a 20-min time period at 37 ºC. Red Bars: the treated solution was further
followed by the addition of 700 U mL–1 hNQO1 and incubated for a second 20-min time period
at 37 ºC. Reducing agent concentrations: 100 M for NADH, and 1 mM for DTT, AA, GSH,
Cys, and HCy.
2.3.13 hNQO1 Expression and Activity in Tumor-derived Cancer Cell Lines
After demonstrating that Q3STCy can detect hNQO1 in an effective and selective manner
in vitro, I sought to investigate its capability to measure endogenous hNQO1 in cells. Three wildtype cell lines and a gene-transfected cell line were examined. Wild-type cell lines include a
colorectal carcinoma cell line (HT-29), an ovarian cancer cell line (SHIN3), and a non-small cell
lung carcinoma cell line (H596). HT-29 was established as an hNQO1-expressing cell line with
high hNQO1 activity.69 H596 was reported to have undetectable hNQO1 activity, resulted from a
gene point mutation.70 HT-29 and H596 were previously employed as representive hNQO1positive and -negative cell lines in the McCarley group. An hNQO1 gene-transfected H596 cell
line (H596 (+)) was also exploited as an hNQO1-positive control model. H596 (+) should possess
the same cellular environment but enhanced hNQO1 activity in comparison to H596. SHIN3 was
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used for the first time in the McCarley lab or others in order to investigate whether the developed
Q3STCy probe was appropriate to visualize SHIN3-derived metastases.
The hNQO1 expression level in these four cell lines was studied with conventional
Western blot assay, Figure 2.19. hNQO1 presence was clearly visualized in HT-29, H596 (+), and
SHIN3 cell lines. In contrast, no hNQO1 presence was observed in the H596 cell line. Their
hNQO1-specific activities were also measured, Figure 2.20. 24-h-old plated cells were used for
the measurement. The cells were first lysed and centrifuged to acquire their lysates.
Dichlorophenolindophenol (DCPIP) was selected as the hNQO1 substrate to examine the
reduction capability of the acquired lysates.39 Dicoumarol-inhibited reduction capability was
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Figure 2.19. Western blots of protein extracts (20–21 g each) from H596, H596 (+), HT-29,
and SHIN3 cells. -Actin was used as a standard.
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Figure 2.20 hNQO1-specific activities of protein extracts from H596, H596 (+), HT-29, and
SHIN3 cells. DCPIP was used as the substrate.
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calculated to indicate the hNQO1-specific activity. HT-29 was validated to have a high hNQO1
activity, 488 ± 10 nmol of DCPIP min−1 mg protein−1. SHIN3 and H596 (+) had moderate hNQO1
activities, 55 ± 3 and 179 ± 7 nmol of DCPIP min−1 mg protein−1, respectively. H596 had
undetectable hNQO1 activity. In the following cellular imaging experiment, HT-29, H596 (+), and
SHIN3 were used as hNQO1-positive cell lines, while H596 was used as a hNQO1-negative cell
line.
2.3.14 Visualization of Endogenous hNQO1 in Monolayer Cancer Cell Lines with Fluorescence
Microscopy
Wide-field fluorescence microscopy and laser-scanning confocal fluorescence microscopy
were employed to capture the images of Q3STCy-exposed cells, Figure 2.21 and Figure 2.22. In
the following acquired cellular images, only emission signal from the TCy reporter was detected
by customizing the microscopic imaging conditions (e.g., filter switch and excitation/emission
wavelength tune). This was attributed to the large differences in the spectroscopic properties of
the Q3STCy probe and the TCy reporter.
All four cancer cell lines were incubated with 5 M Q3STCy for 30 min under monolayer
cell culture conditions at 37 °C, and then washed with DPBS (pH = 7.3) twice and fixed with 4%
PFA for 15 min. Confocal microscopic images were further captured under the same imaging
conditions. As noted in Figure 2.21, strong cytosolic fluorescence in the near-infrared region (660–
820 nm) was found for the hNQO1-positive HT-29, H596 (+), and SHIN3 cell lines. These
observations indicate the Q3STCy probe is cell membrane permeable, in agreement with its high
log octanol-water partition coefficient of 7.9 at pH 7.4;71 the probe is readily activated by
intracellular hNQO1. In contrast, virtually undetectable fluorescence in this energy range was
emitted in the hNQO1-negative H596 cell line under the same imaging conditions. To offer a more
quantitative approach for distinguishing target cells (positive) from non-target (negative) cells, I
calculated their target-to-background ratios (TBR) based on the acquired cellular images. The
TBR is a significant index for predicting the potency of optical imaging agents in real-time
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cytoreductive surgery for cell/tissue differentiation.72 The TBR is defined as the signal from the
hNQO1-positive (HT-29, OVCAR-3, and SHIN3) cells compared to that from hNQO1-negative
H596 cells. TBR values reported at the 95% confidence interval are 5.4 ± 0.4 for HT-29 (53
cells)/H596 (38 cells), 3.1 ± 0.3 for H596 (+) (45 cells)/H596 (33 cells), and 2.2 ± 0.2 for SHIN3
(32 cells)/H596 (32 cells). All TBR values are sufficiently large to identify targeted regions during
fluorescence-guided surgery, as well as to evaluate hNQO1-related drug efficacy.40, 72 Similarly,
strong cytosolic fluorescence was found in the wide-field microscopic images of HT-29 cells,
Figure 2.22. The acquired HT-29 (20 cells)/H596 (22 cells) TBR value is 29.4 ± 6.8. All the cells
were washed twice with PBS solution (pH = 7.4); the TBR values were still high suggesting that
there is effective cellular retention of the intracellularly produced TCy reporter from the Q3STCy
probe. This property of high cellular retention was not achieved by other enzyme-activated probes
using fluorescein derivatives as reporters;73-75 they underwent significant fluorescence loss after
a washing process.

Figure 2.21 Fluorescence and differential interference contrast (DIC) images of H596
(negative), SHIN3 (positive), H596 (+) (positive), and HT-29 (positive) cells using confocal
microscopy. Cells were incubated with 5 M Q3STCy for 30 min at 37 °C under humidified, 5%
CO2 conditions and fixed with 4% PFA. Fluorescence images were captured using 633-nm
excitation and 660–820 nm emission. Scale bar = 20 m.

120

Figure 2.22 Fluorescence and DIC images of HT-29 (positive) and H596 (negative) cells using
wide-field microscopy. Cells were incubated with 5 M Q3STCy for 30 min at 37 °C and fixed
with PFA. Fluorescence images were captured with a Cy5 (ex = 590–650 nm, em = 662–738
nm; 50 ms exposure time) filter. Scale bar = 20 m.
It came to my attention that the TBR value of HT-29/H596 was relatively smaller than
expected. A possible cause was the microscope imaging setting emitted photons in the 660–820
nm range were collected with the 633-nm illumination light. Emission from the unactivated
Q3STCy probe was also included in the large detection range, possibly, resulting in a large
background signal. In addition, the thioester bond on Q3STCy might be not as stable as an amide
bond in the cellular environment. Nonspecific hydrolysis of Q3STCy, even in trivial amounts, could
lead to an increased background signal. The relatively slow cleavage rate of 1,3-oxathiolan-2-one
might also retard the production of TCy, resulting in a low reporting signal. All the aforementioned
factors may contribute to the observed relatively low TBR value of HT29/H596. These
speculations were evidenced by another crafted probe Q3NTCy. In the Q3NTCy molecule, the 2mercaptoethanol linker of Q3STCy was replaced by N-methyl-p-amino-benzyl alcohol. The
formation of stable amide bond and the fast cleavage rate of the newly introduced linker made
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Q3NTCy achieve a much higher HT-29/H596 TBR value (7.6 ± 0.6). The Q3NTCy probe will be
discussed in the next chapter of my dissertation.
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Figure 2.23 (A) Fluorescence and DIC images of dicoumarol-free and dicoumarol-treated
(hNQO1 inhibitor) HT-29 cells using confocal microscopy. Cells were preincubated
with/without 10 M dicoumarol for 60 min, then incubated with 5 M Q3STCy for an additional
30 min. Fluorescence images were captured using 633-nm excitation and 660–820 nm
emission. Scale bar = 20 m; (B) Mean cytosolic fluorescence intensity of dicoumarol-free and
dicoumarol-treated HT-29 cells.
To assess the selective detection of hNQO1 by the Q3STCy probe, HT-29 cells were
treated with the competitive hNQO1 inhibitor dicoumarol, Figure 2.23. A significantly lower
fluorescence (over 70%) was observed in the dicoumarol-treated cells compared to the untreated
cells. It was an easy conclusion that the inhibited hNQO1 activity led to the observed fluorescence
loss. However, drawbacks of enzyme selectivity assay with chemicals such as inhibitors are
obvious. Inhibitors may perturb a cellular system (e.g., endocytosis inhibition and enzyme
up/downregulation), and react with applied probes or produced reporters, in addition to any
possible selectivity problems they may have. All these factors can lead to a false positive signal.
I further examined the effect of dicoumarol on the TCy reporter. Significant fluorescence loss was
found when an equal amount of dicoumarol (5 M) was added to the TCy solution (5 M).
Therefore, the dicoumarol-induced fluorescence loss of TCy might also be part of the reason for
the fluorescence decrease in the dicoumarol-treated cells. The hNQO1 gene-transfected cell line
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H596 (+) was a better cellular model to study the enzymatic selectivity of Q 3STCy. As shown in
Figure 2.21, higher fluorescence intensity from the H596 (+) cells than that from the H596 cells
showed the high selectivity of Q3STCy toward hNQO1. To strictly rule out the effects of all the
other reducing species in cells, if laboratory conditions allowed, hNQO1 gene knockout
experiment can provide a definitive answer.
2.3.15 Colocalization Study
To track the ultimate location of TCy produced by the hNQO1-stimulated Q3STCy within
the cytosol, colocalization experiments were performed with Q3STCy and organelle trackers
(mitotracker green and lysotracker green DND-26). As shown in Figure 2.24, the fluorescence
signal from the released TCy reporter colocalized well with that from the lysotracker dye. The
acquired images were analyzed with Fiji/ImageJ software. The Pearson correlation coefficient for
colocalization (PCCC) was determined to be 0.77, a value indicative of excellent TCy/lysotracker
colocalization.76 In contrast, cellular images exhibited a low colocalization level between TCy and

Figure 2.24 Live cell fluorescence and DIC images of HT-29 cells using confocal microscopy.
Cells were incubated with Q3STCy (5 μM) for 30 min (633-nm excitation and 660–785 nm
emission) and an organelle tracker (30 nM lysotracker green DND-26, or100 nM mitotracker
green) for 30 min (488-nm excitation and 500–600 nm emission). Scale bar = 20 m.
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mitotracker green. A PCCC value 0.28 was calculated confirming their poor colocalization. These
outcomes indicated that TCy released in the cytosol was accumulated mainly in lysosomes, which
was beneficial for the enhanced intracellular retention of TCy.
The cell viability of Q3STCy and TCy with HT-29 cells was also evaluated, Figure 2.25.
HT-29 cells were exposed to 1 M or 2 M Q3STCy for 3 h, and the live/dead cells were counted
via the trypan blue staining method.77 The cell viability was calculated to be 93.4 ± 2.0% and 88.1
± 1.0%. Similar cell viability for HT-29 cells incubated with 1 M or 2 M TCy was obtained, 84.8
± 7.0% and 96.0 ± 4.0%. Both the Q3STCy probe and the TCy reporter exhibited low cytotoxicity
with similar concentrations and incubation time applied in cellular imaging studies. Due to the
absence of sulfonated groups on the heptamethine cyanine molecules, both the probe and the
reporter are prone to accumulate inside cells.42 This property could result in cell toxicity problems
when cells are incubated with high concentrations of probe for long incubation times.
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Figure 2.25 Cell viability of HT-29 cells treated with 1 M and 2 M Q3STCy and TCy for 3 h.
Percentage values are the average of three independent measurements. Error Bars are ± one
standard deviation.
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2.3.16 Fluorescence Imaging of Multicellular Tumor Spheroids (MCTSs)
After the successful applications of the developed probe/reporter system in monolayer cell
culture, I sought to examine its potential for imaging an avascular tumor model – MCTSs. MCTSs
are laboratory-cultured multicellular aggregates, which have realistic features of in vivo avascular
tumors, such as structure diversity and gradient distribution of nutrients, oxygen, and H+.78 Even
though the two-dimensional cultured cell model is significant in the drug development field, it fails
to resemble avascular tumors. It is often the case that promising preclinical outcomes derived
from cell monolayer-based assays do not translate to the patient in the clinic.79 As a result, the
use of MCTSs is a better drug screening model resulting in improved patient outcomes.
Furthermore, MCTSs resemble disseminated peritoneal metastases from ovarian, colorectal,
gastric, and pancreatic cancers.80-81 The metastases are too small to be readily identified and
removed by surgeons during cytoreductive surgery under white-light illuminated surgical
conditions. They also locate away from blood vessels, which causes the therapeutic drugs to be
unable to reach and kill them. Thus, it is highly valuable to evaluate the ability of enzymeresponsive, fluorescence-based probes to be turned on inside cells of sub-mm-sized MCTSs.
The developed 23-day-old colorectal cancer MCTSs were exposed to 5 M Q3STCy, and
their fluorescence images were captured with wide-field microscopy, Figure 2.26. MCTSs with
advanced culturing age (23 days here) have features more closely related to that of multicellular
aggregates and avascular metastases in vivo.82-83 As shown in the DIC images, the 23-day-old
MCTSs were composed with a ~100-m-thick viable cell layer at the periphery and a necrotic
core (dark part) in the center. The necrotic core was formed because cells in the core had
inefficient supply of nutrients and increased accumulation of produced waste. Because the
Q3STCy probe, and the TCy reporter have distinct emission range, they can be measured
simultaneously with different fluorescence channels. The fluorescence signal collected from the
Cy5 channel (em = 662–738 nm) reflects the emission of TCy, while the signal from the Cy7
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channel (em = 765–855 nm) is the summed fluorescence of the weakly fluorescent unreacted
Q3TCy probe and any formed highly fluorescent STCy intermediate possibly present. Before the
addition of Q3STCy, there was no fluorescence in either detection channel as shown in control
images. Upon exposure of the MCTSs to Q3STCy, both fluorescence channels underwent
immediate fluorescence increases. Relatively linear time-dependent fluorescent responses were
observed for both emission ranges in the entire MCTS region during the 3-h experimental period,
the longest time used, Figure 2.27. Another observation was that the TCy reporter fluorescence
was much brighter near periphery than in the core. This is because the hNQO1 activity in the
viable cell layer is larger than in the necrotic core.84 All the acquired outcomes from the MCTSs
studies indicate that Q3STCy can quickly penetrate into the three-dimensional tumor mimics, enter
their component cells, and report the cytosolic hNQO1 activity.

Figure 2.26 Fluorescence and DIC images of living HT-29 MCTSs (23 days old, 970 ± 24 m
diameter) in a phenol-free RPMI-1640 medium using wide-field microscopy. The MCTSs were
exposed to 5 M Q3STCy at 37 ºC for different times. Images were captured every 30 min
using a Leica DM6 microscope with sequential Cy7 (ex = 672–748 nm, em = 765–855 nm; 50
ms exposure time) and Cy5 (ex = 590–650 nm, em = 662–738 nm; 500 ms exposure time)
filters. The control images are from an MCTS without the addition of the probe. Scale bar =
200 m. The dark center in DIC images is the necrotic core.
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Figure 2.27 Corresponding fluorescence increase of the MCTSs in Figure 2.26. Fluorescence
intensity is the average of measurements from four different spheroids, with error bars of ± one
standard deviation.
2.3.17 Fluorescence Dequenching of Q3STCy under In Vivo Conditions
Before moving on to possible animal studies, I examined whether Q3STCy is stable under
in vivo conditions. The fluorescence response of Q3STCy was measured in the presence of 50%
fetal bovine serum (FBS), Figure 2.28. Even though the immediate fluorescence signal at 820 nm
increased and reached a plateau in less than 10 min, this fluorescence increase profile was
distinct from that with the treatment of hNQO1. The fluorescence wavelength shift did not appear
in the obtained spectra, indicating that treatment with FBS was not able to initiate the production
of TCy. I posit that the fluorescence increase around 820 nm is caused by the unfolding of the
quenched Q3STCy probe in altered environments, not interferent-induced activation/removal of
the quinone group of the probe. To verify this hypothesis, the FBS treated Q3STCy solution for 60
min was inspected by mass spectrometry. Besides ions associated with proteins at m/z > 1000,
only the mass peaks of the unactivated Q3STCy probe (m/z = 842.4534) were observed. The
signal of the TCy reporter (m/z = 506.3535) did not appear in the spectrum, indicating there was
no formation of TCy under these conditions. This outcome supported the conclusion that the
Q3STCy probe is not activated by the presence of FBS, but rather its ~820-nm emission is
increased, most likely the result of decreased PeT quenching from the fluorophore donor to the
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quinone acceptor. FBS is composed of a variety of proteins. The addition of FBS to the PBS
solution greatly altered the viscosity and polarity of the resulting solution. The binding of the
heptamethine fluorophore to the proteins probably separated the fluorophore from the quinone
moiety, resulting in the decreased PeT quenching. The emission peak of Q3STCy shifted from

Figure 2.28 (A) Fluorescence spectra of a 12.5 μM Q3STCy solution in PBS/FBS (50%:50%).
25 μM Q3STCy in PBS (2 ml) was mixed with 100% FBS (2 mL), resulting in the desired
solution, whose fluorescence was monitored for 60 min at room temperature; (B) Mass spectra
of solution from A achieved by electrospray ionization-mass spectrometry.
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798 nm to 820 nm is in accordance with observation stemming from the established emission
peak of ICG in human plasma.85 The latter is well known to bind rapidly to plasma in the human
body.86
2.3.18 Identification of Peritoneal Ovarian Cancer Micrometastases in an In Vivo Mouse
Xenograft Model
Having demonstrated successful detection of upregulated hNQO1 activity within various
cancer cell lines cultured in two and three dimensions, I wished to explore the potential of the
Q3STCy probe for in vivo identification of tiny cancer foci in an animal model. The ability to
visualize and surgically remove <1-mm-diameter metastatic lesions that result from
intraperitoneal dissemination will have important ramifications in the treatment of colorectal,
gastric, pancreatic, and ovarian cancers. For example, it has been shown that the median overall
survival of patients is twice as great (64 months) if the surgeon is able to remove ovarian cancer
tumors less than 1-mm in dimension versus patients with residual diseased tissue larger than 1
mm.87
Successful resection of such small cancers is predicated on their identification/detection,
a feat impeded by poor differentiation of diseased and healthy tissues during traditional white light
examination.88-89 Fluorescence-guided surgery88,

90-91

that is based on topical application of

activatable probes holds much promise for discrimination of tissues,92-94 because such turn-on
probes outshine their always-on fluorescent counterparts as a result of increased target-tobackground signal ratio and exceedingly rapid nature of the visualization events, often times on
the timescale of min.89

Importantly, cell-permeable probes that are activated by cancer-

associated intracellular enzyme targets to yield cell-retained fluorescent reporters hold the
possibility of providing diseased/healthy tissue discrimination with near cellular resolution. To
date, only two intracellular enzyme–probe systems have been used to detect human cancers in
preclinical studies, namely, one based on -galactosidase73 that is overexpressed in ovarian

129

cancers and another targeting hexosaminidase, which is upregulated in colorectal cancer cells;95
both enzymes reside in the lysosomes.
Exposure

of

peritoneal

xenograft

tumors

in

living

mice

to

dilute solutions of Q3STCy probe subsequently affords ready detection of ovarian cancer tumors
as small as ~0.5 mm diameter, Figure 2.29. Although imperceptible by white light, the tiny ovarian
cancer tumors are clearly visible in spectral images of the excised mesentery that correspond to
the red fluorescent protein (RFP)-transfected SHIN3 cells and their interaction with the Q3STCy
probe. We selected the low hNQO1-expressing SHIN3 cells in the xenograft studies so as to
demonstrate the capabilities of the Q3STCy probe. There was no detectable signal in control
animals that were not exposed to Q3STCy; Figure 2.29 Control. Importantly, spectral acquisition
and unmixing allows for examination of the integrity of cancer foci identification by the Q 3STCy
probe, which is achieved by a side-by-side comparison of the resulting “Q3STCy image” and the
“RFP image” produced by the genetically encoded fluorescent protein in the SHIN3-DsRed
ovarian cancer cells.96 As seen in Figure 2.29, the fluorescence signal generated by Q 3STCy
incubation in the peritoneum of mice possessing SHIN3-DsRed tumors is mostly coincident with
RFP-positive foci, thereby demonstrating the ability of the NIR probe to identify the presence of
the hNQO1-overexpressing SHIN3 cells. However, in the Q3STCy image, fluorescence signal is
sometimes noted in areas of the small bowel adjacent to the RFP-labelled tumor nodules,
suggesting possible non-specific activation of the probe within healthy, neighboring cells in these
regions. It is posited this observation is actually due to probe activation in healthy cells having a
higher-than-normal hNQO1 activity that results from their being stimulated by-products released
from their cancer cell neighbors. Such a scenario is supported by reports of higher-than-normal
hNQO1 expression within some healthy tissues in immediate proximity to cancerous tissue;97 this
was attributed to induced hNQO1 activity in normal tissue cells by membrane-permeable
materials released from tumor cells,98-99 with said inducing agents potentially being the cause of
increased hNQO1 activity in cancer cells cultured at high cell density. 37, 100 This observation with
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hNQO1 may eventually lead to limitations in the resolution of surgical resections that rely upon
hNQO1-based probes, similar to what is possible with extracellularly- activated probes whose
reporters may enter cancerous and nearby healthy cells.

White Light

RFP

Q3STCy

5 mm

5 mm

5 mm

Control

SHIN3 Xenograft

It is of particular note that short exposure times and dilute concentrations of the Q3STCy probe in

Figure 2.29 Visualization of peritoneal metastases in SHIN3 mouse model of human ovarian
cancer via fluorescence spectral imaging of mesentery at 1 h post intraperitoneal
administration of Q3STCy (300 L of 100 M probe in pH 7.4 PBS). Red fluorescent protein
(RFP) signal results from the RFP-transfected cells (SHIN3-DsRed). Control designates
mouse having no xenograft and treated with Q3STCy. Scale bar = 5 mm.
the peritoneum result in the effective identification of peritoneally disseminated ovarian cancer by
fluorescence-activated imaging, in a spectral range that allows for deep penetration of light into
tissue. These outcomes are quite valuable, as the construction and successful use of NIR probes
and reporters for in vivo biomedical imaging applications is exceedingly challenging.
Development of enzyme-activatable, cell-penetrable NIR probes is complicated by the multitude
of structure and size limitations imposed on the probe, often times making so poor the efficiency
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of enzymatic activation that topical application of probe is no longer feasible. As a result, the use
of intravenously delivered always-on fluorescent molecules that target cell surface uptake
receptors has been extensively investigated, but they often times yield high background
fluorescence signals that decrease the TBR due to their being taken up by cancer tissue in nonspecific97 or inefficient101 ways. Although synthetic elaboration of the structure of tissue-targeting
NIR molecules can yield lower background signal,102 the time needed for them to reach the target
site is large. Also, due to their intravenous delivery at relatively high concentrations, they face the
prospect of regulatory agency approval, similar to that for new drug molecules. 88 Furthermore,
systemically-introduced reporters cannot access remote diseased tissues, such as multicellular
tumor spheroids associated with ovarian cancer metastasis and reoccurrence.80

Thus, the

achievements with the Q3STCy NIR probe demonstrate the strength of locally applied, activatable
molecules for fluorescence-based identification of diseased tissues, particularly those
overexpressing reductases that are key to disease progression.
2.4

Conclusion
A novel NIR probe, Q3STCy, was designed, synthesized, and biologically evaluated, which

was successfully applied in the detection and visualization of endogenous intracellular human
NAD(P)H: quinone reductase (hNQO1) activity in two- and three-dimensional cancer cell cultures
and an in vivo preclinical model of peritoneally disseminated ovarian cancer. The Q3STCy probe
comprises 1) an hNQO1-specific substrate tri-methyl locked quinone propionic acid (Q3PA) trigger
that is reduced to its hydroquinone effectively by an appropriate reducing agent, 2) a selfeliminating linker, 2-mercaptoethanol that separates the Q3PA trigger from the bulky reporter, and
3) a hemptamethine fluorophore TCy emitting intense NIR light for fluorescence reporting. The
probe

Q3STCy probe and the TCy reporter have distinctive spectroscopic characteristics (𝜆abs
reporter

nm vs 𝜆abs

probe

= 606 nm and 𝜆em

reporter

= 798 nm vs 𝜆em

= 786

= 755 nm). This stark spectral

difference was attributed to their altered electronic molecular orbitals as evidenced by frontier
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molecular orbital calculations. Q3STCy exhibited a low fluorescence efficiency caused by the
donor-excited-photoinduced electron transfer (d-PeT) quenching as verified by electrochemical
voltammetry.
Upon hNQO1-specific reduction, the quinone recognition substrate (Q3PA) was reduced
to its corresponding unstable hydroquinone that was cleaved through the intramolecular formation
of lactone. This process triggered the removal of the 2-mercaptoethanol linker through the
formation of 1,3-oxathiolan-2-one, resulting in the release of the highly fluorescent NIR
heptamethine TCy reporter. The detection mechanism was substantiated by the unique spectral
response of the Q3STCy solution to the addition of hNQO1 and by the LCMS studies of the
probe/enzyme reaction mixtures. The cloaked fluorescence of Q3STCy was revealed by hNQO1
in aqueous solutions within a brief period course (< 30 min) with a large SBR ratio (193-fold).
Further enzymatic kinetics evaluation exhibited that Q3STCy had a strong affinity to hNQO1 (Km
= 1.09 ± 0.471 M) and an unprecedented high catalytic efficiency (kcat/Km = 1.49 × 105 ± 0.682 ×
105 M–1s–1). This is probably caused by the effective separation between the hNQO1 recognition
substrate (Q3PA) and the bulky fluorophore TCy by the flexible 2-mercaptoethanol linker allowing
the immediate penetration of Q3STCy into the reactive site of hNQO1. Stability and selectivity of
the probe/reporter system were examined by exposing both probe and reporter to putative
competing reducing interferents (thiols and reductases) and various pH solutions.
The ability of Q3STCy to differentiate cell lines with various intracellular hNQO1 activities
(HT-29, H596 (+), SHIN3, and H596) was investigated using fluorescence microscopy. A large
fluorescence turn-on was observed in hNQO1-expressing cell lines (HT-29, H596 (+), and SHIN3),
but limited fluorescence was formed in hNQO1 non-expressing cell line (H596); these outcomes
reflect the ability of Q3STCy to detect and differentiate human cancer cells possessing varied
hNQO1 activity levels. The high fluorescence observed for the hNQO1-gene transfected H596
cell line, H596 (+), clearly indicated that Q3STCy was activated by hNQO1 in a highly selective
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manner. Through the colocalization study, the ultimate location of the produced TCy reporter was
shown to be mainly in lysosomes, thereby offering enhanced cellular retention.
Furthermore, it was demonstrated that the developed probe/reporter system allowed facile
detection and imaging of three-dimensional multicellular tumor spheroids (MCTSs) possessing
spatially heterogeneous hNQO1 activities. In a mouse xenograft model, peritoneal injection of
dilute solutions of the probe led to ready identification and visualization of human ovarian cancer
tumors as small as 0.5-mm dimension. The specificity and sensitivity of detecting disseminated
ovarian metastases in vivo were further studied by a collaborating group, and reported in a
separate publications.103 It was found that Q3STCy can provide high sensitivity (96.9%) and
moderate specificity (61.0%). Both sensitivity and specificity can be improved to 100% by
employment of clinically relevant imaging methodologies.
2.5
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CHAPTER 3
A NEAR-INFRARED, FAST-RESPONSIVE, AND ON-ON FLUORESCENT PROBE TO
VISUALIZE AN INTRACELLULAR CANCER-ASSOCIATED QUINONE REDUCTASE IN
CELLS AND MULTICELLULAR TUMOR SPHEROIDS
3.1

Introduction
Smooth progression of dynamic biological processes in living subjects relies on the

precise and deliberate actions of abundant enzymes. Abnormal enzymatic activities often indicate
the onset and progression of some specific diseases. Sensitive, selective, and rapid detection of
enzyme activity will unravel the roles of such an enzyme in biological processes, greatly broaden
human understanding of physiological and pathophysiological mechanisms, and potentially
contribute to the successful design of precision medicines.1-2 Fluorescence imaging as a sensitive
and non-invasive technique has the potential to report the enzymatic presence in vitro and in vivo
in conjugation with the use of enzyme-targeting fluorescent probes in real-time and high resolution.
The development of enzyme-specific, small-molecule fluorescent probes is based on always-on
and off-on probe design strategies.3 Highly specific always-on fluorescent probes can be
constructed through direct conjugation of fluorophores to specific enzyme targeting groups, such
as monoclonal antibodies (mAbs), aptamers, and enzyme-specific binding molecules with high
affinity. However, to generate a detectable target-to-background ratio (TBR), a longer exposure
period is required for the systemic clearance of the unbound fluorescent probe.4 Always-on probes
do not fully exploit the catalytic feature of an enzyme, which is very important to amplify the signal
in the targeted area to report enzyme presence. In contrast, high TBR values can often be
achieved with an off-on fluorescent probe due to the enzymatic amplification effect.4 However, to
achieve rapid and sensitive detection of enzymes with activatable fluorescent probes, the
designed probes are required to have certain characteristics such as efficacious enzyme kinetics
and a rapid fluorescence turn-on rate.
Reductases, which are overexpressed in tumor and other diseased cells often caused by
the cellular accumulation of the reactive oxygen species (ROS), have been broadly investigated
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as biomarkers to design targeted medicines.5 Among the reductase family, hNQO1 has attracted
great attention in the scientific community due to its close relation to tumor invasiveness and
progression, and its overexpression in a multitude of tumor cell lines.6 Optical imaging of hNQO1
in vitro and in cellulo with the use of enzyme activatable fluorescent probes has been recently
investigated by the McCarley group7-10 as well as the colleagues groups.11-15 However, both the
absorbance and fluorescence of all the developed probes for hNQO1 lie within the ultraviolet (UV)
and visible range of the electromagnetic spectrum. Short excitation and emission wavelengths
suffer from strong autofluorescence and shallow detection depth; in addition, their use can cause
damage to applied biological systems.16 Considering that NIR light is capable of avoiding the
aforementioned drawbacks, I described in the previous chapter a fluorescent probe Q3STCy
whose NIR fluorescence was selectively and effectively decloaked by hNQO1. Q3STCy was also
successfully employed to report hNQO1 activity in hNQO1-expressing cells, multicellular tumor
spheroids (MCTSs) with spatially heterogeneous hNQO1 expression, and ovarian cancer
derivative metastases in mouse xenograft models.17 Despite its high enzyme kinetics, the
relatively slow cleavage of the 2-mercaptoethanol linker curtailed the release rate of the strongly
fluorescent reporter. The linker is flexible and thus the distance between the hNQO1 recognition
substrate, Q3, and the fluorophore, TCy, can become short in aqueous solutions due to its folding
structure. The short distance greatly enhanced the photoinduced electron transfer (PeT) efficiency
and quenched the fluorescence of Q3STCy, thus making Q3STCy an ideal off-on probe. Hence, if
the 2-mercaptoethanol linker were to be substituted by a rigid and fast-eliminating linker, a
fluorescent probe could be crafted with improved imaging capability, such as faster reporter
release and on-on fluorescence in an energetically distinct wavelength range. The linker Nmethyl-p-aminobenzyl alcohol (NMPABA) has a fast cleavage rate (within minutes) and the
methyl group can inhibit the formation of a spirolactam with quinone.18-20 Therefore, NMPABA was
selected as the linker to construct a new fluorescent probe, dubbed Q3NTCy.
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Herein, a fast-responsive NIR fluorescent probe, Q3NTCy, was designed, which is capable
of sensitive and selective detection of hNQO1 in both off-on and on-on imaging modes. It was
successfully employed for imaging hNQO1-expressing cells and multicellular tumor mimics with
spatially heterogeneous hNQO1 expression. Q3NTCy had a tripartite structure: 1) the Q3
recognition substrate, which can be selectively reduced by hNQO1 in the presence of its cofactor
NADH; 2) the rigid and fast-eliminating linker N-methyl-p-aminobenzyl alcohol (NMPABA),
predicted for effectively separating efficiently the Q3 substrate and the fluorophore TCy; 3) the
bright fluorophore TCy, acting as a reporter emitting NIR light. The cleavage mechanism was
proposed as in Scheme 3.1. Upon the reduction by hNQO1, the Q3 motif was rapidly reduced and
cleaved off in the form of lactone, followed by the cleavage of the self-eliminating linker NMPABA
and the production of the strongly fluorescent TCy reporter.

Scheme 3.1 Proposed activation mechanism of Q3NTCy by hNQO1.
3.2

Experimental Section

3.2.1

Synthetic Materials and Methods
All the chemicals and solvents in the synthesis were purchased from Sigma-Aldrich or

Fisher Scientific, unless otherwise stated, and used without further purification. Thin-layer
chromatography (TLC) separation was performed on Aluminum-backed 60 F254 silica plates
purchased from EMD Chemicals. Preparative separation and purification of crude products were
performed on a FlashMaster Personal (Biotage) with Biotage SNAP KP-Sil flash cartridges (50-g,
25-g, or 10-g size). 1H and 13C NMR spectra were measured in deuterated chloroform (CDCl3) on
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a Bruker AVIII-500 nuclear magnetic resonance (NMR) spectrometer at 25 ºC. Chemical shifts in
the NMR spectra were reported in the standard  notation of parts per million, and calibrated by
the residual protio-solvent of CDCl3 (7.26 for 1H and 77.16 for 13C). Absorption bands in the NMR
spectra were listed as singlet (s), doublet (d), triplet (t), or multiplet (m), and coupling constants
(J) are reported in hertz (Hz). Mass spectra were measured with an Agilent 6210 ESI-TOF high
resolution mass spectrometer.

Scheme 3.2. Synthetic scheme of Q3NTCy.
3.2.2

Synthesis
The starting materials quinone propionic acid (Q3PA), and tricarbocyanine compound

(TCy) were obtained as described in Chapter 2. 4-(tert-butyldimethylsilyloxy)-N-methylamino)
benzyl alcohol was synthesized by following the reported procedures with necessary
modifications.20 The synthetic route of Q3NTCy is outlined in Scheme 3.2.
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Synthesis of compound 2. Q3PA (250 mg, 1 mmol) was dissolved in 18 mL anhydrous
DCM in a 25 mL round-bottom flask under nitrogen conditions. The solution was cooled to – 50
ºC in an acetone/dry ice cooling bath, followed by the injection of N-methylmorpholine (330 L, 3
mmol) and isobutyl chloroformate (145 L, 1.1 mmol). The reaction was allowed to proceed for
15 minutes, then 4-(tert-butyldimethylsilyloxy)-N-methylamino) benzyl alcohol (276 mg, 1.1 mmol)
in 2 mL anhydrous DCM was injected into the solution slowly. After 6 h, the solution was washed
with water and brine, then dried by magnesium sulfate, which was removed through filtration.
After removing the organic solvent in a rotary evaporator, the crude product was purified with a
silica gel column using hexane/ETHYL ACETATE (6/1) as the eluent yielding a pale yellow oil
product (391 mg, 81%). 1H NMR (500 MHz, CDCl3)  7.38 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.0 Hz,
2H), 4.77 (s, 2H), 3.13 (s, 3H), 2.73 (s, 2H), 2.08 (s, 3H), 1.99 (s, 3H), 1.95 (s, 3H), 1.28 (s, 6H),
0.95 (s, 9H), 0.12 (s, 6H). 13C NMR (126 MHz, CDCl3)  191.33, 187.80, 172.26, 154.98, 143.76,
142.77, 141.30, 137.80, 136.25, 127.41, 127.36, 64.52, 47.63, 38.17, 37.21, 28.52, 26.06, 18.54,
14.16, 12.85, 12.22, -5.15. ESI-HRMS: for C28H41NO4Si: expected m/z = 484.2878 [M + H]+; found
m/z = 484.2891 [M + H]+; 2.7 ppm error.

Synthesis of 3-(3ʹ,6ʹ-dioxo-1ʹ,2ʹ,4ʹ-trimethylcyclohexa-1ʹ,4ʹ-dienyl)-3,3-dimethylpropionic
acid 4-(N-methylamino) benzyl alcohol amide (4). Compound 2 (95 mg, 0.2 mmol) was dissolved
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in 5 mL anhydrous THF solvent in a 20 mL round-bottom flask under nitrogen. The solution was
then cooled to 0 ºC in an ice-water bath. 1 M TBAF in THF (220 L, 0.22 mmol) was diluted further
by 0.8 mL THF, which was injected to the previous solution slowly. After 10 minutes, the reaction
was quenched by saturated ammonium chloride solution. The quenched reaction solution was
put in a rotary evaporator to remove THF, followed by extraction with DCM. The combined organic
phase was then washed with water and brine, and then dried with MgSO4. The crude product was
then purified using a silica gel column with hexane/ethyl acetate (1/1) as the eluent, yielding a
pale yellow solid product 3 (53 mg, 72%). 1H NMR (500 MHz, CDCl3)  7.43 (d, J = 8.0 Hz, 2H),
7.18 (d, J = 8.0 Hz, 2H), 4.74 (s, 2H), 3.14 (s, 3H), 2.73 (s, 2H), 2.08 (s, 3H), 1.99 (s, 3H), 1.94
(s, 3H), 1.28 (s, 6H).

C NMR (126 MHz, CDCl3)  191.36, 187.83, 172.24, 154.89, 143.73,
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143.34, 140.73, 137.89, 136.36, 128.41, 127.64, 64.68, 47.71, 38.19, 37.24, 28.56, 14.19, 12.86,
12.23. ESI-HRMS: for C22H27NO4: expected m/z = 370.2013 [M + H]+; found m/z = 370.2023 [M
+ H]+; 2.7 ppm error.

Synthesis of Q3NTCy. Compound 3 (30 mg, 0.081 mmol) in 5 mL anhydrous THF solvent
was cooled to 0 ºC in an ice-water bath in a sealed 20 mL vial, followed by the injection of 15%
phosgene (caution: toxic) in toluene (0.6 mL, 0.84 mmol). After 2 h, the solvent was removed in
a rotary evaporator with aqueous NaOH solution (1 M) in the trap to neutralize the extra phosgene.
The afforded residue was then dissolved in 1 mL anhydrous DCM, and this was then injected to
TCy (10 mg, 0.016 mmol) in an anhydrous DCM solution with N,N-diisopropylethylamine (DIPEA,
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0.1 mL) under nitrogen. The solution was allowed to stir for 6 h at room temperature, during which,
a change of the solution color from blue to green was observed. After removing the solvent in a
rotary evaporator, the crude product was purified using a silica gel column with methanol/DCM
(1:99 to 5:95) as the eluent to yield a green product Q3NTCy (14 mg, 85%). 1H NMR (500 MHz,
CDCl3) (rotamers)  7.63 (d, J = 14.0 Hz, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H),
7.29 (d, J = 8.0 Hz, 2H), 7.22 (t, J = 7.5 Hz, 2H), 7.13 (d, J = 8.0 Hz, 2H), 7.05 (d, J = 8.0 Hz, 2H),
6.23 (d, J = 14.0 Hz, 2H), 5.24 (s, 2H), 4.26 (q, J = 7.5 Hz, 4H), 3.35 (s, 3H), 3.05 (s, 3H), 2.84–
2.7 (m, 4H), 2.59 (s, 2H), 2.15–1.80 (m, 11H), 1.66 (s, 6H), 1.50–1.36 (m, 12H), 1.20 (s, 6H). 13C
NMR (126 MHz, CDCl3) (rotamers)  191.17, 187.63, 171.85, 171.08, 155.66, 155.19, 154.50,
143.53, 143.41, 141.81, 141.41, 141.13, 141.00, 137.84, 136.31, 136.13, 128.92, 128.74, 127.80,
127.45, 125.26, 122.34, 122.23, 110.66, 101.35, 101.15, 66.66, 49.08, 47.66, 39.97, 39.85, 38.52,
37.91, 36.95, 28.47, 28.36, 28.06, 25.06, 24.78, 20.84, 14.06, 12.71, 12.56, 12.44, 12.11. ESIHRMS: for C58H69N4O5: expected m/z = 901.5262 [M]+; found m/z = 901.5259 [M]+; 0.3 ppm error.
3.2.3

Spectroscopic Measurement Methods
Q3NTCy and TCy were dissolved in DMSO to make their respective stock solutions (1 mM)

and stored in a refrigerator (– 20 °C) until use. The stock solutions were used to prepare their
corresponding diluted sample solutions. Spectroscopic measurements were performed in 0.1 M
phosphate-buffered saline/0.1 M KCl (PBS, pH = 7.4). The PBS buffer was prepared with water
(> 18 MΩcm) from a Barnstead NANOpure Diamond water System. UV-visible absorption
spectra and fluorescence spectra were recorded in a 10-mm path length quartz cuvette on a
Varian Cary-50 spectrophotometer and a PerkinElmer LS55 spectrofluorometer.
3.2.4

Quantum Yield Measurement for Q3NTCy and TCy
The measurement of quantum yield of TCy was described in Chapter 2. The quantum

yield of Q3NTCy in 2% DMSO/PBS solution (pH = 7.4) was measured with indocyanine green
(ICG,  = 0.012 in water) as a standard.21 The quantum yields of Q3NTCy, Q3NNTCy, Q3STCy,
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iBuTCy in acetonitrile were measured with ICG ( = 0.13 in DMSO) as a standard.21 ICG was
purchased from Sigma-Aldrich. Relative quantum yields () of respective compounds in PBS or
acetonitrile were calculated relative to ICG using the following equation:
𝐺𝑟𝑎𝑑

𝛷x = 𝛷𝑠𝑡 (𝐺𝑟𝑎𝑑 𝑥 ) (
𝑠𝑡

𝜂𝑥2

2
𝜂𝑠𝑡

)

where the subscripts st and x stand for standard and test sample, respectively. is the quantum
yield,  is the refractive index of solvent, and Grad is the gradient from the plot of integrated
fluorescence intensity vs absorbance.
Stock solution of Q3NTCy (1 mM in DMSO) was diluted by 0.1 M PBS solution, resulting
in 0.8, 1.4, 1.8, and 2.2 M Q3NTCy solution with 2% DMSO as a co-solvent. The absorbance at
725 nm was maintained between 0.02–0.10 to minimize reabsorption effects. The Q3NTCy
solutions of various concentrations were excited at 725 nm and their corresponding emission
spectra were collected. Both absorption and emission spectra of each solution were collected
three times. Similarly, the absorption and emission spectra of ICG solutions with various
concentrations were collected. The gradients of Q3NTCy and ICG were plotted and obtained, with
them being used in the previous equation to calculate the quantum yield of Q3NTCy. The quantum
yield of Q3NTCy was determined to be 0.012.
3.2.5

Enzyme Kinetics
The hNQO1 enzyme (500,000 U mg–1, 1 U = 1 nmol of cytochrome C reduced min–1) was

purchased from Sigma-Aldrich. hNQO1 was dissolved in 0.1 M PBS to prepare the hNQO1 stock
solution (0.5 mg mL–1). Reduced -nicotinamide adenine dinucleotide (NADH, Sigma Aldrich) and
bovine serum albumin (BSA, Sigma Aldrich) were dissolved in 0.1 M PBS (pH = 7.4) to yield a
solution containing 100 M NADH and 0.007% BSA; this solution was prepared freshly and used
for the following tests. Q3NTCy sample solutions with 0.5–12 M final concentration were
prepared using the previously prepared stock solution. 1.5 mL of a given Q3NTCy sample solution
was added with 3 L of the hNQO1 stock solution (0.5 mg mL–1), resulting in a 1 g mL–1 hNQO1
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concentration (500 U mL–1). After the hNQO1 was added, fluorescence at the TCy reporter energy
(ex = 600 nm, em = 755 nm) was immediately collected every 2 s over a 5-min time period using
a PerkinElmer LS55 spectrofluorometer at 25 °C. Each solution was measured three times.
Released TCy reporter concentration was obtained by converting the fluorescence signal with a
calibration curve of TCy in the same buffer system. By fitting the TCy reporter release velocities
versus Q3NTCy concentrations via nonlinear least-squared analysis, the apparent kinetic
parameters Km and Vmax were obtained.
3.2.6

Cell Culture
HT-29 (human colorectal adenocarcinoma), A549 (non-small cell lung cancer cells), and

H596 (human nonsmall cell adenosquamous lung carcinoma) were all purchased from American
Type Culture Collection (ATCC; Manassas, VA). SHIN3 cells were provided by Dr. Hisataka
Kobayashi at National Cancer Institute of U.S. National Institutes of Health. Unless stated
otherwise, cell culture media, fetal bovine serum albumin (BSA), and other supplements were
also purchased from ATCC. HT-29 cells were cultured in McCoy’s 5A medium, while A549, SHIN3,
and H596 were cultured in RPMI-1640 medium. All the media were supplemented with 10% fetal
bovine serum, 10 IU mL−1 penicillin, and 10 g mL−1 streptomycin (Life Technologies). Cells were
incubated in 75 cm2 treated tissue culture flasks in the dark at 37 °C under 5% CO 2/95% air in a
humidified incubator.
3.2.7

Cellular Fluorescence Imaging Using Confocal and Wide-field Microscopy
HT-29, A549, SHIN3, and H596 cells (0.3 million each) were cultured overnight in the dark

at 37 ºC on 22 × 22 mm sterile glass coverslips (no. 1-1/2; Corning). After the old medium was
replaced and the cells were washed with PBS once, the cells were cultured with 5 × 10-6 M
Q3NTCy in the phenol red and L-glutamine free RPMI-1640 medium at 37 ºC for 20 min. The
medium was then removed, and the cells were washed with PBS (pH 7.3, Dulbecco) twice. 4%
paraformaldehyde (PFA) was used to fix the cells for 15 min with shaking at room temperature in
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the dark. After the PFA solution was removed, the fixed cells were bonded to microscope glass
slides with a mounting medium (Immu-Mount, Fisher Scientific). These prepared slides were left
in the dark overnight at room temperature to allow the mounting medium to dry. Then the slides
were used for confocal microscopy and wide-field microscopy imaging experiments.
Confocal cell images were captured with a Leica TCS SP2 spectral laser-scanning
confocal microscope. The microscope was used with a 40× oil immersion objective (NA: 1.25)
and a beam splitter (TD 488/543/633). The pinhole was set as 1.0 airy unit (AU, 82 m). The
prepared cell slides were excited at 633 nm with a helium-neon laser (laser intensity = 25%), and
the emitted photons in the range of 670–750 nm wavelengths were collected with a photomultiplier
detector (PMT, voltage = 533 V). Cellular images were zoomed 3.2 fold and captured after being
frame and line averaged 4 times.
Conventional (wide-field) fluorescence images were captured with a Leica DM6 wide-field
microscope equipped with an ORCA-Flash 4.0 Hamamatsu Digital CMOS camera. A 40x oil
immersion objective (1.30 NA) was used. A Cy5 filter (excitation: BP 590–650 nm, dichroic mirror:
660 nm; and emission: BP 662–738 nm) was selected to capture the fluorescence images from
the TCy reporter, with 500 ms exposure time. The Cy7 filter (excitation: BP 672–748 nm, dichroic
mirror: 760 nm; and emission: BP 765–855 nm) were selected to capture the fluorescence images
from the Q3NTCy probe with 50 ms exposure time. Image analysis and statistical evaluation of
cytosolic intensities from both confocal and conventional fluorescence microscopes were
accomplished with Fiji/ImageJ software.
3.3

Results and Discussion

3.3.1

Spectroscopic Properties of the Probe/Reporter Pair
Q3NTCy was prepared efficiently in a facile synthetic route (Figure 3.2). All the obtained

compounds were characterized and their structures were determined by 1H, 13C-NMR, and HRMS.
With the synthesized Q3NTCy probe in hand, its spectroscopic characteristics in an aqueous
solution (0.1 M PBS, pH = 7.4) was firstly measured. As shown in Figure 3.1, the absorption and
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𝑝𝑟𝑜𝑏𝑒

emission peaks of the Q3NTCy probe (𝜆𝑎𝑏𝑠

𝑝𝑟𝑜𝑏𝑒

= 786 nm and 𝜆𝑒𝑚

= 798 nm) had bathochromic
𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑟

shifts of 180 nm and 43 nm respectively compared to that of the TCy reporter (𝜆𝑎𝑏𝑠
𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑟

and 𝜆𝑒𝑚

= 606 nm

= 755 nm). This prominent difference in their spectroscopic properties was attributed

to the change of electronic energy levels of Q3NTCy and TCy. The introduction of the electron-
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Figure 3.1 Absorption and emission spectra of 2 × 10–6 M Q3NTCy (A) and 3 × 10–6 M TCy (B)
in 0.1 M PBS solution (pH = 7.4) with DMSO (2%, v/v) as co-solvent. T = 25 ºC.
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the HOMO-LUMO energy gap of Q3NTCy, resulting in its longer absorption/emission
wavelength.22-23 The quantum yield of Q3NTCy in aqueous solution (2% DMSO: 98% PBS, pH =
7.4) were measured as 0.012 relative to indocyanine green (ICG). Q3NTCy had a similar
fluorescence efficiency as ICG, which was three-fold higher and two-fold lower than the probe
Q3STCy ( = 0.0046) and the fluorophore analogue iBuTCy ( = 0.024), without the Q3PA moiety,
described in Chapter 2. Considering the rigid linker NMPABA of Q3NTCy separated the
fluorophore and the quinone moieties more efficiently that the flexible linker 2-mercaptoethanol of
Q3STCy, the degree of photoinduced electron transfer (PeT) of Q3NTCy from the fluorophore
donor to the quinone acceptor was lower than for Q3STCy. The quantum yield of TCy in the same
solution was determined to be 0.063.23 Both the Q3NTCy probe and the TCy reporter had high
fluorescence efficiencies and their absorption/emission wavelengths were located in energetically
distinct wavelength regions, which made the probe/reporter pair suitable to act as an on-on
fluorescence reporting system.
3.3.2

hNQO1-initiated Spectral Response of Q3NTCy
The hNQO1-initiated absorption/emission spectral response was next examined in an

aqueous solution (0.1 M PBS, pH = 7.4) in the presence of the hNQO1 cofactor NADH (NADH)
at room temperature. A solution of Q3NTCy (4 M) was treated with hNQO1 (1000 U mL–1, U = 1
nmol of cytochrome c reduced min–1), it was observed in the absorption spectra of Q3NTCy that
an immediate slight increase and then a decrease at 786 nm accompanied by an increase at 606
nm with an isosbestic point at 655 nm, Figure 3.2. The 786 nm and 606 nm absorption bands
were in agreement with that of the Q3NTCy probe and the TCy reporter, respectively. The spectral
changes were caused by the hNQO1-induced consumption of Q3NTCy and concomitant
production of TCy. HPLC-mass spectrometry data also corroborated TCy release.
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Figure 3.2 Time-dependent absorption spectra of Q3NTCy (4 M) in 0.1 M PBS solution (pH =
7.4) containing NADH (100 M) and BSA (0.007%) initiated by the addition of hNQO1 (2 g mL–
1
, 1000 U mL–1). The spectra were measured every 4 min. T = 25 ºC.
The

prominent

photophysical

properties

of

Q3NTCy

and

TCy

(the

distinct

absorption/emission profiles and high fluorescence efficiencies) motivated me to investigate the
possibility of the probe/reporter pair to be a ratiometric system. A solution of Q3NTCy (4 M) upon
the addition of hNQO1 (1000 U mL–1) was excited at its isosbestic point 655 nm, and emission
spectra were collected every 2 min, Figure 3.3. An immediate fluorescence increase at 798 nm
was observed, and the peak gradually moved to 755 nm. The initial cleavage of the quinone
moiety by hNQO1 was most likely the cause of the fluorescence increase at 798 nm. The
corresponding ratio of fluorescence intensity at 755 nm to that at 798 nm was plotted, Figure 3.3.
As time increased, the ratio showed a decrease at the onset of the experiment, then a steady
linear increase occured, followed by a plateau. These outcomes indicated that the ratio
interpretation was affected by the slight fluorescence quenching of Q3NTCy in the PBS solution.
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Figure 3.3 (A) Time-dependent emission spectra of Q3NTCy (4 M, ex = 655 nm) in 0.1 M PBS
solution (pH = 7.4) containing NADH (100 M) and BSA (0.007%) initiated by the addition of
hNQO1 (2 g mL–1, 1000 U mL–1). The spectra were collected every 2 min. (B) The corresponding
fluorescence intensity ratio (F765/F798) change. T = 25 ºC.
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Figure 3.4 (A) Time-dependent emission spectra of Q3NTCy (2 M, ex = 655 nm) in FBS/PBS
(20%:80%, v/v) containing NADH (100 M) and BSA (0.007%) initiated by the addition of hNQO1
(1 g mL–1, 500 U mL–1). The spectra were collected every 3 min. (B) The corresponding
fluorescence intensity ratio (F745/F810) change. T = 25 ºC.
The cytosol is rich in proteins, and its viscosity and polarity are different from the PBS
solutions.24 I next sought to examine the fluorescence response of Q3NTCy towards hNQO1
under cytosol-mimicking conditions. A 20% with fetal bovine serum (FBS) in 0.1 M PBS (pH = 7.4)
solution was employed to mimic the protein-rich conditions. Upon the addition of hNQO1 (500 U
mL–1) to the solution of Q3NTCy (2 M), a slight decrease in fluorescence intensity of Q3NTCy at
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808 nm and a simultaneous fluorescence increase at 750 nm were observed during the 90-min
time period, Figure 3.4. The corresponding ratio of fluorescence intensity at 745 nm to that at 810
nm exhibited a steady increase. These results showed that Q3NTCy could act as a ratiometric
probe under cellular conditions that mimic those inside cells.
3.3.3

Stability of Q3NTCy
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Figure 3.5 (A) Fluorescence spectra of a 25 M Q3NTCy solution (ex = 660 nm) in PBS (20 mM,
pH = 7.4) or PBS/FBS (50%:50%). The fluorescence spectra of 25 μM Q 3NTCy in PBS/FBS
(50%:50%) were collected every 3 min for 30 min at room temperature; (B) Mass spectra of 25
M Q3NTCy upon exposure to the solution of PBS/FBS (50%:50%) for 60 min.
The stability of Q3NTCy in the presence of FBS was further evaluated to investigate
whether there are concerns with its non-specific activation. The fluorescence response of Q3NTCy
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was measured in the presence of 50% fetal bovine serum (FBS), Figure 3.5. Similar to Q3STCy,
fluorescence intensity at 820 nm increased two-fold and reached a plateau in less than 10 min,
and the fluorescence intensity at 755 nm did not increase. The binding of the heptamethine
fluorophore to the proteins probably inhibited the PeT quenching and rigidified its structure,
resulting in the observed fluorescence increase at 820 nm. The behavior of the emission peak at
820 nm is in agreement with the established emission peak of ICG in the human plasma. 25 The
FBS-treated Q3NTCy solution at 60 min was investigated with mass spectrometry. The mass peak
of the unactivated Q3NTCy probe (m/z = 901.5268) was observed, while that of the TCy reporter
(m/z = 506.3535) did not appear in the mass spectra. This result further demonstrated that the
Q3NTCy probe was chemically stable in the presence of FBS, and the two-fold fluorescence
increase at 820 nm was caused by the inhibited PeT quenching of the fluorophore donor to the
quinone acceptor.
3.3.4

Enzymatic Kinetics of hNQO1 with Q3NTCy as a Substrate
To investigate whether the purportedly fast-eliminating linker NMPABA resulted in a rapid

production of TCy, the reporter release rates of Q3NTCy and Q3STCy (Chapter 2) under the same
conditions was measured. As shown in Figure 3.6, the half-time (t1/2) of Q3NTCy to achieve its
maximum TCy release was 15 minutes, a value much faster than that of Q3STCy. To quantitatively
evaluate Q3STCy and Q3NTCy activation by hNQO1, the kinetics of hNQO1 activation of Q3STCy
and Q3NTCy as substrates were measured at room temperature. The apparent parameters were
acquired by plotting the TCy release rate initiated by hNQO1 (1 g mL–1, 500 U mL–1) with various
concentrations of Q3STCy (0.5–12 M) and Q3NTCy (0.5–12 M). For Q3STCy, the enzyme
affinity (Km) was 2.9 ± 0.8 mol, maximum velocity (Vmax) was 0.031 ± 0.004 mol min–1 mg
hNQO1–1, catalytic constant (kcat) was 0.016 ± 0.002 s–1, and catalytic efficiency (kcat/Km) was 5.5
± 1.7 × 103 M–1s–1). In contrast, for Q3NTCy, the enzyme affinity (Km) was 4.5 ± 0.5 mol, maximum
velocity (Vmax) was 0.22 ± 0.01 mol min–1 mg hNQO1–1, catalytic constant (kcat) was 0.12 ± 0.01
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s–1, and catalytic efficiency (kcat/Km) was 2.6 ± 0.3 × 104 M–1s–1). Q3NTCy has a slightly lower
enzyme affinity than Q3STCy, which is evidenced by the larger Km value of Q3NTCy. However,
the catalytic efficiency of Q3NTCy is 5 times larger than that of Q3STCy. Moreover, all the acquired
values for Q3NTCy were comparable to our previous reported probes constructed by directly
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coupling the Q3PA recognition substrate to the fluorophores without a linker.7, 10, 26 This further

16000
14000
12000
10000
8000
6000

5 M Q3NTCy + 1 g/mL hNQO1
5 M Q3NTCy + No hNQO1
5 M Q3STCy + 1 g/mL hNQO1
5 M Q3STCy + No hNQO1

4000
2000
0

0 20 40 60 80 100 120 140 160 180
Time (Min)
Figure 3.6 The fluorescence intensity at 755 nm of 5 M Q3NTCy and 5 M Q3STCy (ex = 600
nm) in aqueous solutions (0.1 M PBS, pH = 7.4) containing 100 M NADH and 0.007% BSA
was recorded with and without the addition of hNQO1 at the 5-min time point. T = 25 ºC.
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Figure 3.7 Kinetic plot of hNQO1 (1 g mL–1, 500 U mL–1) with Q3STCy (A) and Q3NTCy (B)
as substrates in the aqueous solution (0.1 M PBS, pH = 7.4) containing 100 M NADH and
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proved that the NMPABA linker can be automatically cleaved off rapidly. In contrast, the probe
with a naphthalimide reporter had much lower enzymatic kinetic behavior.20 Considering that the
naphthalimide compound is more hydrophobic than the cyanine compound, the quinone
recognizing moiety folding with the naphthalimide group might block its interaction with hNQO1,
thus leading to a non-efficient enzymatic activation.
3.3.5

Cellular Imaging with Q3NTCy as an off-on Fluorescent Probe
Assured by the effective and efficient activation of Q3NTCy by hNQO1 in vitro, I next

sought to examine the capability of Q3NTCy to detect hNQO1 activities in cells. Four cancer cell
lines with various hNQO1 activities were utilized to examine the imaging potential of Q3NTCy. HT29 (colorectal carcinoma cells, hNQO1-expressing), A549 (non-small cell lung cancer cells,
hNQO1-expressing), SHIN3 (ovarian cancer cells, hNQO1-expressing), and H596 (non-small cell
lung cancer cells, hNQO1 non-expressing) cell lines were included as hNQO1-positive and
hNQO1-negative cell lines.
I first utilized Q3NTCy as an off-on probe to examine the intracellular production of the TCy
reporter in the hNQO1-positive cell lines (HT-29, A549, and SHIN3). All four types of cells were
incubated with 5 M Q3NTCy for 20 min under the humidified cell culture conditions with 5% CO2
at 37 °C. Cellular fluorescence images were captured using a Leica TCS SP2 spectral laserscanning confocal microscope. The prepared cellular samples were excited at 633 nm, and their
emission in the range of 660–750 nm was collected. The excitation/emission settings matched
perfectly with the excitation/emission spectra of TCy, while they did not match with that of Q3NTCy.
The minimally excited Q3NTCy emitted light in a longer wavelength range, which would not
interfere the detection signal of TCy-coating cells. Therefore, the settings promised that only the
emission from the hNQO1-induced production of TCy in cells was detected, making Q3NTCy an
off-on probe. As shown in Figure 3.8, strong cytosolic fluorescence was observed in hNQO1positive cells (HT-29, A549, and SHIN3), while almost no detectable fluorescence was observed
in hNQO1-negative cells (H596) under the same imaging conditions. These outcomes indicated
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that Q3NTCy was cell membrane permeable, and it can be rapidly converted to the TCy reporter
by the intracellularly present hNQO1 enzyme. The target-to-background ratios (TBR) of the
acquired cellular images were also determined. The TBR was defined as the emission signal from
the hNQO1-positive cells (HT-29, A549, and SHIN3) compared to that from the hNQO1-negative
cells (H596). It was found that the TBR values of HT-29 (33 cells)/H596 (28 cells), A549 (21
cells)/H596 (28 cells), and SHIN3 (31 cells)/H596 (27 cells) were 7.6 ± 0.6, 6.5 ± 1.0, and 9.8 ±
0.7 (95% confidence) respectively. It was noticed that the obtained TBR values of Q 3NTCy were
much higher than that of Q3STCy; the TBR values for Q3STCy treated cells are 5.4 ± 0.4 for HT29 (53 cells)/H596 (38 cells) and 2.2 ± 0.2 for SHIN3 (32 cells)/H596 (32 cells). As discussed in
the Chapter 2, probable causes were the higher chemical stability of Q3NTCy than that of Q3STCy,
resulting in smaller non-specific activation of Q3NTCy and thus low background signal, and the
fast cleavage rate of the NMPABA allowing more effective production of TCy.
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Fluorescence
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Figure 3.8 Confocal and differential interference contrast (DIC) images of H596, A549, and HT29 cell lines. All the cells were incubated with 5 M Q3NTCy for 20 min under 5% CO2, humidified
conditions at 37 ºC. Fluorescence images were captured in the 670–750 nm emission range upon
excitation by a 633-nm laser. Scale bar = 20 m.
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3.3.6

Cellular Imaging with Q3NTCy as an on-on Fluorescent Probe
After verifying the effective production of TCy inside hNQO1-positive cells, I next

examined the applicability of Q3NTCy to work as an on-on fluorescent probe. An on-on fluorescent
probe is defined as one where both the probe and the reporter are highly fluorescent but their
emitted light is located in different energetic ranges of the electromagnetic spectrum. In contrast
to an off-on probe, an on-on probe has the advantages of being able to monitor the presence of
both the unactivated probe and the produced reporter, which allows for the avoidance of false
negative signals. Probes of this type also allow for gaining information about probe entry into cells.
Q3NTCy treated cellular samples were imaged using a Leica DM6 wide-field microscope. Cy5
and Cy7 filter sets were applied. The Cy5 filter sets (excitation: 590–650 nm, dichroic mirror: 660
nm, and emission: 662–738 nm) have different excitation/emission wavelength range from the
Cy7 filter sets (excitation: 672–748 nm, dichroic mirror: 760 nm, and emission: 765–855 nm). The

TCy
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662-738 nm

Q3NTCy
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Negative

hNQO1 Positive

DIC

Figure 3.9 Wide-field and DIC images of HT-29, A549, and H596 cells. All the cells were
incubated with 5 M Q3NTCy for 20 min under 5% CO2, humidified conditions at 37 ºC.
Fluorescence images were captured with Cy7 (765–855 nm; 50 ms exposure) and Cy5 (662–
738 nm; 500 ms exposure) filters sequentially.
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Cy5 filter sets were utilized to collect emission signal from the TCy reporter, while the Cy7 filter
sets to collect that from the Q3NTCy probe. As shown in Figure 3.9, in the hNQO1-positive cells
(HT-29 and A549), strong fluorescence signal in the 662–738 nm range and dim fluorescence
signal in the 765–855 nm range were observed; the latter comes from the unreacted probe. These
results indicated that Q3NTCy was converted to TCy by hNQO1, which was in agreement with the
previous cellular imaging data of Q3NTCy as an off-on probe. In contrast, for hNQO1-negative
cells (H596), strong fluorescence in the 765–855 nm range, while limited fluorescence in the 662–
738 nm range were observed. This observation proved that Q3NTCy entered H596 cells when it
emitted fluorescence in its original probe state due to the lack of hNQO1 activity in the hNQO1negative cell line. This demonstration clearly showed that an on-on probe has advantages over
an off-on probe that a false negative signal attributed to cellular impermeability of a probe can be
avoided. These cellular imaging experiments indicated that the developed Q3NTCy/TCy pair can
act as both off-on and on-on systems to detect and imaging hNQO1 in cells.
3.3.7

Fluorescence Imaging of Three-Dimensional Tumor Mimic Sections

Figure 3.10 Immunohistochemistry of 5-day-old and 30-day-old MCTS sections. The hNQO1
enzyme was treated with primary mouse anti-hNQO1 monoclonal antibody and biotinylated
secondary antibody conjugated with horseradish peroxidase (HRP). The treated sections were
further stained with ImmPACT novared HRP substrate. Red color indicates the presence of
hNQO1. Scale bar = 100 m. 27
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Although monolayer cell culture is a powerful tool for testing drugs and small molecules,
it fails to resemble tissue microenvironments.28 For example, in vivo avascular tumors have
features of structural diversity and nutrient/waste gradients, leading to varying levels of cell
proliferation in cell collections or tumors. To overcome the drawbacks of a two-dimensional cell
culture model, a 3-dimensional multicellular aggregate model was developed as an easy and
simple laboratory-cultured model to mimic the realistic in vivo features. In this research, hNQO1positive HT-29 cells were utilized to construct multicellular tumor spheroids (MCTSs). As shown
in Figure 3.10,27 the immunohistochemistry images of 5-day-old and 30-day-old MCTSs sections
exhibited spatially heterogeneous hNQO1 expression. The 5-day-old MCTS had apparently
equivalent hNQO1 expression across the spheroid region. In contrast, the 30-day-old MCTS
formed a necrotic core, and it had uneven hNQO1 distribution. Its inner necrotic core had
significantly less hNQO1 expression than the peripheral layer.

Figure 3.11 Fluorescence images of 5-day-old and 30-day-old MCTS sections. The 20-m-thick
MCTS sections were incubated with 5 M Q3NTCy for 10 min. Fluorescence images were
captured in 670–750 nm emission range upon excitation by a 633-nm laser. Scale bar = 100 m.
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To examine the ability of Q3NTCy to detect hNQO1 activity in the solid tumor mimics, living
MCTS sections were treated with 5 M Q3NTCy for 10 min and then imaged with confocal
microscopy, Figure 3.11. In accord with the hNQO1 expression data, an even fluorescence signal
was observed across the microregions of the young MCTSs. In contrast, a weaker fluorescence
in the interior region than the peripheral layer was observed in the aged MCTS with a necrotic
core. These observations demonstrated that Q3NTCy was capable of being specifically activated
by hNQO1 in the solid tumor mimic model, and it provides a new route to in enzyme activity levels
in tumor mimics.
3.4

Conclusion and Outlook
In this chapter, a new hNQO1-targeting fluorescent probe/reporter pair was presented,

which is capable of reporting the activity of human NAD(P)H:quinone oxidoreductase isozyme I
(hNQO1) in a rapid, selective, and sensitive manner. Both the Q3NTCy probe and the TCy reporter
emit strong near-infrared (NIR) light; however, the emitted light for the probe and the reporter
occurs in different energetic ranges of the electromagnetic spectrum. The effective reduction of
Q3NTCy by hNQO1 initiated a chain reaction, which rapidly produced the TCy reporter. In
comparison with the previous Q3STCy probe, Q3NTCy had a rigid and rapid-eliminating linker,
thus making it have high fluorescence efficiency ( = 0.012) and rapid fluorescence turn-on (t1/2
= 15 min). Due to the unique photophysical properties of the probe/reporter pair, Q3NTCy can act
as an off-on, on-on, and potentially ratiometric fluorescent probe under protein-rich cellular
conditions. The enzymatic kinetic experiment showed that Q3NTCy was an excellent substrate
of the hNQO1 enzyme. The acquired parameters (enzyme affinity and catalytic efficiency) was so
effective that they were comparable to that of the hNQO1-specific probes without a linker.
Cellular imaging experiments showed that hNQO1-positive (HT-29, A549, and SHIN3) and
hNQO1-negative cells (H596) could be differentiated by the developed probe/reporter system with
high integrity and large TBR values. Both hNQO1-positive and hNQO1-negative cells can be
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visualized at the same time in different fluorescence energy range, thus making the system able
to avoid false negative signals. Q3NTCy was further investigated for imaging three-dimensional
colorectal tumor mimics. The fluorescence response was in agreement with the spatially
heterogeneous hNQO1 expression demonstrated by immunohistochemistry. In sum, Q 3NTCy
was a highly selective probe to measure hNQO1 activity in biological samples.
Although the Q3NTCy/TCy system was demonstrated to be useful as off-on and on-on
systems to detect hNQO1 activities in cells and tumor mimics, the initial proposal was to develop
a ratiometric reporting system that would offer potential route to quantify the hNQO1 enzyme in
biological milieu. The PeT-based fluorescence quenching of Q3NTCy in aqueous solution, even
to a lower degree than that of Q3STCy, still occurred upon the introduction of the rigid linker. This
was evidenced by their respective quantum yields in aqueous solution, Table 3.1. Therefore, only
under specific conditions such as high protein concentration, can Q3NTCy act as a ratiometric
probe.
Table 3.1 Photophysical data for iBuTCy, Q3STCy, and Q3NTCy in aqueous solution
Compounds
abs (nm)
em (nm)
a
(M–1cm–1)
iBuTCy
783
798
0.0243
111100
Q3STCy
786
798
0.0046
60600
Q3NTCy
785
798
0.0122
63500
a
ICG ( = 0.012 in water) was used as a fluorescence standard;21 the quantum yields of
compounds were measured in 0.1 M PBS solution (pH = 7.4) with 2% DMSO as a co-solvent with
ex = 725 nm
To craft an ideal ratiometric fluorescent probe, the structure of Q 3NTCy was modified.
Because PeT is a distance-dependent process, increase of the distance between the donor and
the acceptor can significantly decrease the PeT quenching efficiency.29 A compound, Q3NNTCy,
with two rigid NMPABA linkers was synthesized in order to separating the quinone moiety further
from the TCy fluorophore, Scheme 3.3. Unexpectedly, Q3NNTCy did not exhibit improved
fluorescence efficiency compared to Q3NTCy in aqueous solutions. As shown in Table 3.2, the
quantum yields of iBuTCy, Q3NTCy, and Q3NNTCy were similar in acetonitrile pointing out that
the fluorescence of both Q3NTCy and Q3NNTCy was not compromised by the PeT quenching.
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That means, in unfolded molecules, the distance between the donor and the acceptor separated
by one linker was long enough to inhibit the PeT process. The probable cause of the low
fluorescence of Q3NNTCy was that introduction of the second linker increased its hydrophobicity,
thus making it exist in a folded state in aqueous solution. Upon incubation with hNQO1, Q3NNTCy
exhibited a slow release of TCy (t1/2 > 60 min) showing that TCy production required elimination
of two linkers. I posit that if Q3NTCy could exist in the unfolded structure in solution, it would
exhibit a ratiometric response towards hNQO1. Improving the water solubility of Q3NTCy may be
an effective way to construct a ratiometric probe like Q3NTCy-O in Figure 3.12.

Figure 3.12 Molecular structures of Q3NNTCy and Q3NTCy-O
Table 3.2 Photophysical data for iBuTCy, Q3STCy, Q3NTCy, and Q3NNTCy in ACN
Compound
abs (nm)
em (nm)
a
iBuTCy
785
803
0.193
Q3STCy
785
803
0.134
Q3NTCy
785
803
0.202
Q3NNTCy
785
803
0.193
a
ICG ( = 0.13 in DMSO) was used as a fluorescence standard;21 the
compounds were measured in acetonitrile (ACN) with ex = 725 nm.

(M–1cm–1)
193400
178600
170400
178900
quantum yields of
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CHAPTER 4
A RATIOMETRIC FLUORESCENT PROBE FOR THE DETECTION AND IMAGING OF
ENDOGENOUS BETA-GALACTOSIDASE IN OVARIAN CANCER CELLS
4.1

Introduction

-Galactosidase (-D-galactohydrolase, EC 3.2.1.23, -gal), encoded by lacZ gene, is a
glycoside hydrolase enzyme. Its function is to catalyze the hydrolysis of terminal linkages of

-D-galactosides, such as the disaccharide lactose, into monosaccharides through recognition
and cleavage of the -D-galactose moiety.1 -Gal has been exploited in many applications
including food science,2-3 genetics,4-10 and molecular biology.11-15 There are two major applications
of -gal in the food industry: the hydrolysis of lactose from dairy products to yield galactose and
glucose, and the production of galactosylated products.2 To improve sweetness, solubility, and
flavor of dairy products, or meet the consumption requirements of lactose intolerant individuals,
immobilized -gal is often used to hydrolyze and convert the lactose present in foods into the
easy-digesting galactose and glucose. -gal can act as a reporter gene to measure gene
transfection efficency.7-8 Genetically engineered sensing systems employ a reporter genes fused
with another regulatory sequence of interest to study biological processes (e.g., cellular
metabolism and gene transcription). The commonly used reporter genes include the lacZ, cat, lux,
luc, bla, gfp, and dsRed genes, which encode -gal, chloramphenicol acetyltransferase, bacterial
luciferase, firefly luciferase, -lactamase, green fluorescent protein, and red fluorescent protein,
respectively. Reporter genes, fused with the genes of interest, can be inserted into cells or living
organisms in the form of circular plasmids, and, if expressed, will produce a detectable signal. 10
Escherichia coli (E. coli) -gal, one of the extensively exploited members of the reporter gene
family, is often utilized to examine the transcription efficiencies of cloned genomic sequences or
genes of interest in molecular biology due to its high catalytic efficiency, high sensitivity, high
stability, excellent specificity, low endogenous expression, and availability of versatile detection
methods. The exogenous chromogenic substrate molecule 5-bromo-4-chloro-3-indolyl--D171

galactopyranoside (X-gal) has been conventionally employed to stain -gal-expressing tissues.8,
16

Upon reacting with -gal, soluble and colorless X-gal is converted into 5-bromo-4-chloro-3-

hydroxyindole, which subsequently forms the blue precipitate 5,5’-dibromo-4,4’-dichloro-indigo.
The blue color is used to indicate the presence of gal in a histochemical tissue sample.
Aside from its applications in food science and reporter genes, -gal is also involved in
cellular replicative senescence processes where it serves as one of the most utilized cell
senescence biomarkers in some types of human cells.12, 17 After a number of cellular divisions,
normal cells cease to proliferate and enter an irreversible cellular stage, known as replicative
senescence, which is believed to be a tumor-suppressive process and an underlying cause of
aging. Characteristics of senescent cells include permanent growth arrest, shortening of
chromosomal telomeres, enlarged and flattened cellular morphology, and increased levels of
intracellular reactive oxigen species (ROS). Further studies suggested that the high catalytic
activity of -gal in senescent cells is caused by the overexpression of the GLB1 gene, resulting in
the accumulation of -gal in lysosomes.12, 18

-Gal was also reported to be overexpressed in cancerous ovaries when compared to
normal ovaries, indicating it can serve as an ovarian cancer-associated biomarker.15 Primary
ovarian cancer is a type of peritoneal carcinoma that seriously affects female individuals.19-20 Early
diagnosis is very difficult for ovarian cancer due to lack of obvious symptoms in its early stages,
which is one of the causes of low patient survival rate.21 Cytoreductive removal of cancer tumors
followed by chemotherapy is one of the most effective treatments for ovarian cancer. By exploiting
the nature of -gal upregulation in ovarian cancer, Asanuma et al. developed fluorogenic smallmolecular substrate probes to detect small-sized ovarian metastases in the peritoneum of mouse
xenograft models.22 Cellular lysate studies showed that all the seven investigated ovarian cancer
cell lines (SHIN3, SKOV3, OVCAR3, OVCAR4, OVCAR5, OVCAR8, and OVK18) exhibited
higher -gal activities than the normal human umbilical vein endothelial cells (HUVEC), and all
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the ovarian cancer metastases models derived from the seven ovarian cancer cell lines were
successfully visualized with the developed fluorogenic probe, HMRef-Gal. That study
corroborated that -gal is a promising biomarker that can be exploited to develop prodrugs and
imaging agents that targets ovarian cancer.22
As reviewed in Chapter 1, a large amount of effort has been made to establish methods
to visualize its activity, which includes magnetic resonance imaging (MRI), 23-25 positron emission
tomography (PET),26 and optical imaging. Compared to MRI and PET, most of the research is in
the development of optical imaging due to its high sensitivity. Many chromogenic, bioluminescent,
and fluorescent probes have been developed and applied to detect -gal in vitro and in vivo.
My interest to investigate the ovarian cancer-associated -gal enzyme motivated me to design a
novel ratiometric probe with distinct characteristics (high cellular impermeability, pH
independency, and ratiometric fluorescence response) that may allow its use in providing
quantitative information on -gal activity. Different from turn-on/off fluorescent probes, ratiometric
fluorescent probes exhibit shifts in their fluorescence energy upon probe reaction with analytes of
interest to yield a reporter. The reporter/probe ratio, instead of fluorescence increase/decrease,
is utilized to build a relationship with the concentrations of analytes of interest, an approach more
suitable for quantification applications because this measurement is independent of probe
concentrations (cellular size and probe penetration rate), illumination intensity, and probe
bleaching.27-28 Therefore, a cell-permeable and ratiometric probe will be beneficial for the
detection and quantification of -gal in vitro and in cellulo. To date, several fluorogenic probes are
available to detect -gal. However, most of them suffer from cellular impermeability, reporter
leakage out of cells, and pH dependency, all which limit exciting more applications in biological
milieu. Moreover, most of the probes operate via a turn-on response mode, which makes them
vulnerable to environmental variables, such as pH and viscosity, fluctuations in illumination power,
and variations in detector efficiency. More recently, two ratiometric probes were developed by
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modifying 6-(benzo[d]thiazol-2’-yl)-2-(methylamino)-naphthalene29 and 4-hydroxyl-N-butyl-1,8naphthalimide fluorophores30 to report senescence-associated and LacZ gene encoded -gal,
respectively.

However, the 4-hydroxyl-N-butyl-1, 8-naphthalimide reporter suffers from low

quantum efficiency ( = 0.06) and pH dependency (ca. pKa = 5.8). Its fluorescence efficiency can
be affected by acidic biological environments such as that in lysosomes and tumor
microenvironment. Its possible expulsion from cancerous cells by endogenous organic anion
transporters may occur, due to its intrinsic negative charge at physiological pH, similar to
fluorescein dyes.31 Moreover, none of the reported enzyme-activatable ratiometric fluorescent
probes provide the theoretical correlation between fluorescence ratios and concentration of
enzyme.
Described herein is the design, synthesis, and evaluation of a previously unreported
ratiometric fluorescent probe, GalNap, used to track endogenous -gal upregulation in ovarian
cancer cells in both off-on and ratiometric fluorescence modes. The green-emitting fluorophore
4-amino-9-(n-butyl)-1,8-naphthalimide (Nap) was connected to the -D-galactose recognizing
moiety through a self-cleavable 4-hydroxylbenzyl alcohol linker to construct the blue-emitting
probe, GalNap (Figure 4.1). Nap is a “push-pull” ICT fluorophore with characteristics of high
brightness, high stability, and pH independency.32 The introduction of an electron-withdrawing
carbamate bond on its amino donor makes the naphthalimide backbone electron-deficient,
resulting in an increased HOMO-LUMO gap that provides a hypsochromic shift of the Nap
absorption and emission spectra. Both GalNap and Nap have high quantum efficiencies (GalNap:
0.32 and Nap: 0.19) in aqueous solutions. When excited at the absorption maximum of the
reporter, GalNap showed a rapid fluorescence increase upon reaction with -gal, indicating its
ability to be effectively and rapidly hydrolyzed by -gal. By plotting the release rate of different
concentrations of GalNap treated with -gal, the enzyme kinetic parameters were acquired; these
values demonstrated that GalNap is a good substrate for -gal. When excited at the isobestic
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point, GalNap exhibited an immediate spectral profile shift from the blue emission range to the
green emission range. Its ratiometic response towards -gal activity was plotted, agreeing with
my proposed theoretical equation.-Gal-expressing ovarian cancer cell lines (OVCAR3 and
SHIN3) and -gal-non-expressing cell line (HEp2) were further applied to examine its imaging
capability. Confocal cellular imaging experiments showed that GalNap can penetrate the cellular
membrane, thus allowing endogenous -gal activity to be monitored in both off-on and ratiometric
fluorescence imaging modes.

-D-Galactose
Trigger

-D-Galactose

Probe

Reporter

Figure 4.1 Design concept of the -gal responsive ratiometric fluorescent probe GalNap.
4.2

Experimental Section

4.2.1

Materials and General Methods
Unless otherwise stated, all chemicals and materials were purchased from Sigma-Aldrich

or Fisher Scientific, and they were used without further purification. Column purification was
performed on a Biotage Flashmaster Personal with SNAP KP-Sil cartridges (50 g, 25 g, or 10 g).
1

H and 13C NMR spectra were collected using Bruker AV-400 or AV-500 spectrometers at 25 ºC.

All chemical shifts are reported in ppm (parts per million) using residual protio-solvent of CDCl3
(7.26 for 1H and 77.16 for

13

C) and DMSO-d6 (2.50 for 1H and 39.52 for

13

C) as a calibration

standard. ESI-MS spectra were acquired on an Agilent 6210 electrospray ionization time-of-flight
mass spectrometer.
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4.2.2

Synthesis
The synthetic procedure of the designed probe GalNap is outlined in Scheme 4.1. Nap

and 4-hydroxymethylphenyl (2, 3, 4, 6-tetra-O-acetyl--D-galactopyranoside) (3) were
synthesized through reported procedures with necessary modifications.33-34 The compound
MeNap was prepared as an electronically similar analogue to act as a control probe for GalNap.

Scheme 4.1 Synthetic route for GalNap probe and the electronically similar analogue MeNap.

Synthesis of AcGalNap. To a solution of Nap (54 mg, 0.2 mmol) and 4dimethylaminopyridine (50 mg, 0.41 mmol) in 18 mL DCM, 15% phosgene (caution: toxic) in
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toluene (0.9 mL, 1.26 mmol) was added slowly at – 10 ºC, under nitrogen. After stirring for 3 h,
the excess phosgene was removed by bubbling the solution with nitrogen gas in the hood with a
base trap. Compound 3 (100 mg, 0.22 mmol) in 4 mL DCM was added to the previous solution.
The reaction was stirred overnight at 0 ºC. Upon removal of the organic solvent with a rotary
evaporator, the crude product was purified using a silica gel column with DCM/ethyl acetate (1/1)
as elute to afford the pale yellow solid product, AcGalNap (170 mg, 94%). 1H NMR (400 MHz,
CDCl3)  8.56 (d, J = 7.3 Hz, 1H), 8.52 (d, J = 8.3 Hz, 1H), 8.30 (d, J = 8.3 Hz, 1H), 8.18 (d, J =
8.6 Hz, 1H), 7.71–7.67 (m, 2H), 7.36 (d, J = 8.5 Hz, 2H), 6.98 (d, J = 8.5 Hz, 2H), 5.52–5.42 (m,
2H), 5.21 (s, 2H), 5.11 (dd, J = 10.4, 3.4 Hz, 1H), 5.05 (d, J = 7.9 Hz, 1H), 4.26–4.02 (m, 5H),
2.16 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H), 2.00 (s, 3H), 1.73–1.61 (m, 2H), 1.43–1.37 (m, 2H), 0.94
(t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  170.45, 170.30, 170.19, 169.47, 164.17, 163.68,
157.21, 153.21, 139.04, 132.46, 131.28, 130.43, 130.40, 128.93, 126.62, 126.14, 123.45, 123.07,
117.97, 117.11, 116.97, 99.53, 71.14, 70.83, 68.68, 67.44, 66.92, 61.38, 40.29, 30.26, 20.80,
20.74, 20.72, 20.66, 20.44, 13.92. ESI-HRMS: for [C38H40N2O14]: expected m/z = 749.2552 [M +
H]+; found 749.2555 [M + H]+; 0.4 ppm error.

Synthesis of GalNap. To a solution of AcGalNap (75 mg, 0.1 mmol) in 20 mL anhydrous
MeOH, NaOMe in MeOH (25% wt, 92 L, 0.4 mmol) was added at 0 ºC under nitrogen. After
stirring for 3 h, the reaction was quenched with saturated NH4Cl solution. Upon removing the
solvent, the crude product was directly loaded on a silica gel column and purified with DCM/MeOH
(10/1). The desired pale yellow solid product, GalNap (35 mg, 60%) was obtained. 1H NMR (400
MHz, DMSO)  10.35 (s, 1H), 8.71 (d, J = 8.4 Hz, 1H), 8.51 (d, J = 7.2 Hz, 1H), 8.49 (d, J = 8.4
Hz, 1H), 8.22 (d, J = 8.4 Hz, 1H), 7.83 (dd, J = 8.4, 7.2 Hz, 1H), 7.44 (d, J = 8.6 Hz, 2H), 7.07 (d,
J = 8.6 Hz, 2H), 5.22 (s, 2H), 5.16 (d, J = 5.1 Hz, 1H), 4.86 (d, J = 1.7 Hz, 1H), 4.84 (s, 1H), 4.60–
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4.64 (m, 1H), 4.50 (d, J = 4.6 Hz, 1H), 4.05 (t, J = 7.4 Hz, 2H), 3.76–3.40 (m, 6H), 1.68–1.55 (m,
2H), 1.33–1.39 (m, 2H), 0.93 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, DMSO)  163.48, 162.93,
157.50, 154.00, 140.76, 131.71, 130.90, 130.05, 129.28, 128.33, 127.69, 126.37, 123.80, 122.22,
118.08, 117.01, 116.25, 115.94, 100.86, 75.53, 73.32, 70.27, 68.15, 66.42, 60.39, 29.69, 19.82,
13.74. ESI-HRMS: for [C30H32N2O10]: expected m/z = 581.2130 [M + H]+; found 581.2147 [M + H]+;
2.9 ppm error.

Synthesis of MeNap. To a solution of Nap (28 mg, 0.1 mmol) and DMAP (24 mg, 0.2 mmol)
in 6 mL anhydrous DCM solution, phosgene (caution: toxic) in toluene (15% wt, 0.6 mL, 0.84
mmol) was added at –10 ºC. After stirring for 3 h, the extra phosgene was removed with nitrogen
bubbling, and 2 mL MeOH was added to the solution. The reaction was allowed to stir overnight.
Upon removing solvent under reduced pressure, the residue was further eluted using a
hexane/ethyl acetate (1/1) solvent with a silica gel column. The pale yellow solid product MeNap
(30 mg, 92%) was obtained. 1H NMR (400 MHz, CDCl3) 8.61 (dd, J = 7.4, 0.8 Hz, 1H), 8.58 (d,
J = 8.2 Hz, 1H), 8.33 (d, J = 8.2 Hz, 1H), 8.17 (dd, J = 8.4, 0.8 Hz, 1 H), 7.75 (dd, J = 8.4, 7.4 Hz,
1H), 7.47 (s, 1H), 4.16 (t, J = 7.5 Hz, 2H), 3.89 (s, 3H), 1.76–1.65 (m, 2H), 1.50–1.37 (m, 2H),
0.97 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  164.28, 163.78, 153.82, 139.00, 132.62,
131.35, 129.05, 126.76, 125.93, 123.64, 123.09, 118.09, 116.97, 53.23, 40.37, 30.35, 20.52,
13.98. ESI-HRMS: for [C18H18N2O4]: expected m/z = 327.1339 [M + H]+; found 327.1348; 2.8 ppm
error.
4.2.3

Spectroscopic Measurement Methods
Absorption and fluorescence spectra were recorded in a 10 mm × 10 mm quartz cuvette

on a Varian Cary-50 UV-Visible spectrophotometer and a PerkinElmer LS55 spectrofluorometer,
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respectively. Water (> 18 MΩ cm) from a Barnstead NANOpure Diamond Water System was
used to prepare phosphate-buffered saline (PBS) and all relevant aqueous solutions. Stock
solutions of GalNap and MeNap in DMSO were stored at low temperature (– 20 ºC) in the dark.
Fresh sample solutions prepared with stock solution were used for all experiments.
4.2.4

Quantum Yield Measurements of GalNap and Nap
The quantum yield of Nap ( = 0.19) was obtained from previously reported data from our

group.34 The fluorescence quantum yield of GalNap was determined in reference to quinine
sulfate in 1 N sulfuric acid solution ( = 0.51).35 A stock solution of GalNap (1 mM in DMSO) was
diluted in 0.1 M PBS solution (pH = 7.4) to yield an absorbance at 360 nm between 0.02–0.10 to
minimize reabsorption effects and maximize illumination homogeneity. Co-solvent DMSO was
maintained at 1%. Samples with four different concentrations (2, 4, 6, and 8 M) were prepared,
and each sample was measured three times. Similarly, quinine sulfate was dissolved in 1 N
sulfuric acid solution to yield an absorbance at 360 nm between 0.02–0.10. Samples with four
different concentrations (4, 8, 12, and 16 M) were prepared, and each sample was measured
three times. Fluorescence spectra of all the prepared samples were obtained with the same
excitation wavelength 360 nm. The quantum yield of GalNap was calculated using the following
equation 4.1:
2

𝐺𝑟𝑎𝑑𝑥
𝛷x = 𝛷𝑠𝑡 (𝐺𝑟𝑎𝑑
) (𝜂𝜂2𝑥 )
𝑠𝑡

𝑠𝑡

Equation 4.1

where the subscripts st and x stand for standard and test sample, respectively.36 is the quantum
yield,  is the refractive index of solvent, and Grad is the gradient from the plot of integrated
fluorescence intensity vs absorbance. The calculated quantum yield of GalNap was determined
to be 0.32.
4.2.4

Enzyme Kinetics Measurements

-Gal from Escherichia coli (Sigma-Aldrich) was stored as 1000 U mL–1 (1.35 mg mL–1) in
PBS solution. The enzymatic reactions in 1.5 mL GalNap solutions with varing concentrations (2–
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60 M) were initiated by the addition of 4.5 L -galactosidase stock solution resulting in 3 U mL–
1

(4 g mL–1) enzyme per assay. Fluorescence due to release of the fluorophore Nap (ex = 450

nm, emis = 550 nm) was recorded at an interval of 5 s for 10 min at 25 ºC. Each sample of a
given concentration was measured three times. The concentration of Nap released per unit time
was calculated by converting the fluorescence signal using the Nap calibration curve, which was
acquired under identical measurement conditions. The apparent kinetic parameters (Vmax and Km)
were obtained by plotting the Nap release rate vs GalNap concentrations using nonlinear leastsquares analysis of Origin software.
4.2.5

Cell Culture
The OVCAR3 (human ovarian adenocarcinoma) cell line was purchased from American

Type Culture Collection (ATCC). The SHIN3 (human ovarian carcinoma) cell line was a gift from
Professor Hisataka Kobayashi at the Center for Cancer Research (National Institutes of Health).
The HEp2 (human Hela contaminant carcinoma) cell line was a gift from Professor Graca
Vincente at Louisiana State University. All cell lines were grown in RPMI-1640 medium (ATCC)
supplemented with 10% fetal bovine serum (FBS, ATCC), 10 IU mL–1 penicillin, and 10 g mL–1
streptomycin (Life Technologies). All cell lines were maintained in 75 cm2 treated tissue culture
flasks (Corning) at 37 ºC in 5% CO2 under humidified conditions.
4.2.6

Cellular Imaging via Laser Scanning Confocal Microscopy
Cells (3 × 105) were seeded on sterile six-well glass culture plates (Fisher Scientific) with

the RPMI-1640 medium containing 10% FBS, and cultured for a day at 37 ºC in 5% CO 2 under
humidified conditions. After that, the medium was removed and washed once with warm phenol
red- and serum-free RPMI-1640 medium. Cells were incubated with 10 M GalNap or MeNap in
phenol red- and serum-free RPMI-1640 medium (2 mL) for 1 h. The medium was then removed,
and the cells were washed with DPBS (2 mL) twice. After washing, cells were treated with 4%
paraformaldehyde for 15 min at room temperature to fix the cells. Differential interference contrast
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(DIC) and fluorescence images were acquired using a Leica TCS SP5 spectral laser-scanning
confocal microscope with oil objectives (20×, numerical aperture: 0.70) or (40×, numerical
aperture: 1.25). The airy pinhole was set to 1.0 (60.6 m). A 405-nm laser (30% output) was
employed with the same HyD detector gain (100.0) in both 430–495 nm and 535–600 nm
emission regions for ratiometic fluorescence images of cells exposed to GalNap. Likewise, the
same laser line with 20% output was employed with the same HyD detector gain (100.0) in both
regions for that of MeNap. Image and statistical analysis were performed using Fiji/ImageJ
software following reported procedures.37
4.3

Results and Discussion

4.3.1

Design of the -gal Responsive Ratiometric Probe GalNap
The fluorophore 4-amino-9-(n-butyl)-1,8-naphthalimide (Nap) was selected to design a -

Gal responsive ratiometric probe, because of its high fluorescence quantum efficiency, stability,
pH insensitivity, and excellent push-pull internal charge transfer (ICT) characteristics.32 Moreover,
its 4-amino group provides a handle to install moieties that are capable of recognizing
endogenous species; such incorporation further delivers an alteration on the spectroscopic
properties due to a change in electron distribution on its backbone. Introduction of an electronwithdrawing carbamate bond on the 4-amino position decreases its push-pull effect, hence
hypsochromically shifting both absorption and emission profiles of the reporter. A direct
connection between the -gal-recognizing unit (the galactopyranoside moiety) and the
fluorophore, Nap, to build a -gal responsive probe would hinder the breakage of the so formed
N-glycoside bond by -gal. Therefore, the self-cleavable 4-hydroxyl benzyl alcohol linker was
inserted between the galactopyranoside trigger and the Nap fluorophore reporter. As a result,
the probe GalNap with a tripartite structure was designed, which can undergo a spontaneous
linker cleavage followed by release of the bathochromically-shifted fluorophore Nap upon its gal hydrolysis, Figure 4.2. Ratiometric probes based on an ICT fluorophore have advantages over
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those designed using FRET strategies. FRET strategies require two fluorophores, one as an
energy donor and the other as an energy acceptor; in the intact probe, the excited donor transfers
energy to the acceptor, resulting in emission from the acceptor. Breaking apart the two
fluorophores will block the FRET effect and cause emission from the donor. The fluorescence
ratio is utilized to indicate the amounts of analytes. However, environmental variations can also
change the fluorescence ratio by affecting the distance between the two fluorophores in the FRET
probe.

Figure 4.2. Schematic representation of Nap reporter release, triggered by -gal.
4.3.2

Spectroscopic Characterization of GalNap/Nap System
The GalNap probe and the control MeNap probe were synthesized through conventional

synthetic procedures, as described in Scheme 4.1.

With the GalNap probe in hand, the

spectroscopic properties of GalNap and Nap were first measured in aqueous phosphate buffer at
𝐺𝑎𝑙𝑁𝑎𝑝

physiological pH (pH = 7.4), Figure 4.3. As expected, the spectral profiles of GalNap (𝜆𝑎𝑏𝑠
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Figure 4.3 Absorption and emission spectra of 5 × 10–6 M GalNap (A) and Nap (B) in 0.1 M
PBS solution (pH = 7.4) with 1% DMSO as co-solvent. T = 25 ºC.
𝐺𝑎𝑙𝑁𝑎𝑝

368 nm and 𝜆𝑒𝑚

= 470 nm) are hypsochromically shifted roughly 64 nm for absorption and 78
𝑁𝑎𝑝

𝑁𝑎𝑝

nm for emission in comparison with that of Nap (𝜆𝑎𝑏𝑠 = 432 nm and 𝜆𝑒𝑚 = 548 nm), which is in
agreement with previously observed spectral changes upon the introduction of electron-deficient
group to the ICT fluorophore Nap. The Stokes shift of GalNap is 102 nm, which is smaller than
that of Nap (116 nm). The smaller Stokes shift of GalNap is caused by its decreased ICT effect.
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Both GalNap and Nap have high quantum efficiencies in aqueous phosphate buffer (GalNap =
0.32 and Nap = 0.19). All these properties of GalNap and Nap make them an excellent
probe/reporter pair to potentially act as a ratiometric system. The ratio of fluorescence of the green
energy range (F535–600) and the blue energy range (F430–495) were calculated to be 0.19 and 29 for
GalNap and Nap respectively, thus exhibiting a broad dynamic range (153-fold). In comparison,
𝑀𝑒𝑁𝑎𝑝

𝑀𝑒𝑁𝑎𝑝

= 368 nm, 𝜆𝑒𝑚

the control compound MeNap has similar spectroscopic properties (𝜆𝑎𝑏𝑠

=

470 nm, F535–600/F430–495 = 0.20) to GalNap, thus making it an excellent negative control compound
(Figure 4.4).
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Figure 4.4 Absorption and emission spectra of 2 × 10–6 M MeNap in PBS buffer (pH = 7.4) with
1% DMSO as co-solvent. T = 25 ºC.
4.3.3

Spectroscopic Response of GalNap to gal
I next examined the spectral change of GalNap upon the reaction with -gal in aqueous

buffer solution (pH = 7.4), Figure 4.5. After the addition 3 U mL–1 -gal to GalNap solution for 1
h, the maximum absorption peak was shifted from its initial 368 nm value to 432 nm, and the
maximum emission peak moved from 432 nm to 548 nm, thereby exhibiting a ratiometric
fluorescence response change. Both the resulting absorption and emission profiles of GalNap
upon -gal treatment corresponded to that of Nap, proving the effective release of Nap. The
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change in emission spectra with various excitation wavelengths is also shown in Figure 4.6.
GalNap and Nap can be excited for different degrees by use of different excitation wavelengths,
thus making the GalNap/Nap pair suitable as an on-off, off-on, or ratiometric system. To further
demonstrate that the release of Nap caused its spectroscopic response, HPLC-Mass
spectrometry was employed to analyze the products released after -gal treatment. The lack of
the GalNap m/z peak and appearance of the new Nap m/z peak clearly demonstrated release of
Nap.
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Figure 4.5. Absorption (A, 5 M GalNap) and emission (B, 2 M GalNap, ex = 415 nm) spectra
before and after the addition of -gal (3 U mL–1) for 1 h in 0.1 M PBS solution (pH = 7.4). T =
25 ºC.
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Figure 4.6. Fluorescence spectral changes of GalNap (2 M) triggered by -gal (3 U mL–1) in
1% DMSO 0.1 M PBS (pH = 7.4) solution with different excitation wavelengths: (A) 380 nm,
(B) 400 nm, (C) 410 nm, (D) 415 nm, and (E) 430 nm. Spectra were recorded every 3 min. T
= 25 ºC.
4.3.4

Stability and Enzymatic Activity of GalNap
High chemical and photochemical stability and rapid activation of developed

probe/reporter systems in biological systems are principle factors that greatly affect their detection
efficiency. Thus, GalNap in the presence and absence of -gal in aqueous solution was recorded
using fluorescence spectrometry, Figure 4.7. The excitation and emission wavelengths (ex = 450
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nm, em = 500 nm) were selected to ensure that only the signal from the Nap reporter was
monitored. When GalNap was not exposed to -gal in aqueous solutions, the fluorescence
increase was not observed in the time course of 60 min, Figure 4.7 (blue line). This result showed
that the non-specific activation of GalNap in aqueous solution is low. In contrast, when GalNap
was exposed to 3 U mL–1 -gal, an immediate fluorescence increase was observed with a short
half-time (t1/2 = 10 min) to achieve its plateau signal, Figure 4.7 (red line). The plateau signal was
invariant over 20 min, indicating that the released reporter is stable in the presence of -gal under
physiological conditions. This experiment showed that GalNap can be effectively activated by gal through the breakage of the glycosidic bond, which subsequently initiates the rapid cleavage
of the self-immolative linker 4-hydroxyl benzyl alcohol, ultimately leading to the release of Nap,
Figure 4.2.
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Figure 4.7. Fluorescence response (ex = 450 nm, em = 500 nm) of GalNap (5 M) to the
addition of -gal (3 U mL–1) at 4 min in 0.1 M PBS buffer (pH = 7.4). T = 25 ºC.
To obtain quantitative information about the ability of -gal to activate GalNap, the
apparent kinetic parameters were acquired by fitting the Nap production rate from various
concentrations of GalNap catalyzed by -gal to the Michaelis-Menten equation, Figure 4.8. From
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this were obtained the Michaelis constant (Km) = 12.0 M, maximum velocity (Vmax) = 0.12 ± 0.01

mol/min/mg protein, catalytic constant (kcat) = 0.24 ± 0.01 s–1, and catalytic efficiency (kcat/Km) =
2.02 ± 0.35 × 104 M–1s–1, indicating that GalNap is an effective substrate of -gal. Also, enzyme
inhibition was not observed when the enzyme was treated with high concentrations (up to 60 M)
of GalNap. The kinetics values demonstrated that GalNap is an effective substrate to reach the

mol/min/mg protein

catalytic sites of -gal where it is rapidly hydrolyzed, resulting in the rapid formation of Nap.
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Figure 4.8 Kinetic plot of -gal (4 × 10–6 g mL–1, 3 U mL–1) with GalNap as substrate in 0.1 M PBS
buffer (pH = 7.4). Values shown are average of three trials with error bars (± standard deviation).
T = 25 ºC. Line is best fit to data (2 = 0.00003).
4.3.5

Theory Development for the Ratiometric Properties of GalNap
After establishing that GalNap was an effective substrate of -gal, which yielded a

ratiometric fluorescence response for measurement of -gal activity, I sought to study the
relationship between the fluorescence ratio and -gal activity. As depicted in Figures 4.5 and 4.9,
the fluorescence signal at 470 nm that corresponds to the fluorescence maximum of GalNap is
composed of signal only from GalNap, while the fluorescence signal at 548 nm (corresponding to
the maximum of Nap) is made up of signal from both GalNap and Nap.
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Figure 4.10 Schematic derivation of ratiometric fluorescence response of probe towards
analytes of interest.
To further investigate the theoretical quantitative relationship between the fluorescence
ratio and -gal concentrations, a descriptive figure was drawn, Figure 4.10. The solid blue line
represents the fluorescence spectrum of GalNap with fluorescence maximum wavelength 1. The
solid green line represents the spectrum of Nap with maximum wavelength 2. The dashed red
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line represents the spectrum of some mixture of GalNap and Nap, which represents entry what I
refers to as the intermediate spectrum of GalNap treated with -gal. An equation describing the
relationship between fluorescence ratio and -gal concentrations is derived as follows.
At any time point for a GalNap solution which is treated with -gal, the total concentration of the
unreacted GalNap probe and the released reporter Nap is equal to the initial concentration of the
GalNap probe.
𝑝

𝐶0𝑃 = 𝐶𝑡 + 𝐶𝑡𝑅

4.3.4.1
𝑝

where 𝐶0𝑃 indicates the initial concentration of GalNap, 𝐶𝑡 indicates the concentration of
unreacted GalNap at a specific time point (t), and 𝐶𝑡𝑅 is the concentration of released Nap at the
same specific time point (t).
The released reporter concentration is proportional to enzyme concentration and time.
𝐶𝑡𝑅 = 𝑘𝑐𝑎𝑡 × [𝐸0 ] × 𝑡

4.3.4.2

where 𝑘𝑐𝑎𝑡 is the catalytic constant, and [𝐸0 ] is the enzyme concentration.
𝑅 𝑅
The fluorescence signal intensity at wavelength 1 (𝐼𝜆1 ) is solely contributed by GalNap (𝑘𝜆1
𝐶𝑡 =
0), and the fluorescence signal intensity (𝐼𝜆2 ) at wavelength 2 is contributed by both GalNap and
Nap.
𝑝

𝑅 𝑅
𝐼𝜆1 = 𝑘𝜆1 𝐶𝑡𝑃 + 𝑘𝜆1
𝐶𝑡
𝑝

𝐼𝜆1 = 𝑘𝜆1 𝐶𝑡𝑃

4.3.4.3
4.3.4.4

𝑝

𝑝

𝑅 𝑅
𝐼𝜆2 = 𝑘𝜆2
𝐶𝑡 + 𝑘𝜆2 𝐶𝑡

4.3.4.5

𝑝

𝑅
where 𝑘𝜆1 is the fluorescence constant of GalNap at wavelength 1, 𝑘𝜆2
is the fluorescence
𝑝

constant of Nap at wavelength 2, and 𝑘𝜆2 is the fluorescence constant of GalNap at wavelength

2.
The fluorescence ratio (R) is defined as 𝐼𝜆2 /𝐼𝜆1. Solving for R yields the calibration equation.
𝑅=

𝐼𝜆2
𝐼𝜆1

=
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𝑝

𝑝

𝑅 𝑅
𝑘𝜆2
𝐶𝑡 +𝑘𝜆2 𝐶𝑡
𝑝
𝑘𝜆1 ×𝐶𝑡𝑃

4.3.4.5

=

𝑅
𝑘𝜆2
×𝑘𝑐𝑎𝑡 ×[𝐸0 ]×𝑡
𝑝
𝑝
𝑘𝜆1 ×(𝐶0 −𝑘𝑐𝑎𝑡 ×[𝐸0 ]×𝑡 )

+

𝑝

𝑘𝜆2
𝑝

𝑘𝜆1

4.3.4.6

Based on the acquired calibration equation, the fluorescence ratio is a function of both the
incubation time (t) and the amount of -gal ([E0]). The predicted schematically defined curve
shown in Figure 4.11 represents what is expected for conditions when one of the two variables is
kept constant, with increasing enzyme concentration or time, the ratio rises slowly followed by a
rapid increase before it plateaus. The plateau results from the complete consumption of GalNap,

I2/I1 Ratio

with the ratio approaching the value in 4.3.4.6.

Enzyme Activity or Time
Figure 4.11 Prediction curve of response of GalNap towards -gal concentrations or time
4.3.6 Experimental Investigations on the Ratiometric Response of GalNap Toward -gal
To verify that the experimental response ratio is in agreement with the denoted equation (4.3.4.6),
both the fluorescence ratio (F535–600/F430–495) change with time at a specific concentration of -gal
and the ratio change with various amounts of -gal at a specific time were measured under
physiological conditions (pH = 7.4). As shown in Figure 4.12, GalNap (15 M) solutions were
treated with various concentrations of -gal (1–12 U mL–1) and their fluorescence spectra were
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Figure 4.12. Fluorescence spectral change of GalNap (15 M, ex = 415 nm) with time with the
addition of -gal (1, 2, 3, 4, 6, 8, 10, and 12 U mL–1) in PBS solution (pH = 7.4). T = 25 ºC.
recorded every 2 min. The blue emission band F430–495 gradually decreases, corresponding to the
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hydrolysis of GalNap. Simultaneously, the green emission band F535–600 gradually increases,
corresponding to the production of Nap. The fluorescence ratio (F535–600/F430–495) was first plotted
against time with fixed -gal concentration, Figure 4.13. It was also plotted against -gal
concentrations at a given fixed time, which showed an increase with enzyme concentration range
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Figure 4.13 Plot of the emission intensity ratios (F535–600 nm/F430–495 nm) of GalNap (15 M)
against time (up) or the concentration of -gal enzyme (1–12 U mL–1), in pH = 7.4, 0.1 M PBS,
ex = 415 nm; T = 25 °C.
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studied. Both plots showed that the ratio changed in a sigmoidal-like manner in response to the

-gal catalysis, which agrees with the prediction of theory. When either the incubation time or gal amounts were increased, a plateau was attained due to the complete consumption of the gal substrate GalNap.
4.3.7

Visualizing Endogenous -gal with GalNap as a Turn-on Probe in Ovarian Cancer Derived

Cell Lines
After demonstrating that GalNap is an effective probe for detecting -gal activities in vitro
via both off-on and ratiometric modes, I sought to further investigate its ability to track endogenous

-gal in human cells, specifically in a turn-on mode (monitoring reporter production). The
overexpression of -gal in primary ovarian cancer cells15 and the lack of -gal activity in Hela
cells38 has been established previously. Therefore, cellular imaging with confocal microscopy
was performed with OVCAR3 (human ovarian cancer cells, -gal-expressing) and HEp2 (human
Hela contaminant carcinoma cells, -gal non-expressing) cell lines. After OVCAR3 and HEp2

DIC

HEp2

OVCAR3

Confocal

Figure 4.14. Differential interference contrast (DIC) and confocal fluorescence images of
OVCAR3 (-gal expressing) and HEp2 (-gal non-expressing) cells incubated with 10 M
GalNap for 60 min at 37 ºC. Fluorescence images were obtained in the 506–640 nm emission
range utilizing a 458-nm laser as the light source. Scale bars = 50 m.
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were incubated with 10 M GalNap for 1 h in a humidified incubator with 5% CO2 at 37 ºC, they
were fixed for further imaging with a confocal microscope. The fixed cells were measured in the
506–640 nm emission range by exciting with a 458-nm laser. These excitation and emission
settings assured that the measured fluorescence signal is solely from the released Nap instead
of from GalNap. As shown in Figure 4.13, strong fluorescence in the OVCAR3 cell line was
observed in contrast with virtually no fluorescence in the HEp2 cell line, which is in accordance
with the high -gal activity in OVCAR3. To quanitify the Nap fluorescence signal in cells, the
positive to negative (PNR) value, for OVCAR3 (33 cells) versus HEp2 (31 cells) was calculated
to be 8.8 ± 1.1 (95% confidence). This imaging experiment corroborated that GalNap can
effectively pass through the cellular membrane and rapidly react with -gal present inside cells.
Although D-galactose of high concentration (mM levels) can competitively inhibited -gal activity,
its application in cellular environment may also affect the cellular uptake of the probe.
4.3.8

Visualizing -gal with GalNap as a Ratiometric Probe in Ovarian Cancer-Derived Cell

Lines
To demonstrate the applicability of GalNap as a ratiometric fluorescent probe for detecting

-gal activities in cellular environments, ovarian cancer cell lines (SHIN3 and OVCAR5)
expressing the -gal enzyme were also investigated, Figure 4.15. Upon incubating the studied
cell lines with GalNap under identical conditions, cellular fluorescence signals in the blue range
(430–495 nm) and in the green range (535–600 nm) was collected using the same detector
efficiency and the same 405-nm laser line excitation intensity. The ratiometric images were
generated based on the blue and green range fluorescence following reported procedures.37 As
shown in Figure 4.15, all of the acquired ratios for -gal-expressing cell lines (0.70 for OVCAR3
and 0.47 for SHIN3) were significantly higher than that of -gal-non-expressing HEp2 (0.21)
resulting from the production of Nap in -gal-expressing cell lines. Moreover, the control probe
MeNap was also used to treat all three cell lines. As shown in Figure 4.16, bright fluorescence
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was observed in the blue range indicating the effective penetration of MeNap into cells. However,
virtually no fluorescence was observed in the green range indicating the lack of Nap production.
The acquired ratios (0.24 for OVCAR3 and 0.16 for SHIN3) exhibited cellular ratios similar to that
of HEp2 (0.13), which further demonstrated that MeNap cannot produce Nap. All these
experiments demonstrated that the different cellular ratios acquired after the treatment with
GalNap result from the different endogenous -gal activities of cells.
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Figure 4.15 Confocal fluorescence images of OVCAR3 (positive), SHIN3 (positive), and HEp2
(negative) incubated with GalNap (10 M) for 60 min at 37 ºC. Blue images (430 – 495 nm
range) and green images (535 – 600 nm range) were obtained with the 405 nm excitation.
Ratio images (F535 – 600 nm/F430 – 495 nm) were generated using ImageJ software. Scale bars = 40
m.
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Figure 4.16 Confocal fluorescence images of OVCAR3 (positive), SHIN3 (positive), and HEp2
(negative) cells incubated with MeNap (10 M) for 60 min at 37 ºC. Blue images (430–495 nm
range) and green images (535–600 nm range) were obtained with the 405 nm excitation. Ratio
images (F535–600 nm/F430–495 nm) were generated using ImageJ software. Scale bars = 30 m.
4.4

Conclusion
In summary, a previously unreported, well-described ratiometric fluorescent probe,

GalNap, capable of selectively detecting -galactosidase, was developed by adding a
galactopyranoside moiety to an ICT fluorophore Nap. Both GalNap and Nap have high quantum
efficiencies (GalNap = 0.32 and Nap = 0.19) in aqueous solutions. When excited at the absorption
maximum of the reporter, solutions of GalNap showed a rapid fluorescence increase upon
reaction with -gal, indicating the ability of the probe to be hydrolyzed by -gal effectively and
rapidly. By plotting the release rate of different concentrations of GalNap treated with a specific
amount of -gal, the enzymatic kinetics parameters were acquired, which demonstrated that
GalNap is a good substrate for -gal. When excited at the isobestic point, GalNap exhibited an
immediate spectral profile shift from blue emission range to green emission range. The resulting
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ratiometirc response towards -gal was plotted, and agreed with my proposed theoretically
derived equation. Its capability to measure and differentiate -gal-expressing cells was also
demonstrated through confocal microscopy imaging of -gal-expressing ovarian cancer cell lines
(OVCAR3 and SHIN3) and the HEp2 cell line that does not express -gal.
4.5
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CHAPTER 5
A RATIOMETRIC AND NEAR-INFRARED FLUORESCENT PROBE FOR SELECTIVE
DETECTION AND QUANTIFICATION OF CYSTEINE IN HUMAN PLASMA
5.1

Introduction
Biological thiols are important biological components and they play crucial roles in

maintaining cellular redox homeostasis.1 Free sulfhydryl groups (–SH) of proteins and amino
acids can scavenge reactive oxygen species (ROS), thereby protecting cells from oxidative stress.
Meanwhile, the sulfhydryl group is converted to its disulfide form (–S–S–). Glutathione (GSH),
cysteine (Cys), and homocysteine (Hcy)—each having one sulfhydryl group—are the three major
components of biological thiols. Aberrant levels of GSH, Cys, and Hcy are associated with a
variety of pathological processes.
Cys, which has versatile functions in protein synthesis and structure, is a metabolite
derived from the amino acids serine and methionine. In the metabolic processes, Cys is produced
through the transsulfuration of the hydroxyl group of serine by the sulfhydryl group from
methionine.2 Although Cys is conventionally considered to be a non-essential amino acid, it can
become an essential amino acid for infants, elders, and some individuals who suffer from
metabolic diseases.3 Cys deficiency leads to a variety of disorders, such as lethargy, hair
depigmentation, skin lesions, to name a few.4 Notably elevated levels of Cys are associated with
neurotoxicity and cardiovascular diseases.5-6 The concentrations of Cys in human plasma for
healthy individuals span from 135.8 to266.5 M.7 Therefore, fast, sensitive, and selective
detection of Cys will greatly contribute to the insightful understanding of its biological and
pathological functions.
Several analytical techniques are employed to measure the presence of biological thiols,
including high-performance liquid chromatography (HPLC),8 capillary electrophoresis,9-10 mass
spectrometry,11-13 and spectrophotometry.14 Although these techniques are useful in detecting
biological thiols, they often require tedious and time-consuming steps such as separation,
derivatization, and determination. Due to their high sensitivity, ease of use, and low cost,
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fluorescence-based probes have attracted intense interest and investigation. A large number of
thiol-reactive reagents and probes were developed and evaluated over the past decade. 15-19
Relying on the strong nucleophilicity and low basicity of the sulfhydryl group, the strategies for
developing fluorescent probes include Michael addition to maleimide and alkyne bonds,20-22
exchange of disulfide and Se-N bonds,23-28 disruption of metal coordination,29-32 and cleavage of
sulfonamide and sulfonate esters.33-36 Upon conjugation or fragmentation by thiols, the profluorogenic probes normally exhibit a strong increase in fluorescence intensity in the visible or
near-infrared energy ranges. Albeit probes of this kind show some advantages in detecting
biological thiols as a group, most have been limited to the selective detection of an individual thiol.
Furthermore, in situations where low Cys concentrations are indicative of a health disease, such
blood plasma levels associated with various diseases such as cardiovascular disease.37 The
ability to determine Cys levels in the presence of high GSH concentrations is highly valuable.
Because GSH, Cys, and Hcy play different physiological and pathological roles, it is of great
significance to develop fluorescent probes to achieve the selective determination of thiols.
To overcome this challenge, aldehyde-conjugated fluorophores were developed to
achieve the selective detection of Cys and Hcy.38-40 Because both Cys and Hcy have amino and
sulfhydryl groups, the aldehyde recognition group (a hard electrophil) is initially attacked by the
hard nucleophilic amine group, followed by cyclization with the sulfhydryl group, which leads to
the formation of a thiazolidine or thiazinane ring. The cyclization process of Cys and Hcy with
aldehyde greatly changes probe photophysical properties, thus allowing the selective
differentiation of Cys and Hcy from other amino acids. However, because the amine attack is the
initial step, both Cys and Hcy have similar reactivities toward the designed fluorescent probes.
Moreover, the aldehyde group suffers from attack by other interfering nucleophiles, thereby
decreasing sensitivity, and thus, limit of detection.
In 2011, Strongin’s group took advantage of the well-known condensation reaction of
acrylates with Cys and use it to discriminate Cys from Hcy.41 In this design, the fluorophore,
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(hydroxymethoxyphenyl)benzothiazole (HMBT), was conjugated to an acrylate recognition group.
The hydroxyl group of HMBT can undergo excited state intramolecular proton transfer (ESIPT)
when the molecule is irradiated at 304 nm, thus allowing HMBT to fluoresce in two different
wavelength ranges (enol band and keto band). In the developed probe, keto band fluorescence
was inhibited by cloaking the hydroxyl group, and the fluorescence of enol band was quenched
by the alkene moiety through the photo-induced electron transfer (PeT) process. Because Cys
and Hcy react differently with the acrylate group, Hcy increased the enol band fluorescence while
Cys increased the keto band fluorescence under specific solution conditions. This novel design
strategy made it possible to differentiate Cys from Hcy. Subsequently, the acrylate recognition
group was exploited to develop several turn-on and ratiometric probe/reporter systems.42-49
However, most of the probes exhibited quenched fluorescence by the alkene bond. Disruption of
the alkene bond by other biological nucleophiles present cells can also induce the fluorescence
increase, thus causing the probes to suffer from interference (low selectivity). In addition, most of
the new acrylate-based probes had very short excitation and emission wavelengths, thus limiting
their further applications in biological systems.
Because near-infrared (NIR) light has the advantages of high tissue penetration depth,
low tissue autofluorescence, and low tissue absorption, NIR fluorescent probes are more suitable
for biological applications. It would be of great value to have in hand an NIR probe that is selective
for Cys, and one that may provide more quantitative information via use of ratiometric
characteristics. Recently, a cyanine-based NIR fluorescent probe (CyAC) was developed in the
hopes of selective detection and quantification of Cys over Hcy and GSH. 50 Although the
absorption and emission bands of CyAC are located in the NIR energetic range, the reporter
formed by reacting Cys with CyAC has a hypsochromically shifted absorption band in the visible
energy range. In addition, the fluorescence of the reporter was greatly affected by pH. Thus, new
approaches to address Cys detection and quantification are in great demand.
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Scheme 5.1 Proposed Mechanism of the CysTCy Probe Reacting with Cysteine
Herein, I present a new ratiometric and NIR fluorescent probe (CysTCy) for selective
detection of Cys over GSH and Hcy, Scheme 5.1. The cysteine-selective acrylate moiety and pHindependent and NIR fluorescent tricarbocyanine fluorophore (TCy) were connected through a
fast and self-eliminating 4-hydroxybenzyl alcohol linker. In the developed probe/reporter system,
both the CysTCy probe and the TCy reporter exhibited strong fluorescence efficiency (Probe =
0.17 and Reporter = 0.31 in acetonitrile) in different energy ranges of the electromagnetic spectrum.
Fluorescence quenching of CysTCy by the alkene bond was not observed thus pointing to the
potential use of the CysTCy/TCy pair as a ratiometric Cys-responsive system. Upon treatment
with Cys, solutions of CysTCy exhibited a ratiometric response in both their absorption and
emission spectra in a quick fashion, accompanied by an obvious color change from light-green to
dark blue. By plotting the fluorescence ratio as a function of various concentrations of Cys, it was
observed that CysTCy provided a linear response curve for Cys concentrations over the range of
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0–10 M. The limit of detection (LOD) of CysTCy toward Cys was determined to be 623 nM. The
selectivity of CysTCy toward Cys over GSH and Hcy was also confirmed under physiological
conditions. Further examination of CysTCy under a clinically relevant conditions (deproteinized
human plasma) verified probe stability and its capability for detection and quantification of Cys.
5.2

Experimental section

Scheme 5.2 Synthetic Route of CysTCy
5.2.1

Synthetic Materials and Methods
All the chemicals and solvents in the synthesis were purchased from Sigma-Aldrich or

Fisher Scientific, unless otherwise stated, and they were used without further purification.
Preparative separation and purification of crude products was performed on a FlashMaster
Personal (Biotage) with Biotage SNAP KP-Sil flash cartridges (50-g, 25-g, or 10-g size). 1H and
13

C NMR spectra were measured in deuterated chloroform (CDCl3) on a Bruker AVIII-500 nuclear

magnetic resonance (NMR) spectrometer at 25 ºC. Mass spectra were measured with an Agilent
6210 ESI-TOF mass spectrometer.
5.2.2

Synthesis
The tricarbocyanine compound (TCy) was obtained as described in Chapter 2.51 The

intermediate compound 4 was synthesized via reported procedures with necessary
modifications.42 The synthetic route of CysTCy is outlined as Scheme 5.2. The synthetic
procedures for CysTCy are described as follows. Compound 4 (90 mg, 0.5 mmol) was dissolved
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in 10 mL anhydrous THF solvent in a 25-mL round-bottom flask. The solution was cooled to 0 ºC
in an ice-water bath, followed by the injection of 15% phosgene (caution: toxic) in toluene (4 mL,
5 mmol). After 2 h, the solvent was removed in a rotary evaporator with aqueous NaOH solution
(1 M) in the trap to neutralize any excess phosgene. The afforded residue was then dissolved in
2 mL anhydrous DCM; the solution was added slowly to a solution of TCy (15 mg, 0.024 mmol)
and N,N-diisopropylethylamine (DIPEA, 0.1 mL) in anhydrous DCM solution (10 mL) under
nitrogen. The solution was stirred overnight at room temperature. The reaction color changed
from blue to green. The solvent was removed in a rotary evaporator, and the crude product was
purified using silica gel column with methanol/DCM (1:99 to 5:95) gradient to yield the green
product CysTCy (16 mg, 80%). 1H NMR (500 MHz, CDCl3) (rotamers)  7.56 (d, J = 14.1 Hz, 2H),
7.42–7.30 (m, 4H), 7.25–7.21 (m, 4H), 7.15 (d, J = 8.0 Hz, 2H), 6.97 (d, J = 8.5 Hz, 2H), 6.45 (d,
J = 18.0 Hz, 1H), 6.39–6.11 (m, 3H), 5.95 (d, J = 11.1 Hz, 1H), 5.09 (s, 2H), 4.30–4.09 (m, 4H),
3.27 (s, 3H), 2.81–2.57 (m, 4H), 2.11–1.87 (m, 2H), 1.63 (s, 6H), 1.51–1.33 (m, 12H). 13C NMR
(126 MHz, CDCl3) (rotamers)  171.22, 164.42, 155.73, 155.33, 150.41, 142.00, 141.91, 141.41,
141.22, 141.20, 133.94, 133.14, 132.93, 130.31, 129.18, 128.92, 128.78, 127.86, 127.74, 127.67,
127.48, 125.28, 122.56, 122.36, 122.10, 121.72, 115.88, 110.75, 110.69, 101.28, 101.22, 66.93,
49.22, 40.13, 40.03, 38.75, 38.49, 28.44, 28.35, 28.05, 27.96, 25.13, 24.88, 20.87, 12.60, 12.53.
ESI-HRMS: for C58H69N4O5: expected m/z = 710.3958 [M]+; found m/z = 710.3948 [M]+; 1.4 ppm
error.
5.2.3

Spectroscopic Measurement Methods
The stock solutions of CysTCy and TCy (1 mM in DMSO) were used to prepare their

corresponding diluted sample solutions. Phosphate-buffered saline (PBS, 20 mM, pH = 7.4) was
prepared with water (> 18 MΩ cm) from a Barnstead NANOpure Diamond water System.
Spectroscopic measurements were performed on a Varian Cary-50 spectrophotometer and a
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PerkinElmer LS55 spectrofluorometer. The absorption spectra and fluorescence spectra were
recorded in a 10-mm path length quartz cuvette.
3.3.4

Quantum yields measurement for Q3NTCy and TCy
The method of measuring quantum yields was the same as described in Chapter 2 and

Chapter 3. The quantum yields of CysTCy and TCy in acetonitrile were measured relative to
indocyanine green (ICG,  = 0.13 in DMSO) and the synthesized 1,1’,3,3,3’,3’-hexamethyl-3,5propylene-4-(dimethylamino)-2,2’-indotricarbocyanine perchlorate (HPDITCP) in ethanol ( =
0.161).52-54
5.3

Results and Discussion
The synthetic route of CysTCy is depicted in Scheme 5.2. The in-house prepared

tricarbocyanine TCy fluorophore was coupled to the acrylic benzyl alcohol compound 4 using
phosgene with a high yield (80%). The structures of the synthesized molecules were confirmed
with

1

H,

13

C NMR, and mass spectrometry. The purity of the CysTCy probe was also

demonstrated by HPLC-MS. In the presence of Cys, CysTCy is proposed to undergo a cascade
reaction-based fragmentation as shown in Scheme 5.1. As a soft nucleophile, the sulfhydryl group
of Cys firstly attacks the ,-unsaturated acrylate moiety through Michael addition reaction. Then,
the free, adjacent, hard nucleophile amine group attacks the hard electrophile carbon of the
carbonyl bond to form a cyclized thiol-lactam compound. This process initiates the cleavage of
the linker as a quinone methide and carbon dioxide gas, thus leading to the release of the highly
fluorescent TCy reporter.
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5.3.1

Spectroscopic Characterizations of CysTCy and TCy
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Figure 5.1 Absorption (black) and emission (red) spectra of CysTCy (A, 2 M) and TCy (B, 2 M)
in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). T = 25 °C.
With the synthesized CysTCy probe and TCy reporter in hand, their spectroscopic
properties were further measured in aqueous solution, as shown in Figure 5.1. The absorption
and emission maxima of CysTCy were at 787 nm and 808 nm, respectively; those of TCy were
at 615 nm and 763 nm, respectively. The observed bathochromic shift of CysTCy in comparison
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to TCy was attributed to the introduction of the electron-withdrawing carbamate bond to the meso
position of TCy. The carbamate group significantly decreased the HOMO energy of CysTCy and
led to a smaller HOMO-LUMO energy gap, which corresponded to its longer absorption and
emission wavelength.51 The quantum efficiencies were also measured in acetonitrile and the 
were found to be 0.17 and 0.31 for CysTCy and TCy respectively. These photophysical properties
of the CysTCy/TCy pair assured its suitability as a ratiometric system under such solution
conditions.
5.3.2

Spectral Response of CysTCy toward Cys
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Figure 5.2 Time-dependent (every 5 min for a 120-min time period) absorption (A) and emission
(B) spectral changes of CysTCy (2 M) upon addition of Cys (40 M) in 20% (v:v) ethanol in PBS
(20 mM, pH = 7.4). T = 37 °C.
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The solution of CysTCy was treated with 40 M Cys in an aqueous solution (20% EtOH
in PBS, v/v, pH = 7.4) at 37 ˚C, Figure 5.2. The addition of Cys induced a decrease in the
absorption band at 787 nm indicative of reaction of CysTCy. At the same time, a new absorption
band at 615 nm was formed indicating the production of TCy, leading to observation of an
isosbestic point at 675 nm, Figure 5.2 A. The solution color changed from its initial light-green
color to the dark blue color, Figure 5.2 A inset. A similar time-dependent response was found in
the emission spectra of CysTCy, Figure 5.2 B. When excited at the isosbestic point 675 nm,
solutions of CysTCy exhibited decreases of the emission band near 808 nm, accompanied by the
appearance of a new emission band near 763 nm. Importantly, there was no observed
fluorescence increase at 808 nm upon treatment with Cys, indicating lack of any PeT-based
fluorescence quenching between the fluorophore and the alkene bond. This observation is of
great significance; although other biological thiols without an adjacent amine group may
competitively add to the alkene bond, such a reaction will not induce any fluorescence ratio
changes.
To investigate the proposed activation mechanism, the components of the Cys-treated
CysTCy probe in the 20% ethanol in PBS (v/v, 20 mM, pH = 7.4) for 1 h at 37 °C were separated
and identified using HPLC-MS. Only the TCy reporter was observed indicated by its mass weight
(calculated m/z: 506.3535; observed m/z: 506.3523; error: 0.39 ppm). No residual CysTCy probe
was left indicating an effective and efficient conversion from CysTCy to TCy induced by Cys. In
sharp contrast, without addition of Cys, only the CysTCy probe (calculated m/z: 710.3958;
observed m/z: 710.3951; error: 0.99 ppm) was observed in the mass spectra, indicating that the
probe is structurally stable under aqueous solution conditions.
5.3.3

pH Independence of the CysTCy/TCy Pair
Because biological environments can have various pH, a pH-independent probe/reporter

system is advantageous for detection of species of interest under biological conditions. The
fluorescence intensity of CysTCy and TCy were examined in an aqueous solution in a wide pH
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range (4.5–9.5), Figure 5.3.51 The outcomes did not show obvious fluorescence changes,
because of their lack of pH responsive chemical moieties, such as amino or hydroxyl groups.
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Figure 5.3 Plot of fluorescence intensity of CysTCy (2 M, ex = 725 nm) at 808 nm in 20% (v:v)
ethanol in PBS (20 mM, pH = 7.4) at various pH (4.5–9.5). T = 37 °C.
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Figure 5.4 Color changes (A), absorption spectra changes (B), and emission spectra changes
(C) of CysTCy (2 M) upon 2 h incubation without addition or with addition of corresponding
Cys (50 M), Hcy (50 M), and GSH (250 M) in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4).
T = 37 °C.
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5.3.4

Selectivity of CysTCy Toward Cys over GSH and Hcy
The selectivity of CysTCy toward Cys over GSH and Hcy was further examined. After

incubation of 2 M CysTCy solution with 50 M Cys, 50 M Hcy, or 250 M GSH for 2 h at 37 °C,
the color of the Cys-treated solution was changed to blue, while the other solutions treated with
Hcy and GSH maintained the initial light-green color, Figure 5.4. This observation supports use
of CysTCy as a colorimetric probe. The absorption and emission spectra of the treated solutions
were further measured. Although solutions treated with Hcy and GSH had spectra having the
same absorption and emission wavelengths as CysTCy, the solution treated with Cys possessed
spectra whose absorption and emission maximal wavelengths were shifted from those of
untreated CysTCy. The resulting absorption and emission spectra were identical to those of TCy.
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Figure 5.5 Time-dependent fluorescence of 2 M CysTCy (ex = 600 nm and em = 750 nm)
incubated with or without addition of corresponding Cys (50 M), Hcy (50 M), or GSH (250 M)
in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). Inset is time-dependent (every 5 min for a 120min time period) emission spectral changes of CysTCy (2 M) with the addition of Cys (50 M)
with ex = 600 nm. T = 37 °C.
Solutions of CysTCy were treated with Cys, Hcy, and GSH, and the production rate of TCy was
recorded by monitoring the fluorescence increase at 750 nm (ex = 600 nm), Figure 5.5. Upon the
addition of Cys, a rapid fluorescence increase was observed (t1/2 = 20 min, time to achieve 50%
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of maximum fluorescence response) with the response becoming roughly invariant after ~ 60 min
for times up to 120 min. In contrast, addition of GSH and Hcy, the two most common interfering
species in the detection of cysteine, did not result in significant fluorescence increases. For
example, at 60 min incubation time point, both the Cys/GSH and Cys/Hcy response ratios are
about 15-fold. Although both GSH and Hcy have a sulfhydryl group that can attack the alkene
bond through Michael addition, they are much less likely to initiate the cyclization with the free
amine group in the following step, which unleashes the TCy reporter. For GSH, there is no free
amine group to accomplish the cyclization. For Hcy, formation of the eight-membered ring is
thermodynamically disfavored in comparison to the seven-membered ring formation with Cys,
thus making Hcy-initiated reporter release exceedingly slow.
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Figure 5.6 (A) Time-dependent fluorescence spectra (ex = 675 nm) of CysTCy (every 5 min over
a 120-min time period) in the simultaneous presence of Cys (40 M) and GSH (200 M) in 20%
(v:v) ethanol in PBS (20 mM, pH = 7.4). T = 37 °C. (B) The corresponding fluorescence ratio as
a function of increasing time.
To examine the potential influence of GSH on the response of CysTCy in the presence of
Cys, solutions of 2 M CysTCy were incubated with both 40 M Cys and 200 M GSH, Figure
5.6. The GSH concentration is 5-fold high compared to Cys similar to the ratio in biological
samples. A gradual increase in the fluorescence ratio (F765/F808) was observed. These outcomes
indicate that Cys has an extremely high reactivity toward CysTCy than GSH in the presence of 5fold more GSH, a very important result. The most likely explanation for this observation is that
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the sulfhydryl group of Cys has a lower pKa value than those of GSH and Hcy. For Cys, the pKa
is 8.3, due to its close proximity to the strong electron-withdrawing protonated amine group. In
contrast, GSH and Hcy have pKa values of 9.63 and 10.0, respectively.55-56 The lower pKa value
of Cys indicates that there is more Cys existing in the thiolate form (~ 13% for Cys, 0.6% for GSH,
and 0.3% for Hcy), which favors reaction of Cys with the alkene.
5.3.5

Quantification of Cys in an Aqueous Solution with the CysTCy/TCy Ratiometric System
In contrast to a turn-on fluorescent probe, a ratiometric fluorescent probe can act as a

“self-calibrated” probe for applications requiring quantification of species. Such truly ratiometric
probes have the advantages of avoiding the negative effects resulting from changes in excitation
light power and detector detection efficiency. Environmental factors, such as viscosity and polarity,
which affect the emission efficiency of fluorophores, can also be avoided. Considering the
advantages of ratiometric probes, the quantification potential of the CysTCy/TCy pair was further
investigated in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). The changes of fluorescence intensity
of 2 M CysTCy upon titration of different Cys concentrations (0–100 M) were recorded with the
excitation wavelength at its isosbestic point (= 675 nm) after 1 h incubation, Figure 5.7. As the
concentration of Cys increased, the fluorescence at 808 nm decreased accompanied by the
increase at 763 nm. By plotting the ratio of fluorescence intensity at 763 nm to that of 808 nm as
a function of different concentrations of Cys, a response curve was established. The ratio reached
its maximum value at [Cys] ≥ 30 M, indicating maximal reaction rate. More importantly, the ratio
of fluorescence exhibited a linear response in the concentration range of 0–10 M (Ratio =
0.0939[Cys] + 0.0925; R2 = 0.9932) with a high slope (high sensitivity). The anticipated limit of
detection (LOD) was computed to be 0.62 M using the equation LOD = 3/k. The LOD is much
lower than the total Cys concentration in human plasma from healthy individuals (135.8–266.5

M).57 The linear response, low LOD, and high sensitivity of the CysTCy/TCy ratiometric system
promised its ability to quantitatively measure Cys under aqueous conditions.
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Figure 5.7 (A) Fluorescence spectra changes of CysTCy (2 M, ex = 675 nm) upon 1 hour
incubation with different concentrations of Cys (1, 2, 4, 6, 8, 10, 15, 20, 30, 40, 60, and 100
M) in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). T = 37 °C; (B) Corresponding fluorescence
ratio (F763/F808) changes toward different Cys concentrations. Inset is of the linear calibration
(1–10 M); correlation coefficient is 0.0939.
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5.3.6

Stability of CysTCy in Human Plasma
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Figure 5.8 Time-dependent fluorescence (A) of 2 M CysTCy (ex = 600 nm and em = 750 nm)
incubated with or without addition of Cys (50 M). Time-dependent (every 5 min for a 120-min
time period) fluorescence spectra changes of 2 M CysTCy (B, ex = 600 nm; C, ex = 675 nm) in
the presence of Cys (50 M). All the measurement was in 10% deproteinized human plasma in
20% (v:v) ethanol in PBS (20 mM, pH = 7.4). T = 37 °C.
CysTCy was further investigated in deproteinized human plasma to examine its stability
and suitability to measure Cys in an environment that mimics blood. In cellular milieu, GSH is
more abundant (1–10 mM) than is Cys and Hcy (M level), which causes the biggest interference
in the detection of cellular Cys using fluorescent probes. However, only minimal levels of GSH
(3–5 M) are present in human plasma.58 This difference provides an additional advantage for
CysTCy to selectively measure Cys in human plasma with less interference from GSH. Pooled
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normal human plasma (10 mL) was deproteinized by adding the plasma to cooled ethanol (20 mL)
at –20 °C for 3 h. The precipitated proteins were removed by centrifugation at 4000 rpm for 30
min. The collected supernatant was diluted in 20% ethanol (v:v) in PBS solution (20 mM, pH =
7.4) to make 10% deproteinized human plasma solution which was utilized for subsequent
analysis. During this process, the human plasma was not reduced, which should provide for the
minimal levels of unbound Cys in the prepared plasma. As shown in Figure 5.8, without the
addition of Cys, no large fluorescence signal response was noted in the first 60 min of incubation,
indicating its stability under the deproteinized plasma conditions. In contrast, with the addition of
40 M Cys, a rapid increase in fluorescence was observed indicating the quick production of TCy.
The time-dependent turn-on and ratiometric fluorescence spectra of CysTCy treated with Cys
were also recorded, Figure 5.7 B and 5.7 C.
5.3.7

Quantification of Cys in Human Plasma
In 10% human plasma, the fluorescence response of CysTCy toward different

concentrations of Cys was further investigated. Upon incubating CysTCy with different amounts
of Cys for 1 h, CysTCy exhibited a similar ratiometric fluorescence change to in 20% (v:v) ethanol
in PBS (20 mM, pH = 7.4), Figure 5.9. Its fluorescence ratio (F763/F808) was directly correlated to
the amounts of Cys, corroborating its potential for Cys quantification in human plasma.
Finally, CysTCy was used for quantification of Cys in reduced human plasma. Pooled
normal human plasma (0.5 mL) was reduced by addition of 80 L 0.1 M triphenylphosphine in
acetonitrile and 40 L 0.2 M HCl.49, 59 This process breaks disulfide bond and releases the bound
Cys. The reduced human plasma was mixed with cooled ethanol (0.5 mL, – 20 °C) to precipitate
the proteins, followed by centrifugation (4000 rpm) for 30 min. The supernatant was diluted (10%)
and incubated with CysTCy (2 M) in ethanol/PBS (v:v, 2:8) at 37 °C, Figure 5.10. The
fluorescence at 808 nm was gradually decreased, accompanied by the fluorescence increase at
763 nm. The fluorescence ratio, 0.74, (F763/F808, 1-h incubation) was correlated to the Cys
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response linear curve in Figure 5.7. The Cys level in human plasma was calculated to be 98.0 ±
11.1 M. The determined Cys level is slightly lower than that present in human plasma might be
caused by the loss of Cys during the preparation procedures. This outcome demonstrated that
CysTCy is able to quantify Cys in deproteinized human plasma.
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Figure 5.9 (A) Fluorescence spectra changes of CysTCy (2 M, ex = 675 nm) upon 1 h incubation
with different concentrations of Cys (0, 1, 2, 3, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 70, 80, 100, 120,
150, and 200 M); (B) Corresponding fluorescence ratio (F763/F808) for 1-h incubation of Cys with
different Cys concentrations. All the measurements were performed in 10% deproteinized human
plasma in 20% (v:v) ethanol in PBS (20 mM, pH = 7.4). T = 37 °C.
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Figure 5.10 (A) Time-dependent (every 5 min for a 150-min time period) emission spectral
changes of CysTCy (2 M, ex = 675 nm) (B) Two independent emission spectra of CysTCy upon
1-h incubation. The measurement was performed in the 10% reduced human plasma in 20% (v:v)
ethanol in PBS (20 mM, pH = 7.4).T = 37 °C.
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5.4

Conclusion
The CysTCy/TCy pair was developed as a ratiometric probe/reporter system to selectively

detect Cys over other thiols including Hcy and GSH. Its selectivity relied on its unique recognition
pattern involving both the amino and the sulfhydryl groups of Cys to react with an acrylic
recognition moiety. The unleashed reporter by Cys induced a huge color change and fluorescence
switch, thus making it a dual colorimetric and fluorescent probe. The developed system also
exhibited a linear response toward Cys, low LOD, and high sensitivity. Its usefulness was
demonstrated by its application in measuring and quantifying Cys in human plasma.
5.5
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CHAPTER 6
SUMMARY, CONCLUSION, AND OUTLOOK
6.1

Summary and Conclusion
The overall goal of this research was to develop and implement activity-based substrate

probes for the detection and imaging of cancer-associated enzymes (i.e., human NAD(P)H:
quinone oxidoreductase isoenzyme 1 (hNQO1) and -galactosidase) in vitro and in vivo. The
probes were designed to be either non-fluorescent, or fluorescent in a different energy range from
their corresponding fluorescent reporters. Upon enzymatic activation, the developed probes are
converted into highly fluorescent reporters—both selectively and rapidly. Because the targeted
enzymes are upregulated in various cancer cells and tissues, catalysis of probes, and subsequent
release of reporters, cause emission of visible or near-infrared (NIR) photons from the diseased
cells, thus allowing the differentiation of diseased tumor cells from healthy cells.
Because photons in NIR range are most suited for in vivo applications, I put my initial
efforts into the design and synthesis of a probe, Q3STCy, which emits near-infrared light upon
hNQO1 activation, as well as examining probe applicability in visualizing hNQO1-expressing cells
and small tumors. Q3STCy has a tripartite structure (a quinone trigger, a 2-mercaptoethanol linker,
and a heptamethine cyanine reporter). Spectroscopic measurements revealed that the probe and
the reporter have distinct absorption and emission profiles, observations which were further
studied with frontier molecular orbital calculations. Q3STCy has a low fluorescence efficiency,
most likely due to donor-excited-photoinduced electron transfer (d-PeT) quenching. The d-PeT
quenching was verified by outcomes based on photophysical studies and cyclic voltammetry (CV).
Upon NQO1-catalyzed reduction, the probe exhibited a fast and large fluorescence increase in
aqueous solutions. Enzymatic kinetic experiments indicated that Q3STCy is a good substrate for
hNQO1, with unprecedented catalytic formation of the fluorescent reporter. Q 3STCy also
exhibited a high selectivity toward hNQO1 and pH-independence, which makes it advantageous
in biological applications. The differentiation of NQO1-expressing cells (HT29, H596 (+), and
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SHIN3) from NQO1-non-expressing cells (H596) with high integrity was also achieved with the
application of Q3STCy using confocal and wide-field microscopy. Because two-dimensional (2D)
cell culture lacks features of real tumor microenvironments, three-dimensional (3D) colorectal
multicellular spheroids (MCTS) model can better mimic tumor characteristics. Q3STCy was
successfully used to image clinically relevant MCTSs possessing spatially heterogeneous NQO1
activities, and the probe was also applied in fluorescence-assisted identification of metastases in
a preclinical mouse model of human ovarian serous adenocarcinoma.
Moreover, I developed a probe, Q3NTCy, which is capable of reporting the activity of
hNQO1 in a rapid, selective, and sensitive manner. In contrast to Q3STCy, the Q3NTCy probe
exhibited strong fluorescence in a different energy range of the electromagnetic spectrum from
the reporter. Enzymatic evaluation showed that Q3NTCy is a great substrate of hNQO1. The
effective reduction of Q3NTCy by hNQO1 initiated a chain reaction, which rapidly produced the
TCy reporter. Q3NTCy was also successfully employed in the differentiation of hNQO1-expressing
cell lines (HT-29, A549, and SHIN3) from an hNQO1-nonexpressing cell line (H596) in both offon and on-on fluorescence modes. When tissue sections of living 3-D MCTSs were treated with
Q3NTCy, the fluorescence response was found to be in agreement with the spatially
heterogeneous hNQO1 expression as demonstrated by immunohistochemistry. Although both
Q3STCy and Q3NTCy proved to be useful for imaging the small-sized young MCTSs, with the
images reflecting the hNQO1 expression levels in sectioned MCTSs, they failed to diffuse inside
intact MCTSs. When intact MCTSs having uniform hNQO1 distribution were treated with Q3STCy
and Q3NTCy and subsequently sectioned, the peripheral layers were observed to be fluorescent
and the interior regions were non-fluorescent in young MCTSs. Inability of the two probes to
penetrate deep into tissues/mimics limits their applications in the evaluation of drug action, and
drug efficacy, in this specific 3D tumor model.
In an effort to diversify my research, I made a slight change in my research course from
developing NQO1-activatable probes, to probes with the potential to provide quantitative
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information on other enzyme/cofactor systems. First, I chose galactosidase (-gal) as the target
enzyme. -gal is a transgene enzyme upregulated in senescent cells and in primary ovarian
cancer cells. It has been exploited as a biomarker to develop small-molecule fluorogenic probes
for detecting and imaging senescent cells and ovarian cancer cells. A -gal–responsive
ratiometric fluorescent probe has the potential to provide a simple and sensitive way to quantify
the activity of -gal under cellular conditions. Therefore, I developed a previously unreported, welldefined ratiometric fluorescent probe, GalNap, capable of achieving real-time detection and
imaging of endogenous -gal in human ovarian cancer cell lines in both off-on and ratiometric
modes. I have demonstrated that GalNap, having a tripartite structure (a -gal recognizer, a selfimmolative linker, and an intramolecular charge transfer (ICT) fluorophore), is capable of being
effectively recognized and rapidly hydrolyzed under physiological conditions by -gal, resulting in
the production of an ICT fluorophore, as noted by obvious changes in the spectral profile. Using
confocal microscopy, the capability of GalNap to reflect variations in cellular -gal activity was
observed in -gal–overexpressing ovarian cancer cell lines, in both off-on and ratiometric modes.
To further broaden my work, I developed a second ratiometric probe/reporter system
(CysTCy/TCy), designed to selectively detect cysteine over other thiols, including homocysteine
and GSH. Selectivity of the probe/reporter system relies on its unique recognition pattern that
involves both the amino and the sulfhydryl groups of cysteine. The released reporter induced a
significant change in color and fluorescence emission energy, thus making it a dual colorimetric
and fluorescent probe. This system also exhibited a linear response toward change in
concentration of cysteine, and low LOD and high sensitivity for detection of cysteine. Its
usefulness was demonstrated by its application in measuring and quantifying cysteine in human
plasma.

227

6.2

Outlook
My initial research was focused on the development of enzyme-activated fluorogenic

molecular substrate probes and their use in differentiating diseased tissues from healthy tissues.
My efforts resulted in the development of a molecular probe that successfully visualizing ovarian
cancer–derived micrometastases in a xenograft mouse model. Although such probes may have
promising impact in fluorescence–guided cytoreductive surgery, complete resection of all the
small metastases in every patient is highly unlikely. To increase the efficiency, I thought about the
possibility of developing a probe that can not only fluoresce, but can also be toxic toward hNQO1expressing tumor tissues. Certain dyes (i.e., photosensitizer, PS) can produce singlet oxygen ( 1O2)
upon light illumination, thus allowing selective toxicity toward the illuminated tissues. Therefore, I
decided to evaluate the possibility of achieving the simultaneous imaging and killing of hNQO1expressing cells by incorporating a PS molecule with an hNQO1-specific recognition moiety.
Photodynamic therapy (PDT) is an important cancer treatment method that uses light, a
PS, and molecular oxygen to produce toxic 1O2, thus eliciting cell death.1 The mechanism of 1O2
formation is illustrated by a modified Jablonski diagram, Figure 6.1. Upon illumination with a
suitable light source, the PS is excited from its ground state (S0) to its excited singlet state (S1),
which can undergo fluorescence, heat release, or intersystem crossing to the long-lived triplet
state (T1). PS in the triplet state can either transfer energy to a triplet state molecular oxygen (3O2)
molecules to produce 1O2, or transfer an electron to oxygen to produce hydroxyl radical. Because

Figure 6.1 Depiction of mechanism of singlet oxygen (1O2) formation by exciting a PS with light
in the presence of molecular oxygen.
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the half-life of 1O2 in aqueous solution is less than 1 ms, and the diffusion distance of 1O2 is about
10–55 nm in cells, which limits 1O2 leaking out of the illuminated areas, PDT can achieve high in
situ toxicity.2
Conventionally, selective cell ablation is regulated by controlling the light illumination and
PS delivery to the tumor area. However, it is difficult to precisely direct the light illumination to
small targeted areas (e.g., small-sized tumors) without affecting the surrounding normal tissues.
Most of the currently used PSs are based on porphyrins, which distribute in the human body in a
nonspecific manner, leading to serious photo-damage to healthy tissues. To overcome this issue,
PSs are conjugated with targeting groups (e.g., antibodies and peptides) to improve their
tendency to accumulate in the targeted areas. However, they still cause photo-damage to normal
tissues, due to the slow clearance of the unbound PSs. Activatable PSs (aPSs) that do not
produce 1O2 until they are activated by specific disease-linked biomarkers, hold great promise to
overcome the nonspecific phototoxicity issue.3-4 Recently, several cancer-associated enzymes
have been targeted to design PSs, such as caspase 3,5-6 matrix metalloproteinase 7 (MMP-7),7

-galactosidase,8-9 and -glutamyltranspeptidase.10
Quinone propionic acid (Q3PA) is a selective and effective hNQO1 recognition group, as
has been demonstrated in the development of fluorescent probes, and most importantly, it is
electron-deficient in nature. By incorporating a suitable PS with the quinone moiety (Q 3), I
envisioned that 1O2 production by a PS can be inhibited through a photoinduced electron transfer
(PeT) process. Pyropheophorbide a (Pyro) is a PS that has both high fluorescence efficiency (F
= 0.43 in benzene) and high 1O2 production efficiency ( = 0.45 in benzene), and thus displays
dual functions – fluorescence imaging and photodynamic activity.3 Therefore, Pyro was selected
as the PS to be conjugated with the quinone recognition group so as to afford an hNQO1responsive PS, Q3Pyro, Figure 6.2 A. In Q3Pyro, both the fluorescence and photosensitizing ability
are anticipated to be blocked by the PeT process, but specific reduction and cleavage of the Q 3
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moiety by hNQO1 was thought to be restore the fluorescence and photosensitizing ability of Pyro.
Because the two gem-dimethyl groups on Q3PA are the driving force for the cleavage upon
reduction, I designed and synthesized an analog of Q3Pyro that lacks the two gem-dimethyl
groups, Q1Pyro, as a control aPS. Q1Pyro was thought to be unable to release the PS upon
hNQO1 reduction.
The spectroscopic properties of Q3Pyro, Q1Pyro, and Pyro were measured in an aqueous
solution (50% methanol: 50% 20 mM PBS, pH = 7.4). All the three compounds exhibited typical
absorption spectra of porphyrin compounds with similar extinction coefficients, Figure 6.2 B. They
showed an intense absorption band around 405 nm (the Soret band, S0 to S2) and four additional
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Figure 6.2. (A) Design of an hNQO1-responsive aPS, Q3Pyro. Upon hNQO1 reduction, the
toxic PS was released through the elimination of the quinone moiety. (B) Absorption spectra
and (C) emission spectra (ex = 405 nm) of Q3Pyro (5 M), Q1Pyro (5 M), and Pyro (5 M) in
50% (v:v) methanol: 20 mM PBS (pH = 7.4). T = 25 °C.
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absorption bands (Q bands, S0 to S1) in the longer wavelength range (500–700 nm). The intense
absorption at 665 nm is in the near-infrared light range (650–900 nm). Pyro also fluoresces in the
NIR range, with two emission maxima (675 nm and 725 nm), thus allowing it to be suitable for
biological applications. Although Pyro exhibited strong fluorescence, Q3Pyro and Q1Pyro have
very weak fluorescence under the same conditions, Figure 6.2 C. This observation confirmed that
the fluorescence of Pyro is effectively quenched by the Q3 moiety, a primary requirement for the
development of aPSs.
The 1O2 production efficiency of Q3Pyro, Q1Pyro, and Pyro upon light illumination was
studied with the use of 1,3-diphenylisobenzofuran (DPBF, abs = 405 nm) as the 1O2 trapping
molecule, Figure 6.3. Solutions of the respective PS molecule (5 M) and DPBF (40 M) in an
aqueous solution (50% methanol: 50% 20 mM PBS, pH = 7.4) was irradiated with light (665 ± 10

Figure 6.3. Time-dependent (10-min interval) change in absorption spectra of DPBF (40 M)
upon a light irradiation (665 ± 10 nm) in 50% (v:v) methanol in 20 mM PBS (pH = 7.4) in the
presence of (A) Pyro (5 M), (B) Q3Pyro (5 M), or (C) Q1Pyro (5 M). (D) Relative 1O2
production rate. The values were the normalized decrease slope of the absorption intensity at
405 nm. T = 25 °C.
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nm). The change of the DPBF concentration was monitored with absorption spectroscopy. For a
solution of Pyro and DPBF, as irradiation time increased, the absorption at 405 nm gradually
decreased, corresponding to the breakage of DPBF by the produced 1O2. In contrast, for both
solutions of Q3Pyro and Q1Pyro in the presence of DPBF, light irradiation did not induce the
decrease of the absorption intensity at 405 nm, indicating the less 1O2 production of Q3Pyro and
Q1Pyro. By comparing the slope of the absorption decrease at 405 nm, Q 3Pyro and Q1Pyro had
about 11-fold lower 1O2 production efficiency than Pyro, Figure 6.3 D. These outcomes were in
agreement with the hypothesis that the 1O2 production of Pyro can be quenched by the electrondeficient Q3 moiety, most likely through a PeT process.
After demonstrating that both the fluorescence and 1O2 production of Pyro were effectively
quenched by the quinone moiety, I next sought to study the ability of Q3Pyro to be hNQO1 reduced
to release the toxic Pyro. Fluorescence intensities at 670 nm (ex = 400 nm) of aqueous solutions
of Q3Pyro and Q1Pyro in the presence and absence of hNQO1 (4 g mL–1, 2000 U mL–1) were
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Figure 6.4. The fluorescence intensity at 670 nm of solutions of Q3Pyro and Q1Pyro (5 M, ex
= 400 nm) in 5% (v:v) DMSO in 20 mM PBS (pH = 7.4) containing 100 M NADH and 0.007%
BSA was recorded with and without the addition of hNQO1 (4 g mL–1, 2000 U mL–1) at the
20-min time point. Inset is the fluorescence spectral response of Q3Pyro toward hNQO1 during
a 60-min time period. T = 37 ºC.
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monitored. As shown in Figure 6.4 (red line), upon addition of a solution of Q 3Pyro with hNQO1
at the 20-min time point, an immediate increase in the fluorescence intensity at 670 nm,
corresponding to the release of Pyro, was observed (t1/2 = 25 min, the time of Q3Pyro to achieve
half of its maximum Pyro release). In contrast, the control aPS, Q 1Pyro, did not show a similar
fluorescence increase pattern upon the addition of hNQO1; the small fluorescence increase may
be caused by the reduced form of Q1Pyro. Moreover, upon continuous irradiation with 400-nm
light (120 min) in the absence of hNQO1, neither of the solutions of Q 3Pyro and Q1Pyro showed
an increase in fluorescence intensity, indicating their photostability and low non-specific activation
in aqueous solutions.
To demonstrate that Q3Pyro can be specifically activated by hNQO1 in vitro, a cellular
imaging experiment was conducted on a wild-type non-small cell lung carcinoma cell line (H596
(-), hNQO1-non-expressing) and an hNQO1-gene-transfected H596 cell line (H596 (+), hNQO1expressing). As shown in Figure 6.5, H596 (+) cells treated with Q3Pyro showed a strong cytosolic
fluorescence signal, while H596 (-) treated with Q3Pyro showed minimal fluorescence signal under
the same conditions. The target-to-background ratio (TBR) of H596(+) (29 Cells)/H596(-) (30 cells)
was determined to be 2.6 ± 0.7 (95% confidence). In contrast, both H596 (+) and H596 (-) cell
lines without aPS treatment (control) and such cells incubated with the control aPS, Q 1Pyro,
showed minimal fluorescence. This data clearly demonstrated that Q3Pyro can pass through the
cellular membrane and be activated by hNQO1 inside cells, indicating its potential to function as
both a profluorogenic probe and an aPS.
To determine the subcellular location of Pyro produced by the hNQO1-mediated activation
of Q3Pyro, H596 (+) cells were treated with Q3Pyro and the organelle trackers (endoplasmic
reticulum (ER) tracker, mitochondria tracker, and lysosome tracker) and cellular images were
captured with confocal microscopy, Figure 6.6. The fluorescence signal from Pyro showed a high
degree of colocalization with that from the ER tracker, and the Pearson correlation coefficient for
colocalization (PCCC)11 was determined to be 0.83. In contrast, the fluorescence signal from Pyro
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had poor colocalization with the lysosome-tracker and mitochondria-tracker; the PCCC values for
Pyro/lysosome and Pyro/mitochondria were –0.01 and 0.34, respectively. The subcellular location
of a PS plays an important role in the type of cell death mechanism (apoptotic, necrotic, and
autophagy-associated cell death).2 The ER localization of Pyro may indicate that Q3Pyro can
induce the cell death through autophagy-associated pathway.

Figure 6.5. Fluroescence and differential interference contrast (DIC) images of H596 (-) and
H596 (+) cells using confocal microsopy. Cells were incubated with Q3Pyro (5 M) or Q1Pyro
(5 M) for 30 minutes under 5% CO2, humidified conditions in dark at 37 ºC. The treated cells
were washed with DPBS twice, and then fixed by 4% PFA solution for 15 minutes. Control
experiment represents the cells without the incubation with Q3Pyro or Q1Pyro. Fluorescence
images were captured in the 675–750 nm emission range upon excitation by a 665-nm laser.
Scale bar = 20 m.
I next examined via MTT assay the cell viability of H596 (-) cells, upon exposure to different
concentrations of Q3Pyro and Pyro with or without light irradiation, Figure 6.7. The percentages
were normalized to the cell viability of H596 (-) without the Q3Pyro or Pyro treatments. Both
Q3Pyro and Pyro in the studied concentration range (1–10 M) had low dark toxicity, Figure 6.7
A. In contrast, upon irradiation with a 665-nm LED light (10 mW cm–2) for 50 seconds, Q3Pyro had
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a lower cell toxicity than Pyro in agreement with the decreased 1O2 production efficiency of Q3Pyro,
Figure 6.7 B.

Figure 6.6. Fluorescence and DIC images of live H596 (+) cells treated with Q 3Pyro and
organelle trackers. Cells were incubated with Q3Pyro (5 M) and the respective organelle
tracker – ER-tracker Blue-White DPX (60 nM), Lysotracker Green DND-26 (30 nM), and
Mitotracker Green (75 nM) for 30 min. The settings for capturing the Q 3Pyro fluorescence
images were 665 nm excitation and 670–750 nm emission; for ER images, the settings were
405-nm excitation and 500–600 nm emission; for lysosome and mitochondria images, the
settings were 488-nm excitation and 500–600 nm emission. Scale bar is 15 m or 20 m.
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Figure 6.7. H596 (-) cell viability (A) in dark and (B) with light irradiation (665 nm LED, 0.5 J
cm–2) of Q3Pyro and Pyro of various concentrations determined by MTT assay, compared with
untreated cells. Error bars indicate the standard deviations (± s.d.) of triplicate experiments.
So far, my preliminary results have shown that quinone propionic acid is capable of
quenching the toxic singlet oxygen of the photosensitizer, and Q3Pyro has the potential to become
an efficient targetable imaging and anti-cancer agent. The selectivity and efficacy of the Q3 moiety
toward hNQO1 and its electron deficient property has been proved over and over again. And I
believe that further exploration must be continued with the Q3 moiety. Its conjugation with other
types of signal-generating molecules to develop NQO1-activatable contrast agents, such as
photodynamic agents, chemiluminescent probes, and photoacoustic probes is an endeavor worth
pursuing.
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